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ABSTRACT
AFFINITY MATURATION AND CHARACTERIZATION OF NOVEL BINDERS TO THE
HIV-1 TAR ELEMENT BASED ON THE U1A RNA RECOGNITION MOTIF
The increased understanding of the importance of RNA, both as a carrier of information and
as a functional molecule, has led to a greater demand for the ability to target specific RNAs, but
the limited chemical diversity of RNA makes this challenging. This thesis documents the use of
yeast display to perform affinity maturation for the ability of a protein to bind the TAR element
of HIV-1, which is a desirable therapeutic target due to its prominent role in the HIV-1 infection
cycle. To accomplish this, we used a “semi-design” strategy—repurposing a natural RNA binding
protein to bind a different target—by creating a library based on important binding regions (es-
pecially the β2β3 loop) of the U1A RRM. Following selection for TAR binding, a strong consensus
sequence in the β2β3 loop emerged. The affinity of certain library members for TAR was mea-
sured by ELISA and SPR, and it was determined that the best binder (TBP 6.7) had remarkable
affinity (KD = ~500 pM). This TAR binding protein also proved capable of disrupting the Tat–TAR
interaction (necessary for HIV-1 replication) both in vitro and in the context of extracellular tran-
scription. Through collaboration, we were able to obtain a co-crystal structure of TBP 6.7 and
TAR. This crystal structure showed that the overall structure of TBP 6.7 was largely unchanged
from that of U1A, thereby validating our semi-design strategy. We also found that the β2β3 loop
played a disproportionately large role in the binding interaction (~⅔ of the buried surface area).
The prominence of this region’s role in the interaction inspired the creation and characterization
of peptide derivatives of the TBP 6.7 β2β3 loop. These β2β3 loop derived peptides maintain affin-
ity for TAR RNA (KD = ~1.8 μM), and can disrupt Tat/TAR-dependent transcription. Ultimately,
the project yielded a novel platform of TAR binding peptides and a crystal structure which will
inform future RNA targeting efforts in addition to generating the tightest known binder of TAR.
ii
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1.1 Biological Macromolecule Background
The intertwined fields of Biochemistry, Molecular Biology, and Chemical Biology can be
imperfectly generalized as the study of the properties and interactions of four major classes of
biological polymers- lipids, carbohydrates, proteins, and nucleic acids. Nearly every genetic sur-
vey, every pharmaceutical, every in vitro cellular study, and every assay in all these fields are
focused on some aspect of chemically classifying one of these four macromolecules and their
interactions with each other and small-molecule adjuncts to form pathways. These four classes
of molecules have not, however, had equal time and resources devoted to them. The degree to
which our understanding of biochemistry is based on giving importance to what we could study,
and that it is based on what we already know is not always appreciated. Practically, this means
that proteins are the most studied molecule, nucleic acids a comfortable second, and carbohy-
drates and lipids far behind
To be fair, proteins account for a vast array of cellular function ranging from catalysis to
structure, but the original conception of the other macromolecule classes as mere facilitators
of protein chemistry was reductive; Wide-ranging their function may be, but proteins do not
tell the whole story of cellular chemistry. Of the non-protein macromolecules, Ribonucleic acid
(RNA) especially has emerged as a material responsible for functional entities ill-defined by the
old Central Dogma. New perspectives are needed to conceptualize the remarkable scope and
dynamism of RNA’s cellular roles, and new tools will need to be developed to study it.
The work described in this thesis advances two goals. The first goal, which sees signifi-
cant progress represented here, is the development and characterization of possible effector
molecules for a single functional RNA of biochemical interest—the Trans-activating Response
element of HIV-1 (TAR). The second, more abstract goal, for which this work represents a small
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but important step, is progress toward the eventual ability to develop binders for arbitrary and
specific functional RNAs.
In the service of understanding these two aims, and why they are only recently coming into
focus, let us take a look back at how our understanding of biochemistry has evolved, how the path
this understanding took has informed our assumptions, and how this has necessarily resulted in
limitations. By understanding this history, we can recalibrate our goals and build new tools to
achieve them.
1.1.1 Proto-Biochemistry was Focused on Proteins
In the 19th century Dutch chemist Gerardus Johannes Mulder came to realize that a vast
amount of biological substances could be well-described by a single empirical formula—
C400H620N100O120P1S1. Mulder’s correspondent Jöns Jacob Berzelius suggested that this massive
class of substances deserved the name “Protein,” which roughly means, from its Greek roots,
“of first importance” [1, 2]. This lofty designation certainly reflects the priorities of the nascent
field of biochemistry. The focus on proteins as the primary enablers of cellular chemistry grew
when James Sumner crystallized Urease in 1926 [3], proving what most enzymologists already
guessed—that enzymes were proteins (Nobel Prize 1946) [4]. Early structural biology was almost
entirely focused on proteins—most notably Linus Pauling’s hydrogen-bond based justification
for the structure of the protein α-helix and β-sheet secondary structure elements [5] (Nobel Prize
1954).
This focus on proteins was not unwarranted, as Table 1.1A shows that this class of molecules
makes up a majority of the dry mass of the cell, and this massive percentage does, in fact, correlate
to a wide array of function.
The common catchphrases of the day demonstrate this explicit focus on protein. One fa-
mous example, “One Gene, One Enzyme” [8] (soon amended to “One Gene, One Polypeptide)
highlights this focus. The “gene” had been formulated purely as an abstraction, and the first, and
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Table 1.1: Composition of a Cell A: Breakdown of mammalian cellular dry mass by molecule type [6] B:
Breakdown of RNA mass by RNA type [7]
A % of Dry Mass B % of RNA
Protein 59.31% rRNA 80%
DNA 0.82% tRNA 15%
RNA 3.62% mRNA 5%
Polysaccharides 6.59% Other Functional RNAs 0.1%
Lipids 16.47%
Small molecules 13.18%
for decades primary, concrete conceptual connection between the abstract idea of the heritable
gene and the gene’s effect on observed reality was as an enabler of protein chemistry.
In the early 20th century, the hypothesis that Proteins were somehow the basis for genetic
transfer was taken as a fait acccompli. How could a molecule as chemically simple as DNA, with
only four bases, possibly conduct the complicated business of genetic transfer? However, the
definitive proof that the nucleic acids were the physical basis of the gene was discovered through
observation of the heritability of infectivity in Streptococcus pneumoniae by Oswald Avery, Colin
MacLeod, and Maclyn McCarty in 1944 [9]. The fact that Avery did not win the Nobel Prize before
his death in 1955 is testament to the unwillingness of his contemporaries to accept his (correct)
conclusions, and not until an experiment by Hershey using bacteriophage was published in 1952
did the conclusion that nucleic acids were the basis for genetics become inescapable [10, 11].
1.2 The Central Dogma
1.2.1 Structure and Function of DNA
The scope and promise of the new field of Molecular Biology snapped into focus in 1953 when
James Watson and Francis Crick proposed a structure for the Deoxyribonucleic acid (DNA) poly-
mer [12]. A final phrase in this seminal paper, “It has not escaped our notice that the specific
pairing we have postulated immediately suggests a possible copying mechanism for the genetic
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material” uses the newly discovered structure of DNA to bridge the gap between the function it
had already been determined to have, and a mechanism for fulfilling that function.
The chemical limitations of the nucleic acids was no longer puzzling, it was a feature. A sam-
ple of DNA was no longer a hodgepodge of functional groups, it was a strand, a linear sequence
which underpins life itself. There is a reason that the enduring public symbol of Biochemistry
and Molecular Biology is the elegant DNA double-helix. From the moment the structure was
known, the broad strokes of how the information that is life had propagated itself from the misty
past, and would continue doing so for the foreseeable future, was obvious. The abstract idea of
the “gene” was now “information [13].”
Life itself was as readable as this sentence, once the code was learned.
1.2.2 Formulation of the Central Dogma
The code correlating DNA and protein sequence was indeed cracked in a very few years, and
Francis Crick formulated the famous Central Dogma of Molecular Biology in 1958:
“[O]nce ‘information’ has passed into protein it cannot get out again. In more detail, the
transfer of information from nucleic acid to nucleic acid, or from nucleic acid to protein may
be possible, but transfer from protein to protein, or from protein to nucleic acid is impossible.
Information means here the precise determination of sequence, either of bases in the nucleic
acid or of amino acid residues in the protein [14, 15].”
This simplifies well to the “DNA→RNA→Protein,” approximation taught in high school bi-
ology, but all the possibilities that Crick foresaw are shown in Figure 1.1, and Crick’s primary
assertion—that sequence-based information only flows from nucleic acid to protein—has been
remarkably robust. However, the initial role that RNA was given—uninteresting messenger—
was quickly found to be too reductive. RNA was soon known to be responsible for catalyzing
peptide bond formation in the ribosome, and for acting as an adapter between mRNA and pro-
tein primary sequence. These two roles actually encompass ~95% of the mass of RNA in the
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cell (Table 1.1) while the sequences and structures of the RNAs involved in these roles are highly
conserved across all phyla of life [6].
Figure 1.1: TheCentralDogmaasFormulatedbyFrancisCrick In Francis Crick’s own words: “A tentative
classification for the present day [1970]. Solid arrows show general transfers; dotted arrows show special
transfers. Again, the absent arrows are the undetected transfers specified by the central dogma.” Adapted
from [15]
1.3 Bioinformatics Era
Counter-intuitive as it may seem, this new focus on DNA actually increased the fixation on
the fact of proteins as being of “first importance.” Once the code was cracked, and it seemed clear
that DNA didn’t (directly) code for anything other than protein, everything else became second-
class. If heritable life was “information,” and all the chemistry that was coded for was contained
in proteins, it follows that the rest of the vast array of chemistry that takes place in the cell can
be extrapolated in total if the information in the DNA is sufficiently understood.
The fundamental promise and hope of this formulation was that Molecular Biology is know-
able. If all function in a cell ultimately derives from DNA, and this DNA is both finite and read-
able, maybe we could understand, and control everything, in a cell. In the 1990s, as the human
genome project was nearing completion, this optimism was at its height. Human Genome Project
luminary Eric Lander penned a roadmap in 1996 that states “[o]nce all proteins are known, it
should be possible to assemble comprehensive ‘interaction maps’ of genomes. [16]” This assump-
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tion that “gene” and “protein” are essentially synonymous, and that a “comprehensive interaction
map” could be assembled using only the genome are hallmarks of the era.
1.3.1 Gene Editing
The therapeutic hope of the bioinformatics era—-that all cell disease states can ultimately be
traced back to the genome and corrected there—has been partially borne out. Our increasing
knowledge of the genome has indeed allowed us map disorders back to the gene variant which
causes them. For instance, Huntington’s Disease is understood to be caused by a mutated version
of the “Huntingtin” protein which has too many glutamine residues near the N-terminus. We
know this because we can read the extra “CAG” repeats in the gene coding for this protein in
Huntington’s sufferers [17]. We also know that in cellulo, correcting the gene fixes the problem [18].
As examples like this demonstrate, there is a great deal of well-placed interest in Gene Therapy
[19–21].
1.3.2 Limits
But the rapid DNA-based increase in our knowledge has, until recently, obscured the limits
of our current approaches and models. The importance of DNA as the source of the master tem-
plates for the proteins in the cell is obvious, but it to call it the “template” or “blueprint” is an over-
statement. In hindsight, the belief that gaining a complete understanding of DNA would grant
anything like total understanding of cellular processes was extraordinarily naïve. The genome
is, more-or-less a parts list, not a manual. Assuming this parts list would be enough to fully un-
derstand the dynamic processes that make up up cellular biology is, at a basic level, comparable
to assuming that the best way to assemble IKEA furniture is to look at a photograph of a com-
pleted item and draw from disorderly piles of every component used by IKEA. Life is not the
inevitable result of recorded information, but instead the result of the careful, ordered, limited,
and precise expression of this information within the pre-existing context of the cell, and within
the derived context of a multi-cellular organism.
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An example of the power, but also the fundamental limitation, of a DNA informatics ap-
proach is the successful synthesis of an artificial genome by Craig Venter’s team. This group
of researchers synthesized a full genome of Mycoplasma mycoides and subsequently successfully
transplanting it into a cell, which then grew normally. The achievement is obvious, but so is the
limitation. This genome doesn’t spontaneously create an organism around it, and would not do
so even if transcription/translation machinery and biopolymer building blocks were available.
The genome contained the “complete” information for replication, but only if the necessity of
an emphM. capriculum cellular environment can be considered free of information [22].
Cellular environment may not follow the clear rules of the DNA code, but it is as important a
form of “information” as the easily readable DNA sequences. To take the next steps in biochem-
ical understanding, we need to understand the interaction of every piece of the cell. Arguably
the most pervasive and dynamic aspect of that cellular milieu is the seemingly boring RNA.
1.4 The Centrality of RNA to Life
In Molecular Biology as described by the Central Dogma, DNA is the master composer cre-
ating a timeless work of genius, Protein is the orchestra expressing that genius, while RNA is
relegated to the role of simple amanuensis, making sure the conductor and players have their
scores. In Crick’s original formulation, RNA dutifully copies down the information contained in
the DNA, transmitting it from the nucleus to the parts of the cell that can bring the coded-for
proteins into existence, and then degrades without a trace. This is an important job to be sure,
but it isn’t an apparently complicated one.
However, ever since that boring relegation, RNA continually gets caught doing something
interesting. Soon after the formulation of the central dogma, RNA was found to be the adapter
between the genetic code and protein synthesis, and to catalyze the synthesis of polypeptides
from amino acids within the ribosome. In fact, the ribosomal RNA (rRNA) and transport RNA
(tRNA) account for ~95% of the RNA in a mammalian cell (Table 1.1). More recently, it was dis-
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Figure 1.2: RNA Roles in the Central Dogma RNA plays a role in every process described in the Central
Dogma, from the A long non-coding RNAs that regulate transcription to the B post-transcriptional splic-
ing needed to make readable mRNA, to the C RNA interference pathways which regulate RNA levels, to
the D transport and ribosomal RNAs which catalyze polypeptide synthesis.
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but needs to be spliced post-transcriptionally into a properly readable form , and that it can even
perform this splicing without the aid of protein [23]. More recently still it was discovered that
long non-coding RNAs (lncRNAs) regulate gene expression prior to transcription [24, 25], mean-
ing that RNA plays a role in every step of the Central Dogma (illustrated in Figure 1.2).
1.4.1 The RNAWorld Hypothesis
More recent decades have seen the discovery of RNAs that could catalyze reactions, now
known as Ribozymes [26], and that the RNA in an RNA/protein complex can act in a catalytic
role outside of the Ribosome [27]. This realization that RNA can both carry and replicate infor-
mation and led to the widespread acceptance of the “RNA World” hypothesis, which posits that
life as we understand it emerged from self-replicating RNA molecules [28].
Though the RNA World hypothesis is not directly germane to the challenge of targeting any
specific RNA, it is always worth considering as a universal effector of life. If the RNA World
hypothesis is correct, then the chemical trappings of life in all their complexity were pulled into
the dance of replication and descent with variation that defines “life” due to their relationship
with RNA. It is unsurprising that hardly any processes in a cell that are unaffected by RNA.
1.5 Roles of RNA in Living cells
1.5.1 Dogmatic Roles of RNA
rRNA and tRNA
The vast majority of RNA in the cell (~95%) [6] is either rRNA (~80%) or tRNA (~15%). This is
important to consider when designing an RNA binding protein, because these abundant RNAs
are not viable therapeutic targets. The structures of rRNA and tRNA are complex, varied, and
highly conserved among species [7]. This means that any possible therapeutic which has spe-
cific activity toward rRNA or tRNA, general activity toward RNA structural elements, or general
activity toward RNA, is simply going to be drawn to the ribosome or the tRNA, which every cell
needs to survive. Any such therapeutic would be too generally cytotoxic to deserve the name.
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RNA asMessenger (mRNA)
The most familiar role of RNA is that of messenger RNA (mRNA), which makes up ~5% of cel-
lular RNA Table 1.1. Messenger RNA is responsible for carrying genetic information (canonically,
the primary sequence of proteins) between the DNA in the nucleus which stores this information
and the ribosomes in the cytoplasm which express it. Even if this were the only variable class of
RNA, mRNA would still be a tempting therapeutic target. The genome is more “parts list” than
“blueprint”, and is identical among all cells in an organism. A human kidney cell and a human
brain cell accomplish very different tasks, but the fundamental genetic difference between them
is not the information that resides within the nucleus (this is identical), but the information that
gets sent out.
Messenger RNA is transcribed from the DNA genome. While ~75% of the DNA genome is
transcribed into RNA, but only about 2% directly codes for protein. Initial transcripts are known
as pre-mRNA [24], and the protein and RNA mediated process known as “splicing” occurs before
the eventual mRNA is exported from the nucleus to the cytoplasm. Indeed, without this splicing
process, it would not be ribosome-readable. Mis-splicing causes many diseases and disorders,
notably certain Muscular Dystrophies (caused by expanded (CUG) repeats), as well as neuron
disorders [29]. Specifically targeting such RNAs is an active area of research [29, 30].
1.5.2 RNA Interference (RNAi)
RNAi is the general term for an extensive set of pathways which regulate cellular RNA levels.
The study of these pathways, and the RNAs and proteins associated with them, is a field of science
in and of itself. Briefly, there are two types of RNAi: microRNA (miRNA) and small interfering
RNA (siRNA). Figure 1.3 summarizes the pathways these RNAs participate in.
siRNA
siRNA involves short, single stranded RNAs which are perfectly complementary to an mRNA
target. The dsRNA complex formed by the siRNA and the target mRNA activates the protein
















































Figure 1.3: Overview of RNA Interference Pathways This figure illustrates the pathways that siRNA and
miRNA utilize to regulate gene expression. Though they have different results, both work, generally
speaking, through their interaction with the RNA binding protein/nuclease Argonaute. Adapted from [31]
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one held in the RISC complex. This is presumably a remnant cellular immune system against
dsRNA, since the most reliable source of dsRNA is an infecting virus.
Though the siRNA knockdown pathway is not as robust in mammals as the analogous path-
way in plants, when it does work, the mechanism of action is catalytic, leading to the targeted
mRNA not being translated [31].
miRNA
miRNA uses much of the same machinery, but importantly, they are not perfectly comple-
mentary to their targets. They adopt a common conformation involving stretches of complemen-
tarity followed by stretches of mismatched “internal loops” (see Section 1.8.2 for a discussion of
RNA structural elements). Transcribed miRNAs are not functional, and need processing (shown
in Figure 1.3) in order to become active. The active form of an miRNAs is a double stranded
stem-loop, and the RNA loaded onto the Argonaute protein which facilitates miRNA regulation
is single-stranded. In general, miRNAs have a distinct stem-loop-bulge shape, and a two nu-
cleotide overhang on their 3′ end. A general survey of miRNAs, covering their processing from
the transcribed pri-miRNA into functional miRNAs can be seen in Figure 1.4.
These RNAs are involved in regulation, rather than the binary knockdown of the vestigial
siRNA cellular immune systems, and are enmeshed into the cellular network, with 92% of cellu-
lar RNA binding proteins likely involved in miRNA binding [33].
miRNAs are a perfect example of the types of RNAs this thesis hopes to outline general strate-
gies for targeting. They are functional based on both sequence and three-dimensional structure,
and many are disease-relevant. For instance, miR-21 is responsible for the regulation of many tu-
mor supressor genes, and its upregulation is associated with many cancers [34]. They are struc-
tured, but not distinct enough to be individually targeted by their structure alone. In short, they











Figure 1.4: micro-RNA Processing Overview The processing steps required between transcription of a





Conceptually similar is the famous CRISPR-Cas system, which evolved to enable a prokary-
ote to store the sequences of viral RNAs into permanent DNA storage is shown in Figure 1.5. The
more groundbreaking application has been the adaptation of this bacterial immune response
system to write arbitrary sequences into DNA storage, and is now most associated with genome
editing. Though genome editing is, of course, a DNA modification, it is worth noting that the
mechanism of action is predicated upon the Cas9 nuclease binding a guide RNA. These RNAs
are frequently engineered to be able to bind effector proteins such as fusions to the MS2-coat
protein [35]. This use of RNA modifications to CRISPR gRNA is llustrated in Figure 1.5. See Sec-




Figure 1.5: CRISPR-Cas9withRNAModificationsThis figure illustrates the CRISPR-Cas9 system, which
utilizes a guide RNA (gRNA) as a means of providing a template for editing the genome, and also illustrates
a method of manipulating the CRISPR-Cas9 system with a well-understood Protein–RNA interaction—
the MS2-MS2 Binding protein pair. Novel synthetic RNA/Protein binding partners would enable further
modifications. Adapted from [35]
1.5.4 Viral RNAs
Viruses, minimal as they are, frequently use RNA in a functional manner, and essentially all
functional RNAs from viruses that infect human cells can be considered disease-relevant.
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Though this thesis focuses nearly exclusively on the HIV TAR element, two additional ex-




Figure 1.6: Two Examples of Functional Viral RNAs A. The poliovirus Internal Ribosome Entry Site
(IRES) Element is required for bypassing the ribosomal requirement for 5′ caps, so the poliovirus ORF
can be translated. The structured cloverleaf and Vpg elements (which do not code for protein) make up
fully ~5% of the poliovirus genome. Adapted from [36]. B The HIV I Frameshift Element allows the
simultaneous transcription of two overlapping, but frameshifted, open reading frames (Gag and Pol) into
a single polypeptide. Remarkably the ratio of Gag to combined Gag-Pol transcription is conserved across
retroviruses [37]. Adapted from [38]
1.6 HIV I TAR RNA
The specific viral RNA target this thesis is most concerned with is the trans-activation response
element of HIV I (TAR). The TAR region of HIV canonically occupies the first 45 nucleotides of
the ~9000 nucleotide HIV I mRNA genome, and is part of the 5′ Untranslated region (5′ UTR)
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[39]. TAR plays two important roles in HIV replication (Figure 1.22) which will be discussed in
detail shortly, but important to note is that the key facilitator of both roles is a small, structured
RNA element occupying positions 17–43 on the HIV genome.
1.6.1 TAR Induces a Transcription Cascade
The first, and most important role TAR plays in the HIV life-cycle, is that of a pseudo-
promoter facilitating the replication of HIV mRNA, which in the case of HIV is both template
for protein production and packaged genome in the virion. Leaky transcription of the HIV I
DNA genome leads to the mRNA transcript of the 5′ UTR of HIV, which base-pairs with the
DNA genome. The trans-activator of transcription (Tat) protein from HIV I [40–42], binds the
TAR element on the mRNA and recruits the elements from the host cell necessary to transcribe
the genome into mRNA with a positive feedback loop [43, 44]. This transcription cascade marks
the shift from latent to active HIV infection (illustrated in Figure 1.7).
1.6.2 TAR as pre-miRNA
The second key feature of the TAR element is its ability to act as an anti-apoptotic miRNA,
keeping the host T-cell “alive” and manufacturing HIV virions [46–48]. The entire canonical
TAR element, as well as a further ~10 nucleotides, are a pre-miRNA, while the mature miRNA is
derived from the base-paired region (with mismatches) immediately before and after the struc-
tured TAR element (see Figure 1.4 and Figure 1.3 for further details). The TAR element can be
seen in the context of the HIV I genome in Figure 1.8.
A key point to note about the two roles of TAR (which are necessary for successful HIV I pro-
liferation), is that they are likely less susceptible to mutational evasion as other HIV I targets,
such as reverse transcriptase [49–51]. This is due to the fact that, in theory, any mutation which
allowed TAR to evade a therapeutic would also require a compensatory mutant to the Tat gene
so Tat/TAR-dependent transcription would occur, or would require any mutation to leave the

















Figure 1.7: Tat–TAR Induced Transcription Cascade The viral transactivation response (TAR) element
RNA comprises lower (S1a) and upper (S1b) stems. The positive transcription elongation factor b (p-TEFb)
comprising cyclin T1 (green) and CDK9 (red) is recruited to TAR by the HIV-1 protein Tat (purple), which
binds the central RNA bulge allowing cyclin T1 to interact with the apical loop. The bound complex stim-
ulates host RNA polymerase II (yellow) by phosphorylation to produce full-length viral transcripts from








































Figure 1.8: TheHIV I TARElement in the Context of theHIVGenomeThe ~5000 bases on the 5′ end of
the HIV I genome, and the secondary structure of same, can be seen inA, with the TAR element indicated
by a box. B shows the regions of the TAR element which engage in the two main functions of TAR: Tat
recruitment and miRNA activity.
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1.6.3 Relevance of TAR RNA
HIV afflicts over 36 million people worldwide, and no cure (or vaccine) yet exists. Current
treatments are effective, but evolving resistance is always a concern, especially since there are
only four current drug targets (entry, reverse transcriptase, integrase, and protease) [52, 53].
For reasons outlined above, much effort has gone into generating binders of TAR RNA. These
efforts have resulted in TAR-binding molecules ranging in size from small molecules to cyclic
peptides [54–58]. These efforts have had various degrees of success, but none has resulted in a
useful therapeutic.
1.7 Basis of Nucleic Acid Behavior
Since the importance of generating specific binders for arbitrary DNAs and RNAs should be
clear, as should the worth of a binder for the HIV I TAR element, let’s look at the challenges
associated with the goal of targeting an RNA.
As a general statement, the first step to targeting anything is understanding how the target
behaves. To understand an RNA target, let’s consider what a typical DNA or RNA macromolecule
is built from and the general properties of a DNA or RNA macromolecule. while using the former
to understand the latter. Finally, we will examine how these emergent properties inform the
challenge of creating a binder for an arbitrary polynucleic acid vs. accomplishing the same for a
protein of similar size.
1.7.1 Nucleotides
The nucleotide is the monomeric building block of an extended DNA or RNA molecule. A
fundamental difference in engineering a protein binder for a nucleic acid vs. another protein
emerges from the differences between their monomers: nucleotides and amino acids respec-
tively. Proteinaceous amino acids account for 20 different side-chains with fairly diverse chemi-
cal functionality including carboxylic acids, primary amines, amides, guanidino, thiol, thioether,
as well as various degrees of hydrophobicity. There are, however, only five canonical nucle-
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obases, and only four can occupy a given position on a DNA or RNA polymer. In addition to
the limited number of possibilities at each position, these nucleobases are limited in chemical
diversity (and are of similar hydrophobicity). All nucleobases can be reductively described as
small, minimally modified heterocycles, with either purine or pyrimidine as the foundational











Figure 1.9: Polynucleotide (RNA) vs. DNA vs. Polypeptide) vs. Polypeptide A polynucleotide is made
up of nucleotides while a polypeptide is made up of amino acids. The key differences between the two
classes of nucleotide are the substitution of thymine for uracil as a nucleobase in DNA and the lack of
a hydroxy group on the 2′ carbon in the backbone sugar of DNA (deoxyribose vs. ribose). The primary
implications of a nucleotide monomer vs. an amino acid monomer are the minimal chemical diversity
of the nucleotides vs. the proteinogenic amino acids, and the largely exposed backbone of a polynucleic
acid vs. the internalized backbone of a polypeptide.
These nucleobases are connected to a cyclic pentose, with the glycosidic bond attached to
carbon 1 on the pentose. RNA (ribonucleic acid) nucleotides have ribose as the backbone pen-
tose, while DNA (deoxyribonucleic acid) has deoxyribose, which lacks a hydroxy group on the 2′
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carbon. This small difference leads to drastically different chemical properties, and affects the
way that RNA and DNA interact with the cellular environment and pathways.
The pentose is attached to a phosphate group through the 5′ oxygen. Since these backbone
elements are identical on any given DNA or RNA they cannot be used to target a specific DNA or
RNA. The nucleobase, sugar, and phosphate together are referred to as a nucleotide (or deoxynu-
cleotide) monophosphate in this form. Importantly, at physiological conditions, the phosphate
groups carries a negative charge in both the monomer form and as part of a polymer. This fact
is critically important to the emergent properties of a polynucleic acid chain.
Since the sugar and phosphate groups are identical scaffolding connecting the different DNA
or RNA bases, they are usually referred together as the sugar/phosphate backbone. Worth noting
is that nucleotide monomers with different numbers of phosphate groups (especially adenine
mono- di- and triphosphate) are also important signaling molecules, energy sources for reac-
tion catalysis, and enzyme co-factors within a cell in addition to their role as building blocks of
complicated polynucleic acids. Therefore, anything which targets an individual nucleotide too
specifically will wreak havoc with almost all cellular processes.
1.7.2 Nucleic acid as a Polymer String
Though the nucleotide monomers are important, DNA and RNA functionality is predi-
cated upon the polymerization of these nucleotides. This polymerization occurs strictly on the
sugar/phosphate backbone, with a phosphate forming a bridge between the 5′ -OH group on one
nucleotide and the 3′ -OH group on the next, in what is referred to as a phosphodiester linkage.
Nucleic acid sequences are conventionally written in the 5′→3′ direction, since this is both the
direction in which they are synthesized by a polymerase, and read by the ribosome [7].
Importantly, if one draws a line through one end of the glycosidic bond, the variable nucle-
obases will all be on the one side of the line, and the sugar/phosphate backbone will be on the
other (as can be seen in Figure 1.9). In contrast, if one draws a line down the peptide backbone
of a protein the functional side chains of the amino acids will be found on either side of the
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backbone. Thus the non-variable backbone of a polynucleic acid cordons off the variable bases,
while in a polypeptide the variable side chains cordon off the non-variable backbone.
This is a gross oversimplification of the actual three-dimensional, structured, reality of both
macromolecule classes, but it is a valuable approximation to build on as we move to the next
model.
1.7.3 Nucleic Acid as Ribbon
Given the nature of a polynucleic acid as segregated anionic and hydrophobic surfaces, a
single-stranded polynucleic acid can be roughly understood as a two-surfaced chemical ribbon
with the same essential properties from end to end, but with drastically different properties on
either side (illustrated roughly in Figure 1.10).
One side of this two-sided ribbon is the sugar phosphate backbone (Figure 1.10A); the salient
characteristic of this side of the ribbon are the regular and identical phosphate groups which
give it a uniform negative charge. Due to this negative charge, a polynucleic acid will have gen-
eral affinity for cations and cationic moieties (notably the side-chains of Lys and Arg residues in
proteins) will have fairly strong non-specific interactions with a DNA or RNA chain.
The other side of the ribbon can be approximated as a regular series of aromatic loops with
the π-systems perpendicular to each other. The variations in this pattern are minor, since any
chemical diversity emerges from a limited set of chemically similar nucleobases. The salient
characteristics of this side of the ribbon is its hydrophobic character (and therefore its tendency
to be buried while in aqueous solution), and the ability of external aromatic π-systems (such as
those found on the side-chains of Tyr, Trp, and Phe) to participate in π-π interactions with the
nucleotides on this chain Figure 1.10B.
Both sides of the ribbon, of course, participate in hydrogen bonding interactions, but the
backbone side has repeating, identical units of sugar hydroxy groups, while the nucleobase sur-
face has heteroatoms on the purine and pyrmidine rings which participate in hydrogen bond-
ing interaction. It is only on this side of the ribbon that there is any variability in the hydrogen
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Figure 1.10: Polynucleotide as a Two-Sided Chemical Ribbon Considering a polynucleic acid as a two-
sided ribbon is an enlightening mental model. The key point of this model is that each surface has dif-
ferent overwhelming tendencies. The nucleobase surface tends toward interaction with hydrophobic ar-
eas, while the backbone side tends toward interaction with cations. A secondary, related, point is that
hybridization tends to bury the nucleobase surface, meaning that the majority of exposed surface in a
double-stranded DNA or RNA is the charged, hydrophobic, constant backbone side of the ribbon.
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bonding pattern. Indeed, minor variations in hydrogen bond and space-filling pattern are the
only chemical difference between polynucleic acids of different sequence.
Considering a nucleic acid in this manner further clarifies the challenge of targeting a
polynucleic acid vs. targeting a protein of similar size. When a nucleic acid hybridizes in this
model, it does so by two nucleobase surfaces coming together, therefore the nucleobase surface
(which is, after all, where specific recognition usually occurs) will expose relatively less surface,
and the more exposed anionic backbone forms a wall around it.
In contrast, while the peptide backbone is obviously the wellspring of many properties of
proteins, it does need not usually need to be considered when targeting a specific protein to
the degree that the negatively charged backbone of a nucleic acid does. Any specific binder of
an RNA walks a tightrope of anionic interaction. Such a binder needs to either interact with or
tolerate the drastic chemical property of a persistent and constant negative charge, but it can’t
interact too strongly with this charge or it will bind all nucleic acids rather than a specific nucleic
acid.
1.7.4 Nucleic Acid Base-Pairing
This “ribbon” model of a nucleic acid also informs an essential emergent chemical prop-
erty of nucleic acids which is the basis for nearly all of the three-dimensional structure of these
molecules—the antiparallel binding of two strands of nucleic acid with complementary se-
quences. On a conceptual level, this can be approximated by thinking of the hydrophobic sides
of two nucleic “ribbons” coming together, burying the hydrophobic bases and exposing the hy-
drophilic sugar-phosphate backbone.
In the nucleotide level view of a double-stranded chain, each nucleobase participates in spe-
cific hydrogen-bonding interactions with a partner nucleobase with the opposite heterocycle
foundation, this is known as “Watson-Crick” base pairing (the two hydrogen-bond mediated A·T
pair, and the three hydrogen-bond mediated G·C pair). There are also alternative base pairings,
such as the “wobble” and “Hoogsteen” base-pairings. These are less favorable than standard
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Watson-Crick base, but can still stabilize the structure of polynucleic acids. The different types
of base pairing are illustrated in Figure 1.11.
Watson-Crick Base Pairing
Wobble Base Pairing Hoogsteen Base Pairing
Adenine – Uracil Guanine – Cytosine
Adenine – UracilGuanine – Uracil
Figure 1.11: Examples of the primarymodes of nucleic acid base pairing The most important base pair-
ing interactions are the Watson-Crick A·T and G·C, but Wobble base pairs can pair non-canonical part-
ners, and Hoogsteen pairs can stabilize alternate conformations (as can be seen in Figure 4.4
The phenomenon of hybridization is often thought of as being drivenby these hydrogen bond
interactions, but it is more accurate to say that it is enabled by them. This becomes clear when
considering the Gibb’s free energy equation (ΔG = ΔH - TΔS). The spatially specific binding of
two massive biopolymer ribbons is most assuredly entropically costly, but so are the ordered,
clathrate-like water formations around the nucleobases of a single-stranded nucleic acid. The
hydrogen bonds between purine and pyrimidine bases allow this ordered water to disperse into
disorder, making the ΔS value of complex formation less negative than it would otherwise be.
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The driving force for hybridization—the ΔH—comes from the hydrophobic effect. When a
nucleic acid is base-paired, it minimizes the surface area exposure of the hydrophobic nucle-
obase side of the ribbon, making the charged backbone the site of the primary interactions.
Though it is, importantly, a more predictable and specific structure formation than protein-
folding, it is driven by the same forces [59].
1.8 Nucleic Acid 3D-Structures
This tendency of a polynucleic acid to base-pair to a complementary strand leads to the for-
mation of complex three-dimensional structures. Unlike the specifics of protein folding—which
remain difficult to predict from a primary sequence—the structure formed by a polynucleic acid
stems from specific and predictable interactions between bases. It is here that the properties and
tendencies of DNA and RNA (at least in a biological context) begin to diverge.
1.8.1 DNA Structure
For DNA, discussion of biologically relevant structure begins with the familiar double-helix.
The double-helix of popular imagination is known as B-DNA. B-DNA is a right-handed double
helix, with constant, uneven spacing between the two helices, creating a major groove (22 Å in
width) and a minor groove (12 Å in width). The helix undergoes a full rotation every ~10.5 base-
pairs. The spatial relationship between bases is repeated constantly with minimal variation [7].
Realistically, this is also where a discussion of the biologically relevant structural variation of
DNA ends. Single-stranded DNA (ssDNA) is certainly a chemical possibility, but is seldom seen in
a cellular context outside of the context of DNA replication. Additionally, other forms of double-
stranded DNA exist, sometimes even in a cellular context, but the proportion of these other forms
can be generously described as “trace” [60]. Ultimately, this lack of structural variation makes
targeting biologically relevant DNA a simpler, more systematic exercise than targeting complex
and amorphous structured RNAs [61]. Though simpler than targeting RNA, the considerations
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involved in targeting DNA inform the challenge of targeting structured RNA, and as such one
such systematic solution will be described at length in Section 1.13 on page 36.
1.8.2 RNA Structure
RNA, in contrast, demonstrates a more expansive palette of structural variation within the
cell. Double-stranded RNA is important to a cell, but unless a cell is infected with a Baltimore
Class III viruses with a dsRNA genome, extensive swaths of dsRNA are not of particular concern.
Longer strands of RNA in a cellular environment are all-but entirely single-stranded mRNA or
essential and conserved tRNAs or rRNA (Table 1.1). And while three-dimensional structural el-
ements are vital in the functional RNAs (such as miRNA or viral RNAs) discussed in Section 1.5,
these structured regions are non-extensive enough that they are best thought of as elements. Prac-
tically, this means that even though a given structured RNA may be locally similar to a B-DNA
double helix, these areas are generally small enough to bend and breathe in a way that chro-
mosomal DNA does not, and structured RNA molecules cannot be assumed to have the same
absolute spatial regularity as a B-DNA helix.
The basic types of RNA structural elements are discussed here and illustrated in Figure 1.12.
Stem-Loops
Stem loops are the fundamental secondary structural element in an RNA. A stem-loop oc-
curs when a series of RNA bases is able to form Watson-Crick base-pairs with a complementary
sequence of RNA on the same strand, which is nearby but not contiguous. The paired bases
form the stem, while the bases between form a loop. Generally speaking, the loop is between
4–8 bases, though this is sometimes as many as 10 bases (as in U1hpII, an important RNA for this
work [62]). A loop at the end of a strand of paired RNA is also called a hairpin loop. A related







Figure 1.12: RNA Secondary Structure Overview Watson-Crick base-pairing results in a variety of loop-
based secondary structure, examples of which are shown here. Important to note is that the base-paired
stem regions are largely helical, while the structure elements represent a departure from helicity. Adapted
from [63]
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Bulges and Internal Loops
1–3 mismatched base pairs on one side of a stem form a bulge, which has the primary effect
of twisting and changing the direction of the stem. This feature is a hallmark of TAR RNA (Sec-
tion 1.6). Internal loops are similar, but have concurrent mismatches on both strands, which has
the effect of distorting the double-helix without altering the direction of its axis. Internal loops
are commonly associated with miRNAs (Section 1.5.2).
Pseudoknot
Pseudoknots are a sort of secondary/tertiary structure hybrid that occurs when two comple-
mentary strands of RNA come near to each other spatially, while being discontinuous (in pri-
mary sequence) to other nearby base-paired RNA. This is not a smooth, continuous base pair-
ing, but instead similar to a break on the groove of a vinyl record causing the needle to change
grooves abruptly.
Higher Order Structural Elements
Nucleic acids form a handful of specialized higher-order structure. One example is the G-
Quadraplex, which is formed by a combination of Hoogsteen pairing of a guanine tetrad. These
tetrads can stack via π-π interactions to form G-Quadraplexes. These structures are most com-
monly found in DNA toward the end of chromosomes as part of the telomere [64], but they
do occur in RNA as well. The most notable example of a functional quadraplex occurs in the
“Spinach” class of fluorescent RNAs, which utilizes a G-Quadraplex in their small-molecule
binding region [65].
Another example of a higher order structure in RNA is a helical stacking (or coaxial stacking)
interface. These interfaces are most common in tRNAs and self-splicing introns, and form when
two helices wrap around each other. The mechanism is most similar to the splicing of woven
rope. These interactions are stabilized by π-stacking interactions between the bases on each
helix.
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1.8.3 RNA Tertiary Structure
RNA does have meaningful spatial tertiary structure, but generally speaking, an extended
structured RNA (like the HIV-1 genome Figure 1.8) is well-defined by the structural elements
within. This is to say that adding or removing a stem-loop in one position is unlikely to have
an effect on a separate stem-loop. Even when the three-dimensional shape is important, it is
well-approximated and understood from examining the base-pairing interactions discussed al-
ready in this section.
To review the general effects of the common structural elements: generally speaking, the
stem of a stem loop structure is a double-helix with a major and minor groove—similar to a
B-DNA double helix. Unlike B-DNA, however, mismatches of 1–3 bases are common. These
mismatches, as already discussed, warp the helix and change its direction. Mismatches with
equal numbers of bases on either side (the internal loops shown in Figure 1.12) tend to warp
the helix without drastically altering the direction of the screw-axis through the center, while
bulges tend to alter the direction of this central axis. Both distort the general structural features
of RNA, and provide a unique shape to each structured RNA. It is important these distortions
are important for function (as with ribozymes or riboswitches) [23, 66], or recognition (as with
regular bulges on miRNAs) [31].
This variability in structure is the fundamental difference in targeting biologically relevant
DNA vs RNA. A profile and top view of dsDNA and various RNAs (including TAR) can be seen
in Figure 1.13. Notable are the differences in the types of distortions due to mismatch (i.e. stem
loops vs. bulges).
1.8.4 Structure Conclusion
Ultimately, the various structural elements of RNA are somewhat numerous, but they are
ultimately more predictable and finite than their protein-based brethren. This makes the chal-
lenge of targeting them both more and less difficult. The added difficulty derives from the lack
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Figure 1.13: DNA vs. RNA Tertiary Structure Comparison A top down and profile view of dsDNA (PDB:
3OMJ), TAR (PDB: 6cmn), lin-41 miRNA (PDB: 2JXV), and U1hpII (PDB: 1URN), with secondary structure
diagrams for the RNAs. This demonstrates the consequences of the propensity of RNA to have mismatches
in base-paired structures. While biologically relevant DNAs tend to be extremely regular helices, biolog-
ically relevant RNAs do not.
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feature of RNA also makes targeting an RNA less difficult in other ways, due to the increased pre-
dictability, and modularity of RNA structure. Once a solution to binding a general class (such
as dsDNA and ssRNA) of nucleic acid has been discovered, and the dictates of that interaction
understood, they tend too be more effective and adaptable in binding targets across that class
(see Section 1.12 and Section 1.14 for examples). Hopefully, this modularity will extend in some
form to structured RNAs.
Ultimately, although they do have some globularity, extended RNAs are usually considered
sequences of structural elements—like beads on a string—rather than an inseparable structural
whole, as a folded protein is. A demonstration of this idea can be seen in a representation of the
HIV-1 genome, which is traditionally shown as a series of isolated elements, shown in Figure 1.8A.
1.9 Nucleic Acid as Sequence
Finally, an important point that is irrelevant when discussing the chemical abstract proper-
ties of nucleic acid, but sprang from the elucidation of the structure of DNA: the most important
emergent property of polynucleic acids is frequently information.
The primary challenge implied by this fact is the difficulty of separating structure and func-
tion. When trying to affect a protein, high-order structure and function are intrinsically tied;
an ATP binding protein has an ATP binding pocket, or it wouldn’t be an ATP binding protein.
But the DNA which codes for the oncogene Myc and the DNA coding for anti-oncogene p53
have identical structures. Likewise, the mRNAs coding for them are identical from a chemi-
cal/structural point of view aside from minor variations in spatial positioning of hydrogen bond
donors and acceptors. Despite their chemical similarity, these two mRNAs lead to opposite ef-
fects in a cell, and this divergence ultimately emerges from the information the mRNAs contain,
rather than any intrinsic feature of the mRNAs themselves.
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1.10 Dictates of Binding Nucleic Acids
Disease relevant RNAs are either a minuscule proportion of the mRNA-ome or one of the
“funtional” RNAs shown in Table 1.1, and both of these classes represent a minuscule portion of
the total RNA, which is dominated by rRNA and tRNA. Any “therapeutic” that non-selectively
affects the wrong mRNA or rRNA is likely to be toxic, rather than therapeutic.
Ultimately, any specific, high-affinity RNA binder must accomplish three primary goals:
• First: an RNA-binding molecule needs to needs to embrace the broad chemical character-
istics of an RNA strand in order to generate affinity. It is hard to imagine an RNA-binder
without cationic moieties to interact with the negative charge of the RNA backbone, and/or
aromatic moieties to participate in π-stacking interactions with an RNA base.
• Second: it must either accommodate the structure of the RNA molecule, or guide the RNA
molecule into such an accommodating conformation.
• Third: It must make specific interactions to generate selectivity. In practice, this means
forming spatially defined, base-dependent interactions (generally hydrogen-bonding, but
sometimes steric). Binding specificity based solely on molecule shape, without contact
with a nucleobase, seems unlikely.
1.10.1 Small Molecules
Traditional small-molecules (<500 Daltons) have the advantages of cell-permeability, but en-
gineering selectivity in such a molecule is a struggle. This is even more true with nucleic acids
than it is with proteins due to the extremely limited chemical variation of nucleic acids, the
greater dynamism in the structures, and the general lack of hyrophobic binding pockets.
Certain small molecules do bind nucleic acids well. Peter Dervan’s lab has designed a small,
modular scaffold for binding DNA with pyrrole-imidazole polyamides (see Figure 1.14 and 1.13.6
for further discussion) [67]. The problem of binding dynamic RNA structural ensembles has been
addressed computationally by Hashim Al-Hashimi’s lab [54,68–70], and some random guy in Ben
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Miller’s lab was able to combinatorially synthesize and screen a library of small molecules to find
a binder to the HIV-1 frameshift element [71] using a high-throughput library of aminoglycosides.
The polyamide scaffold from the Dervan lab is shown in Figure 1.14, and generally works by
fitting into the minor groove of DNA. Such a solution is not likely to be applicable to a structured
RNA, since this binding mechanism relies on the fact that B-DNA has such low structural vari-
ation. A small molecule can be built to bind one structure to bind DNA, while a binder for an
RNA needs to accommodate (and stabilize) multiple structures.
A B
Figure 1.14: Polyamide Scaffold for Binding DNA The general code for the modular dsDNA bind-
ing polyamides developed in the Dervan Lab is shown in A. Pyrrole/imidazole for C·G pairs, pyr-
role/hydroxypyrrole for A·T pairs, hydroxypyrrole/pyrrole for T·A pairs, and imidazole/pyrrole for C·G
pairs. B shows that that these polyamides bind dsDNA by fitting into the minor groove of double-stranded
B-DNA.
1.10.2 Nucleic Acids
Sequence complementary nucleic acid is obviously good for targeting RNAs and reducing
their expression (see Section 1.3), but this strategy is not suitable for all cases. For instance, cat-
alytic siRNA behaving will eliminate translation, while it may be more desirable to reduce trans-
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lation. Furthermore, nucleic acids are more prone to degradation in cellular, serological, and
therapeutic settings.
1.10.3 Proteins
Proteins are the most natural class of molecules to utilize to accomplish the goals outlined
in Section 1.10, since they have a varied chemical and structural toolkit which is naturally com-
patible for interfacing with nucleic acids. Proteins have the ability to form specific shapes in a
variety of sizes, and can bind all scales of structural elements (such as loops, faces, and pock-
ets). This follows, since if we assume the veracity of the RNA World Hypothesis (Section 1.4.1),
the fundamental reason they exist as a class of molecules is due to their ability to associate with
RNA.
Furthermore, proteins exist on approximately the same size scale as DNAs or RNAs on a poly-
mer andmonomer scale. Therefore the combinatorial modules on the protein (residues) are able
to interact with the nucleic acid combinatorial modules at approximately a 1:1 ratio. Proteins are
also exquisitely functionally modular—proteins with multiple different functions can be com-
bined into a single genetic unit—for instance the combination of DNA recognition and editing
in the TALEN domains discussed in Section 1.13. Proteins also have greater potential to attenuate
RNA-related events [72], rather than act in a binary fashion, as an siRNA might do.
Proteins are fairly easy to synthesize recombinantly in E. coli, and more importantly, pro-
tein function (such as RNA binding) is generally easy to screen/select for in an extremely high-
throughput manner, as we do in Chapter 2. An important pre-requisite and enabler of this high-
throughput screening is the broad availability of existing natural RNA binding proteins which
can be used as scaffolds for binding specific RNAs.
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1.11 Thesis Goal
1.11.1 Develop a Protein-Based Binder for TAR RNA
The goal of the work outlined in this thesis was two-fold. The first, concrete goal was to
develop a protein which bound the TAR element from HIV-1 with good affinity and selectivity.
The creation of such a protein is inherently useful as a research tool, and may also be a potential
source of pharmaceutical therapeutics.
1.11.2 Advance Understanding of Protein–RNA Binding
The second, more abstract, goal was to advance the knowledge of the dictates interactions
between RNA-binding proteins and the RNAs they bind. Determining success in this goal will
ultimately be determined by the passage of time, but the hope was that we would leave informa-
tion that can inform and inspire others to new goals and possibilities, just as the current body of
functional and structural knowledge informed the work in this thesis.
Before moving ahead to my own research, I’d like take a look back at some case-studies which
informed it, in which modular binders for entire classes of nucleic acid binding proteins were
developed.
1.12 Development of a Modular Binder for dsDNA
1.12.1 Modular DNA Binding Proteins
Given its permanence and clear importance, DNA has been studied and targeted for many
years. The benefits of being able to selectively target and effect DNA are obvious—if a gene is
defective or detrimental, being able to alter the sequence which codes for that gene will allow a
normal and healthy life for the cell. Additionally, if a problem can be solved by targeting DNA,
then doing so is a fundamentally easier problem, for the simple reason that any DNA edit only
has to occur a single time on each DNA sequence in a cell to result in permanent change.
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As such, a variety of strategies for targeting DNA have emerged which are instructive for the
problem of targeting RNA. All have emerged from the repurposing of well-characterized natural
proteins.
Zinc Fingers
One example of a natural class of RNA binding protein is the Zinc Finger domain (ZF). ZFs are
a broad class of nucleic acid binding proteins found in Nature, and are somewhat engineerable.
They are modular, but the best known classes bind triplets rather than nucleotides. They have
been used functionally [73, 74], but the triplet requirement does makes them harder to utilize,
since there are 64 possible DNA triplets, and not all have an associated zinc finger [75]. They
have been largely superseded by the more modular TAL domains and CRISPR/Cas9 [20, 76].
Leucine Zipper
Leucine zippers (more specifically the helix-loop-helix motif on a single member of a leucine
zipper dimer) are usable functionally, but are only somewhat specific in their original forms.
This class of proteins has a pattern of basic residues which participate in non-specific interac-
tion at the phosphate backbone interface, and more variable helical regions interact with the
major groove/Hoogsteen edge of the nucleobases. Similar to the zinc fingers, leucine zippers
are engineerable, but are not sufficiently amenable to engineering to have become widely uti-
lized [75].
1.13 TALENs
Likely the most well-used genome editing construction prior to the advent of CRISPR/Cas9
was the Transcription Activator-Like Effector Nuclease (TALEN). A TALEN is able to specifi-
cally target regions of double-stranded DNA for editing by utilizing two proteins fused into a
single unit. One part is a general DNA cleavage domain—a non-specific DNA nuclease—and
the other is a DNA binding protein which binds specific sequences. It is this second domain,
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the Transcription Activator-Like Effector (TALE or TAL), whose tale is most applicable to the
problem at hand.
1.13.1 TAL Domain Natural Origin
The TAL domain is derived from Xanthamonas bacteria. Xanthamonas bacteria infect plants,
and have evolved the ability to activate plant genes by contacting the promoter regions for these
genes. Xanthamonas use TAL proteins, which activate specific plant genes that assist the bacte-
rial infection of the organism, and only those genes. It was this specificity that intrigued plant
biologists, and upon recognized a nuclear localization sequence in the functioning proteins, de-
termined that these proteins were likely operating within the nucleus, presumably upon specific
DNA sequences.
1.13.2 TAL Informatics
Even without knowledge of the secondary or tertiary structure of TAL proteins, the primary
sequence indicates the modular nature of TAL bindng. Each TAL domain has 17.5 nearly identi-
cal repeats (typically 34 residues) corresponding neatly to the 18 DNA base length of the class of
promoters they bind. Additionally, the only region on each repeat which demonstrates signifi-
cant variation within or across TAL genes are positions 12 and 13. These two positions together are
known as the Repeat Variable Diresidue (RVD) or, synonymously, the Highly Variable Region
(HVR). In 2009, two research groups [77, 78] performed a comprehensive survey of TAL effectors
and their target promoters and discovered a simple correlation between the identity of the two
amino acids in the HVR of a given repeat, and the identity of the DNA base at that position in the
promoter. Figure 1.15 shows this simple code. In contrast to Pumilio Repeat Domains (discussed
in Section 1.14), all four base-pair possibilities are represented naturally, and a recognition code
for 5-methyl Cytosine would later be discovered [79].
The implications of the discovery of this simple code were far-reaching. Rather than hav-
ing to target an entire sequence as a whole, a TAL domain is engineerable by simply choosing a
module to match a base, and repeating as needed for the length of the sequence. The discovery
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Figure 1.15: TAL Recognition Code Fitting the sequence of TAL domains to the sequence of the promot-
ers they bind revealed that there was a modular code behind this binding. * corresponds to a wild-card
residue, and can be any amino acid (adapted from [77]
of this code allowed relatively straightforward modular engineering of proteins to bind to any
arbitrary, specific sequence of dsDNA.
1.13.3 Structure of TAL Domain
For proteins, unlike nucleic acids, form and function are largely inseparable. Learning about
one will almost always inform and require knowledge of the other. A TAL protein’s overall
shape is a large, right-handed helical superstructure which traces the major groove of the bound
DNA. This superstructure ensures that each repeat, and specifically each HVR pair, is positioned
against the corresponding base in the sequence.
Each TAL domain begins with an N-terminal region consisting of a modified version of the
canonical repeats, similar in both sequence and structure but containing significantly more pos-
itive charge, as well as a tryptophan residue (analogous to the HVR residues in the variable re-
peats) which participates in a packing interaction with a conserved Thymine base present at the
beginning of all TAL binding regions. This combination of positive charge and hydrophobic
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packing generates a certain amount of non-specific affinity which is built upon, with specificity,
by the following repeats.
Figure 1.16: Structure of a TAL domain (dHax3) bound to dsDNA The superhelical structure of a TAL
domain binds to the major groove, while the RVDs make specific contacts. The RVD/DNA translation
is shown o on the right. This TAL domain contains 11.5 repeats with flanking N- and C-terminal helices
shown in cyan. Two perpendicular views are presented, with the DNA duplex shown in sticks. Adapted
from [80]
The structure of these repeats has evolved to perform the single purpose of aligning the HVR
residues into position to contact their respective bases. Each repeat consists of two left-handed
helices connected by a loop that contains the HVR residues. The bundled helices fit roughly
into the major groove of a B-DNA helix, which positions the HVR domains in contact with the
paired bases perpendicular to their Watson-Crick interactions. The HVRs themselves consist of
one structural residue (generally N for an “A” or “T” contact or H for a “C” or “G” contact) that
lines up the second residue. The second residue participates in either a base-specific contact
(based on hydrogen bonding or steric interactions), an exclusionary “interaction” which results
in specificity by having three of four base possibilities be untenable, or a “wild-card” interaction
in which the HVR can accommodate any base.
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1.13.4 TAL Domain Engineering
The major triumph of TAL domain engineering was in deducing, from the function, se-
quence, and structural features of TAL proteins, that they could represent a modular “code”
for binding arbitrary DNA sequences. The natural code as-is has been quite robust and usable.
Within a year of the publication of the initial code, TAL domains had already been engineered
into the TALN genome-editing tool. This code has also proved amenable to further optimization
for specificity by screening the small library made by the two bases in the HVR.
1.13.5 TAL Domain Lessons
The TAL domain is the most robustly modular of proteins that recognize dsDNA, and the
discovery and engineering provide insights which will prove key for the analogous problem of
engineering RNA binders.
• First: the more directly usable the solutions developed by Nature over billions of years
of evolution, the better. In this instance, a human-usable modularity was possible, even
trivial, since Nature’s solution was already modular.
• Second: form follows function—the shape of a protein and the shape of the nucleic acid it
binds need to rhyme. For a large, broadly featureless molecule like a nucleic acid, spatial
specificity is vital.
• Finally: affinity is best achieved through large-scale interacting with features common to
any nucleic acid strand, while specificity is then derived from smaller-scale interactions.
Just as the non-specific hydrophobic effect drives nucleic acid hybridization, but precise
hydrogen-bonding enables it, so too do protein binders need a driving force to bring about
an interaction and a sop against entropy to make that interaction last.
1.13.6 Binding DNA vs. Binding RNA
Though there are lessons to be learned from engineering binders to DNA there are also
caveats in extending these lessons to RNA binders. These caveats primarily derive from the
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fact that DNA has repeatable, extended, and consistent structure. The best way to illustrate this
paradigm is in the fact that TAL domains are able to bind a single DNA conformation (a B-DNA
double-helix), and in so doing bind DNA. Disease-relevant RNA, by contrast, has multiple con-
formations, which implies an entropic cost to get to the correct conformation for binding.
An extreme example of the simplification that this assumption of consistent structure can
provide is demonstrated by the small-molecule polyamide binders developed by Peter Dervan’s
lab [67] (discussed previously in Section 1.10.1 and shown in Figure 1.14). These minimal small-
molecules based on polyamides bind DNA with a simple modular substitution for each Watson-
Crick pair, since they can be designed to match the consistent and predictable B-DNA double
helix. In essence, a DNA binder can be engineered to match a single structure. It is more difficult
to build such a binder for unstructured RNAs, or disease-relevant structured RNAs, which do
not have a structure, but exist as a dynamic ensemble which must be dynamically matched or
stabilized.
1.14 ssRNA binding
1.14.1 Introduction to ssRNA
Aside from the low entropic cost, a complementary way to consider the amenability of
double-stranded DNA to modularly defined binding proteins is the ease of pattern recognition.
The chemical variability of the bases may be minimal, but at least this minimal variation oc-
curs at predictably in space. Therefore, the binding problem can be reduced to matching one
of four hydrogen bond and/or steric patterns, then expanding that pattern in a constant spatial
interval; this is essentially pseudo base-pairing. For RNA this assumption of regular, exposed,
bases is true in one important class: single stranded RNA (ssRNA). Since ssRNA conforms to
this assumption of regular spacing between bases, it is amenable to being coaxed into a pseudo
base-pairing interaction.
As with TAL domains, the most straightforward way to accomplish these pseudo base pairing
interactions is through repurposing of the solutions that Nature has already achieved. The three
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most broadly studied classes of ssRNA binders are Pumilio/fem-3-binding factor (PUF) (widely
known as Pumilio Repeat Proteins), Pentatricopeptide Repeats, and Zinc Fingers. Of these, PUF
proteins are the most important, since they represent an all-but universal solution to the problem
of binding ssRNA. We will examine why PUF proteins have proven so amenable to engineering
by tracing the route from initial discovery to straightforward tool.
1.15 Pumilio Repeat Proteins
1.15.1 Natural Origins of Pumilio Repeat Proteins
Pumilio was initially known as a factor involved in abdominal patterning in Drosophila em-
bryos [81], with an unknown mechanism. The gene for a Pumilio Repeat domain was first se-
quenced in 1995, and by 1999 it was confidently hypothesized to be involved in transcriptional
regulation by binding mRNA [82]. The general fact that these proteins consisted of eight near-
identical repeats was clear, but the implication that the repeats may correspond to one-to-one
repeat/base binding was not understood until the crystallization of Pumilio proteins from hu-
mans and Drosophila with a cognate RNA [83–85].
1.15.2 Structure of Pumilio repeats
A Pumilio Repeat protein binding a single stranded RNA takes on the shape of a gentle arch,
which can be seen in Figure 1.17A. The RNA meets the underside of this arch with the Watson-
Crick edge of its nitrogenous bases, the bases slightly splayed from the curve. The repeated,
modular, structure is readily apparent, with each repeat spaced perfectly to facilitate contact
with a single RNA base. Canonically, natural PUF proteins consist of 8 nearly perfectly repeated
units, with imperfect repeats on the N and C termini. These terminal repeats are more positively
charged than the canonical repeats, and likely provide general RNA-binding functionality.
Each of the canonical repeats consists of 36 residues in three α-helices and associated loops.
and is identical save for 3 variable positions within a series of five residues contained on a single
alpha helix. This region is sometimes denoted as 12XX5, since the 1st, 2nd, and 5th residues vary
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between repeats (the Xs represent constant positions on each repeat). Each repeat unit consists
of three right-handed α-helices. One helix contacts the RNA at a nearly perpendicular angle to
the RNA backbone, while the other two helices and loop regions act as a structural backbone
and somewhat cationic shell. Before the structure of a PUF protein/RNA interaction was solved,
it was hypothesized (reasonably) that the cationic residues were directly contacting the anionic
RNA.
Instead, the actual interaction reveals a striking similarity to that of double stranded nucleic
acid. The relatively hydrophobic face of the PUF protein contacts the hydrophobic RNA bases,
while the charged residues on the shell face out toward the water. Thus, just as in the interaction
between two complementary nucleic acid strands, the interaction between the protein and RNA
is driven by the hydrophobic effect. A side-effect of this feature is prominent in PUF proteins
with more than the usual 8 repeats. PUF proteins with 16 repeats make a pronounced c-shape
when not bound to an RNA as the hydrophobic face minimizes solvent contact, but upon burying
the hydrophobic face into an RNA, the bound protein/RNA combination once again forms the
gentle arch associated with PUF proteins (see Figure 1.17).
1.15.3 Mechanism of Pumilio Repeat Binding
The binding mechanism in PUF proteins is fairly simple, and our understanding of it has re-
mained largely unchanged since its elucidation. In each repeat, residue 2 in the 12XX5 motif is in-
volved in a non-specific hydrophobic/cationic interaction with the RNA chain. This non-specific
interaction involves Arg, His, Tyr, or very rarely Asn residues. Arginine has a bulky side-chain
that can interact with the hydrophobic RNA bases, and terminates in a positive charge, which
may participate in Hydrogen bonds or draw in the anionic RNA backbone. The less common
asparagine has a similar profile of long side-chain terminating with a hydrogen bond partici-
pant. His or Tyr can both intercolate their aromatic side-chain into the π-system. Whatever the
identity, this residue at position 2 is known as the “stacking residue.”
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The residues in positions 1 and 5 participate in specific interactions with their base. These
interactions are either Hydrogen bonds or steric Van der Waals interaction; for instance, an Asn
in position 5 and a Gln in position 1 participate in a total of three hydrogen bonds with a uracil
base. These residues are analagous to the HVR residues in a TAL domain, and will be referred to
as “binding residues” henceforth. Worth noting is that while not all of the important interactions
between binding residues and RNA are hydrogen bonds, the residues are generally capable of
forming hydrogen bonds. An example of a PUF/RNA interaction can be seen in Figure 1.17.
A B
Figure 1.17: Structure of a Pumilio Repeat Domain A the structure of a Pumilio Domain is an arched
superstructure made up of α-helices which position the variable residues into place to bind the RNA, and
B the code for and illustrations of the variable residues which make specific contacts with RNA bases.
Dashed lines correspond to Hyrdogen Bonds, parentheses to Van der Waals contacts. Adapted from [86]
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1.15.4 Engineering Pumilio Repeats
The first attempt at algorithmically altering the Pumilio scaffold to bind a non-native RNA
was a qualified success [86]. The authors showed that altering the PRD HsPUM1-HD protein
predictably alters the specificity of the RNA sequence it binds. For instance, replacing the two
adenine-specific recognition residues in repeat 3 (Cys and Gln) with the two uracil-specific recog-
nition residues from repeat 2 (Ser and Glu) resulted in a protein which binds a G2U RNA with
~55-fold better KD vs. the wild-type RNA. This same strategy resulted in similar changes in speci-
ficity for G→U, U→G, and A→G point mutant RNAs. This strategy also yielded the important
insight that since the aromatic/cationic contact residues of were interacting with general proper-
ties of RNA, using Tyr, His, Arg, or Asn was to some degree irrelevant to the overall RNA binding
properties. Certain stacking residues would prove to be better than others, but none had a binary
effect on RNA binding.
The qualifications in this success were that the engineered proteins had excellent specificity
for their new cognate RNAs, but still demonstrated a worrisome variation in affinity (~100-fold
difference between the A→G and G→U protein/RNA pairs). But the most important issue to
address was, of course, the lack of an algorithmic repeat which could bind Cytosine.
1.15.5 Cytosine Binder Evolution
The development of a cytosine-binding PUF protein is a textbook example of the targeted use
of high-throughput screening to complement rational design. Though high-throughput screens
are by definition random, these screens must be carefully designed if they are to yield good re-
sults.
The fundamental considerations in designing a high-throughput screen are how much ran-
domness is desirable and whether to confine that randomness to a specific region. If the ran-
domness is to be combined, where it should be confined is of critical importance. In the case of
the highly-modular Pumilio repeat domain, the strategies already used to algorithmically engi-
neer the protein directly suggest how to design a high-throughput screen. The bases on an RNA
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8-mer interact with Pumilio repeats in a spatially defined one-to-one manner independent of po-
sition (that is, the “code” for binding is based on target residue identity, rather than placement).
Since the wild-type PUF protein used as the primary basis for engineering natively binds the
RNA sequence 5′-uguauaua-3′, a variant which binds 5′-ugCauaua-3′would only be different on
the sixth repeat, which means only ~30 residues are now considered. To narrow it further, only 3
of the ~30 residues on the sixth repeat form contacts with the RNA, and only 2 of those residues
are expected to participate in specific interactions. This is the beauty of modularity in protein
engineering—knowledge of the model and mechanism of binding allows a massive combinato-
rial problem to be narrowed down to 2 bases, accounting for a manageable 202 = 400 possible
proteins.
To analyze these variants in a high-throughput manner the authors used a variant of the well-
established Yeast-2-Hybrid (Y2H) assay, which operates by expressing the target of binding and
the possible binder as genetic fusions. In this case, the target and binder are a DNA-binding and a
DNA-activation domain respectively. These fusions are then produced, using cellular machinery,
in the cytoplasm of a yeast cell. If and only if the probed interaction occurs do the DNA-binding
and activation domains come together and enable expression of a colorimetric reporter gene, a
gene necessary for survival of the yeast, or both. In this case, a successful binding event triggers
both a histidine synthesis gene which allows the yeast cell to grow on a deficient plate, and the
commonly used colorimetric LacZ reporter gene.
The challenge of using a yeast hybrid screening method to identify a protein–RNA interac-
tion is that it is impossible generate a yeast-expressible protein–RNA fusion. This is addressed
using a known, sequence specific, protein–RNA binding interaction (derived from MS2 bacterio-
phage) as a link [87]. In this case, the LexA DNA binding domain (which binds a specific DNA se-
quence) was fused to the MS2 bacteriophage coat protein (which binds a specific structured RNA,
here called MS2 RNA). To perform the screen, MS2 RNA was fused to the Cytosine-containing
target RNA (5′-ugCauaua-3′). The LexA-MS2 fusion binds the MS2-target RNA fusion, thus form-
ing a bridge between the activation domain and the target RNA. The PUF protein library was
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fused to a DNA activation domain. Therefore, only if the PUF variant binds the target sequence
(containing Cytosine) will both the DNA-binding and DNA-activation domain be in place to lead
to transcription of a gene required for histidine synthesis, as well as the LacZ gene. The system
is illustrated in Figure 1.18. This use of an RNA adapter in the Y2H assay is commonly known as
a Yeast-3-hybrid (Y3H) assay [88]. The Pumilio Repeat Domain, with two randomized residues
corresponding to binding of position 3, was expressed as a fusion with the Gal-4 Activation do-
main. Yeast which grew on His-deficient plates were analyzed, and striking sequence homology
was found [89, 90].
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Figure 1.18: Yeast-3-Hybrid for Finding Cytosine-Binding Pumilio Repeat The A components and B
assembled Yeast-3-Hybrid system used to screen for, and find, a cytosine binding Pumilio Repeat. Adapted
from [88] using the components in [89].
The final determination was that the best specific binding residues for C-binding Pumilio
repeat are Ser and Arg, with Tyr used as the non-specific contact residue. This motif can be
grafted on to any of the repeats in a PUF protein, modularly enabling cytosine binding. Interest-
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ingly, this determination informed the discovery of possible natural PUF proteins with cytosine
binding repeats [89].
This illustrates the ability of high-throughput screening to fill in the gaps left by Nature. The
fundamental idea of using targeted randomness to build on what Nature has already evolved,
forms the basis of affinity maturation work in Chapter 2.
1.15.6 Pumilio Repeat Domain Utilization Arc
The utilization of Pumilio Repeat Domains traces an interesting arc. First, observation and
engineering lead to a simple idea and dream: a protein scaffold that could be used to generate
a binder to an RNA as easily as designing complementary RNA strand. Knowledge and obser-
vation led to a potential method, and experimentation led to a viable proof of concept. This
proof of concept was elaborated on because it is already viable, and increasing amounts of study
and engineering led to more complexity than might be wished. Eventually the knowledge and
understanding reached a critical mass which enabled the full realization of the simplicity of the
original dream. The “pumby” domain discussed in this section represents the modular PUF pro-
tein developed to the point of ultimate simplicity.
The initial efforts at reprogramming Pumilio Repeat Domains were only somewhat modular,
given the large variation in binding affinity between different reprogrammed PUF proteins [86].
This variation in binding affinity occurs since each repeat on PumHD (the PUF protein engi-
neering basis) and its close analogues binds its base in a slightly different manner. As such the
eventual “code” derived solely from the natural proteins was imperfect, and involved one of four
different different possibilities at each repeat. Figure 1.19 shows this code.
Golden Gate assembly (chosen due to its use in studying TAL repeat domains, since similar
engineering challenges require similar tools) was used to rapidly screen variants of each Pumilio
repeat, and a simple, modular code (shown in Figure 1.19) was discovered [91]. A single bind-
ing residue pair was determined for each nucleotide, and Tyr was discovered to be a universal
non-specific stacking residue. Interestingly, later work focused on structural analysis would de-
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termine that substituting Tyr for the uncommon His and Asn stacking residues improved affinity



























Figure 1.19: Modular “Pumby” Domain Code A An overview of a PUF protein with hydrophilic and hy-
drophobic faces marked. B A detail of a simplified “pumby” domain, here shown with a Uracil binding
repeat, is the ultimate expression of modular PUF protein engineering. AA1 and AA5 participate in base-
specific interaction, while AA2—the “stacking” residue is always Tyr in the pumby system. C shows the
full code for the modular Pumby system from [91], PDB: 1M8Y
The modularity of PUF proteins is not dependent on the strict, canonical model of 8 Pumilio
repeat domains binding an 8-mer RNA. For example, a PUF protein with 16 repeats binds a 16-
mer RNA with approximately the same affinity as a PUF protein with 8 repeats binds an 8-mer
RNA, and exhibits similar tolerance for mismatched bases. This plateau does indicate a limit to
affinity, but does not change the essential advantage of a reasonably broad size range available
for engineering binders to specific sequences of varying lengths.
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1.15.7 Other ssRNA binders
Pentatricopeptides
There are other binders of ssRNA that operate in a modular fashion. The most notable of the
alternatives to PUF proteins are the Pentatrico peptide Repeat proteins (PPRs), which consist of
repeated dual-helical units ~30 residues in length which form a superhelix. PPRs have some
advantages over PUF proteins: they are more numerous in the genome of eukaryotes, meaning
that there are more possible foundations for building an arbitrary binder. Most importantly, the
initial rough code found naturally has a solution for binding to Cytosine, something which PUF
proteins initially lacked. PPRs are also more apparently scalable, given there are natural PPRs
with up to 30 repeats, presumably binding RNA chains 30 bases in length.
However, these advantages don’t outweigh the problems. PPRs have a discernible recognition
“code,” but it is less clear than that of PUF proteins. The tolerance for mismatches at any given
position is unpredictable, and the contribution of each repeat/RNA base interaction varies. The
repeats near the 5′ end of the RNA are more important to binding than those near the 3′ [93].
Probably most importantly, Pentatricopeptides are difficult to study closely due to the lack of a
known crystal structure. This means that the excellent understanding of structural vs. contact
residues of PUF proteins isn’t accessible in pentatricopeptides.
Zinc Fingers
Zinc Fingers (ZFs) have been engineered to bind dsDNA, but of the most familiar “CCHH”
type ZFs some in the TFIIIA family do bind ssRNA.
Ultimately, RNA-binding zinc fingers have the same issues as their DNA-binding brethren,
namely that they tend to bind short motifs, rather than exhibiting truly complete modularity
[75, 94, 95].
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1.16 Structured RNA Binding Proteins
1.16.1 Background
The development of a modular code for PUF proteins to bind ssRNAs is indeed a great
achievement. Combined with the lessons learned from TAL domain engineering, this develop-
ment provided a simple, though daunting, set of consideration for the eventual design of binders
to arbitrary structured RNA.
• First: Modularity is key to usability and development
• Second: Structural and functional knowledge are necessary to discern and inform that
modularity
Pre-existing natural PUF proteins left the problem of modular RNA recognition all-but
solved due to the fact that they are naturally and inherently modular. The primary sequences
alone provided the hint and there were numerous good crystal structures which allowed map-
ping repeat to base. Once these requirements were in place, the engineering required to build a
tool that could be understood and adapted by an RNA biologist was time-consuming, but rela-
tively straightforward.
It is unlikely that there is a single class of protein that can bind any arbitrary structured RNA,
but a “flow-chart” style modularity may be possible. A hypothetical possibility of what form this
might take follows: general attributes such as secondary structure type, such as “stem-loop” could
be matched to a class of RNA binding proteins. Once the initial structure type has been matched,
somewhat more specific attributes like loop size, or bulge locations in the stem, can be matched
to a particular scaffold within that class, and sequence could be matched with individual H-
bonding or packing residues.
As has been noted, the variety of RNA secondary and tertiary structure is daunting, but it is
finite. Furthermore, unlike the seemingly infinite considerations that determine the shape pro-
teins, the mechanisms by which RNA folds into its various structural possibilities are well under-
stood. One possibility implied by this reality is that longer, more extensive RNAs (like the HIV-1
51
5′-UTR) may be targetable by modular combinations of smaller proteins which match the indi-
vidual elements within the extended RNA (proposed in an excellent review by Lunde, Moore,
and Varani [61]). If this is true, the challenge of RNA binding would be all but solved as long
as the modular combinations for the (again, daunting but finite) possibilities of structure and
sequence for every folding variety of RNA ~25 in length were known.
Given this paradigm, the first step to finding a good binder for structured RNA is to pick a
scaffold based on existing binders to structured RNAs. Fortunately, many natural RNA binding
proteins exist to provide insight. Examples of these structured RNA binding proteins include
the Muscle-Blind (MBNL) proteins which bind extended CUG repeats, NOVA domains which
bind stem-loops, and PIWI and Staufen domains which bind double stranded RNA. Examples
of these proteins can be seen in Figure 1.20.
1.16.2 RNA RecognitionMotifs (RRMs)
By far he most common, and most studied class of RNA binding proteins is the RNA Recog-
nition Motifs (RRMs), at least one of which is included in ~2% of the proteins coded by the hu-
man genome [97–99]. They have a compact structure which folds well, and are defined by their
βαββαβ structural elements, with the four β-domains making up a compact structural face. The
RRMs have some general chemical features as well: they are highly positively charged, which
provides some necessary general affinity, and there are conserved aromatic residues on the β-
face that participate in non-specific π-stacking interactions with RNA bases [99].
Unlike the PUF domain, which binds ssRNA exclusively, or something like the Staufen do-
main shown in Figure 1.20, which binds dsRNA exclusivley, RRMs (primarily) bind ssRNAs, but
sometimes bind dsRNAs. The RRMs as a class are structurally well-studied, with over 30 crys-
tal structures in the PDB. A few of these RRM/RNA interactions are shown in Figure 1.21. This
abundance of proteins, and the concomitant abundance of crystal structures means that there










Figure 1.20: Example Classes of RNABinding Proteins Shown in this figure are varieties of RNA binding
proteins. Though these classes are not used in this work, it is worth contemplating the variety of RNA
forms which have existing solutions that may be viable to build upon. For more information see [96]
53
RRMs for RNA means that, for better and for worse, a certain amount of interaction can be ex-
pected for any given RNA.
A B
C D
Figure 1.21: Examples RNARecognitionMotif Proteins Structures of RNA-recognition motifs (RRMs) in
complex with their RNAs. The proteins are shown as ribbons, (red: helices; yellow: sheets; green: loops).
Conserved aromatic residues on protein binding surfaces are highlighted. A Single RRM recognition:
crystal structure of the U1A complexed with U1hpII (PDB: 1URN) and B Solution structure of the RBD of
Fox1 in complex with UGCAUGU (PDB: 2ERR) and C Crystal structure of an AU-rich element recognized
by the HuD protein (PDB entry: 1G2E) and D Crystal structure of the poly(A)-binding protein in complex
with polyadenylate RNA (PDB: 1CVJ). Adapted from [61]
Finally, the benefit of all this knowledge is that any given interaction is well understood. The
downside, so far, has been that these binding interactions are too complex to be engineered well.
A 2013 review article from the Varani Lab summarizes the problem well, and is quoted here:
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“So far, no RNA recognition code has been defined for RRM domains, and no successful
attempt has been made to engineer RNA-binding sequence specificity using RRM. For RRMs
that bind RNA specifically and with high affinity, the extensive and non-contiguous RRM–RNA
interfaces present a challenge in constructing a library of mutant RRMs that is large enough to
cover all the protein residues that potentially contribute to RNA binding. In fact, when the struc-
tures of U1A–RNA complexes were first available, it was found that the RNA–protein interface
more closely resembled protein–protein recognition than DNA–protein recognition [100]. Fur-
thermore, specific base recognition is often achieved through protein backbone interactions, a
feature that limits the range of RNA sequences that may be targeted [61].”
The underlying problem in binding structured RNA is too much complexity with too many
dependencies. If one is to engineer such a protein, one should choose a well-understood one, and
we chose the best-understood of this well-studied class: the N-terminal RRM on the U1 Binding
Protein (U1A). U1A exists on both sides of the structured/unstructured RNA binder divide. Since
U1A’s recognition sequence is for unpaired 5′-AUUGCAC-3′ RNA, it is technically correct to de-
scribe it a ssRNA binding protein, but since this sequence is only recognized in the context of
a stem-loop, it is also accurate to say that U1A recognizes a structured RNA, and is similar to a
dsRNA binding protein.
In any case, U1A this unusual binding mode is to an unusual cognate—the U1phII RNA. The
recognition sequence is in the middle of an unusually long 10-base Hairpin Loop (though a loop
of that size bears no resemblance to a hairpin). And this unusual target is bound with unusual
affinity; the KD of the U1A–U1hpII interaction is ~40 pM, a level of binding associated usually
associated with the likes of biotin and streptavidin [101].
1.16.3 U1A–U1hpII Mechanism of Binding
The general mechanisms of binding for this protein are well understood. The first U1A–
U1hpII co-crystal structure was solved in 1994 [102], and has been well-studied since. A crystal
structure can be seen in Figure 1.21A, with an annotated structure in Figure 2.1. U1A is well stud-
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ied enough that we have a good understanding of the nature of the involvment of every piece of
the protein.
For instance, it is understood, down to the individual residue, the role played by the many
lysines and arginines in a two-step process of general recruitment followed by specific recogni-
tion [103,104]. It is also well-known that the Tyr13 and Phe56 (part of a conserved element known
as the RNP face (a name derived from ribonuclear proteins where the element was first observed),
are vital in complex stability, and that these conserved residues are general rather than specific
binders of RNA. Also well-characterized is the helical region near the C-terminal. This helix is
not a usual part of the canonical RRM fold, and it acts as a sort of mobile clamp which forms a
hydrogen bond network on the RNA opposite the protein [103]. Another well-understood region
which is the β1α1 loop, which plays a role in specific RNA contacts [105].
The most important structural element of U1A is the β2β3 loop, the role of which is well-
understood [106]. The β2β3 loop is unstructured in U1A crystals, and only becomes structured
when co-crystallized with the U1hpII cognate RNA. The β2β3 loop extends into the U1hpII loop,
making up a disproportionate amount of contact between U1A and U1hpII RNA. Shortening the
U1hpII loop abolished binding [106,107], indicating that there was a special relationship between
this unusually high degree of contact between the protein loop and the unusually large RNA
loop.
Perhaps most importantly, both high-throughput and fully rationalized engineering on the
U1A protein had already been accomplished by way of the β2β3 loop. For instance, a high-
throughput screen with randomization of β2β3 loop residues resulted in a U1A variant with im-
proved U1hpII affinity [108].
Rationalized engineering predicated upon size discrimination had also been accomplished
prior to our work. This engineering was based on the fact that U1A does not bind a mutant of
U1hpII missing two bases in its stem-loop. Shortening the β2β3 loop by one base does not restore
binding, but compensating for the two missing RNA bases by deleting two bases at the end of the
β2β3 loop (K50 and M51) restored some degree of affinity [106, 107]. Though unspectacular on its
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own, this simple experiment demonstrates a basic confirmation of understanding: if the system
is perturbed, restoring it is somewhat predictable.
1.16.4 U1A E19S
In the course of trying to engineer novel RNA binders, Brett Blakeley, my eventual mentor,
was able to validate these results from the Laird-Offringa lab, and became interested in the con-
cept of the β2β3 loop as a steric ruler. If a region plays such an extended and fundamental role,
surely there must be further engineering to be done… Simultaneously, active work was begun








Figure 1.22: The HIV I TAR Element A The crystal structure of the bulged stem-loop of HIV I TAR RNA
[45] andBThe sequence and putative secondary structure of isolated TAR RNA targeted in this work. The
lower stem (S1a), upper stem (S1b), and distinctive UCU bulge are labelled. The two G·C pairs below the
dotted line are not part of the TAR element, but rather a clamp to ensure that the small RNA maintained
its hairpin structure.
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To this end, Brett was able to find a single point mutation—changing the glutamic acid on the
hydrogen-bonding β1α1 loop to a serine—which greatly lowered the affinity of U1A for U1hpII,
and in fact made U1A somewhat selectively bind TAR. [105]. The process of finding this (only
slightly) improved binder was quite involved. Brett had had to purify and analyze single mutants.
The fact that he found an improved binder at all demonstrates another important necessity for
success in research—luck. It was decided that finding a truly excellent binder for TAR was go-
ing to require more drastic changes to the protein involving synergistic mutations, which would
require high-throughput screening of a large, randomized library (a process known as affinity
maturation). I joined the project just as this affinity maturation began.
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Chapter 2
Affinity Maturation of U1A E19S for TAR RNA
Binding
2.1 Chapter 2 Introduction
2.1.1 Chapter 2 Summary
U1A is the best studied RNA Recognition Motif, with extensive mapping of region to function.
Previous work in our lab leveraged this extensive knowledge to generate a point mutant (E19S)
with specificity for the TAR RNA element of the 5′ UTR region of the HIV genome. In order
to make an avid and selective binder for this RNA, Brett Blakeley and I used yeast display to
express and screen libraries based on U1A E19S. Our initial library had 5 randomized positions
(46, 48–51) in the β2β3 loop region of the U1A protein (3.2 × 106 possible proteins). After three
rounds of selection, the library was diversified by randomizing either the β1α1 region or the C-
helix region of the protein. The C-Helix library proved the most promising, and was screened for
three more rounds. The sequences were analyzed, and found to have a highly convergent β2β3
loop with the consensus sequence of PRTRTP (R47, unbolded here, was left unchanged from the
original protein). We initially attempted to measure the avidity of our screened library proteins
using techniques already established in our lab (Fluorescence Polarization and Yeast Display),
and though we were unable to firmly quantify the TAR Binding Protein–TAR interactions, it
seemed clear that some of our selected proteins had excellent affinity for TAR.
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2.2 Chapter 2 Attribution
This chapter is adapted from [109].1
Brett Blakeley, of the McNaughton Lab, was primarily responsible for the library design and
screening strategy, with help and input from myself. My role increased roughly chronologically
as I took over the project from Brett.
Brett designed the positive control experiments, and observing preparation of same was my
introduction to yeast display. The initial library design was Brett’s, though I assisted in prepa-
ration and added some microbiological advice and assistance. While Brett had final choice in
screening conditions, I also provided input on these conditions, and I helped prepare library
sorts. I provided input and assistance in the diversification of the library.
Once the library sorting was complete, I learned Fluorescence Polarization from Brett and
performed the assays shown in Figure 2.9. I assisted in the yeast display assays shown in Fig-
ure 2.10A, and independently performed the assays shown in Figure 2.10B. I was responsible for
the sequencing and library analysis shown in Table 2.4.
2.2.1 Chapter 2 Background
The field of Biochemistry revolves around interactions. Life at the cellular level is a massive
cascade of logic-gated cause and effect driven by the selective coming-together of large macro-
molecules (as well as the interactions of these large macromolecules with their partner small-
molecules). Both studying and affecting Biochemistry frequently involve engineering synthetic
binding molecules in the hopes of observing, disrupting, or encouraging these interactions. As
de novo protein design remains a daunting challenge, our lab utilizes a strategy of “semi-design”
in which we modify existing proteins that already perform the general function we desire (in this
case, binding to an RNA stem loop), and engineer them to perform a specific subset of that general
function.
1Crawford, DW, Blakeley, BD, Chen, PH et al. An Evolved RNA Recognition Motif That Suppresses HIV-1
Tat/TAR-Dependent Transcription. ACS Chemical Biology, 11(8):2206–2215, 2016
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Our goal was to develop a specific and selective binder for the TAR element of HIV I, which
is vital for the proliferation and infectivity of the HIV virus and as such is a desirable therapeutic
target. The specific scaffold we build upon in order to achieve this goal was the best-characterized
of the common RNA Recognition Motifs, the “A” subunit of the human U1 ribonucleoprotein
(hereafter known as U1A or wtU1A), which is involved in human mRNA splicing, and selectively
binds the U1hpII RNA with exquisite affinity (KD = 40 pM) [102, 106].
Brett Blakeley, in previous work, had shown that a single mutation from Glu→Ser on position
19 on the U1A protein could broaden, and to some degree “switch” affinity. U1A E19S binds U1hpII
with a KD of ~ 12 μM, while binding TAR with a somewhat tighter KD of ~4 μM [105] Realistically,
these low μM KD values indicate broader specificity, i.e. a protein with general affinity for stem-
loop RNA. The goal of this work was predicated upon the fact that this broadened specificity
of U1A E19S made it a good scaffold to use for building a protein with truly altered specificity
for TAR RNA. Position 19 had been chosen for study because it was known that the β1α1 loop
in which it is contained participates in specific hydrogen bonding interactions with U1hpII. The
hope was that by using our knowledge of the protein, we could use high-throughput screening
to produce a more specific binder of TAR RNA.
The logical starting point is the region which contributes the most surface area to the U1A–
U1hpII interaction: the β2β3 loop. It was well-established that the β2β3 loop is disordered in
crystal structures of the U1A protein alone, but in co-crystal structures of U1A and U1hpII (PDB:
1urn) that it fits well into the abnormally large 10 base loop of the U1hpII RNA. Furthermore, it
was well understood due to work by both our lab and the Laird-Offringa lab, that reducing the
size of the β2β3 loop on the protein creates a protein which binds a shorter RNA hairpin loop,
indicating that the β2β3 loop acts as a sort of steric ruler. [106, 107].
Also important to this work, it was known that the “C-Helix”—an α-helical region near the
C-terminus of the protein outside of the canonical βαββαβ structural elements of an RRM—
acts as a clamp to stabilize the protein–RNA interaction [110]. The regions of U1A important in
binding U1hpII are highlighted in Figure 2.1A, the co-crystal structure of U1A–U1hpII is shown
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in Figure 2.1B, and a comparison of the sequences and secondary structures of TAR and U1hpII
is shown in Figure 2.1C.
Figure 2.1: Crytal Structure of wild-type U1A binding U1hpII and comparison between U1hpII and
TAR A Crystal structure of U1A (PDB: 1URN) highlighting four major binding hot-spots, the RNP face
(residues 13 and 56) involved in general stabilization, the β1α1 loop (residues 15, 16 and 19) involved in hy-
drogen bond contacts with U1hpII, the C-terminal Helix (residues 91, 92, and 94) which acts as a mobile
clamp, and the β2β3 loop (residues 46, 48–51) which constitutes the majority of binding B U1A bound to
its natural U1hpII cognate C U1hpII secondary structure compared to D TAR Secondary Structure
2.3 Design of Screening Strategy
We suspected that with U1A E19S we had achieved the reasonable best-case scenario for ratio-
nalized semi-design; no other point mutant of U1A would be a significantly better starting point.
We decided that our next engineering step would be to use a high-throughput screen to find an
avid TAR binder. After all, the ability to easily make and screen large libraries is among the great-
est strengths of proteins as research tools and pharmaceutical leads. Furthermore, it was already
established that U1A was at least somewhat amenable to high-throughput selection [108].
2.3.1 ScreeningMethod
The first consideration was which of the many screening techniques to use, and there are
many indeed, ranging from simple microarrays, phage display, mRNA/ribosome display), bac-
terial display, and yeast display. We rejected the idea of microarray screening since we lacked
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the instrumentation and expertise to utilize it. We also rejected the idea of using mRNA dis-
play due to our lack of experience with such a specialized technique. Phage display, though
previously used for U1A, has several drawbacks, notably the requirement of a solid-state scaf-
fold (sub-optimal for selection), while bacterial display was not considered usable for displaying
something as large as U1A. We chose, for a variety of reasons, to move forward using yeast dis-
play.
Yeast Display
Yeast display originated in the Wittrup lab, and utilizes the existing Aga1/Aga2 membrane
proteins in a yeast cell. The Aga1 and Aga2 proteins are expressed from different transcripts.
The Aga1 protein embeds in the membrane, while the Aga2 protein connects to the Aga1 protein
through two disulfide bonds. Approximately 5–10 × 104 Aga2 fusion proteins can be displayed
on an individual yeast cell. The protein of interest can be expressed as a fusion to Aga2, and
multiple affinity tags can be included. Display can then be confirmed with the use of antibodies
specific to these affinity tags. Therefore, the protein of interest is available for interaction with a
target, and since the interacting protein is tethered to surface of a cell, the sequence which codes
for the protein can be retrieved and amplified simply by allowing the cell to reproduce and later
extracting the DNA. Figure 2.2 shows a diagram of this method.
Yeast display has some intrinsic advantages for this particular screen. The first is that the
technique itself is operationally simple—S. cerevisae yeast take more time to grow than the E.
coli used in phage display, but they are more robust in both their growth and induced display.
Furthermore, genetic manipulation of yeast—including transformation and DNA recovery—is
straightforward, making library creation and diversification relatively simple. Yeast, being eu-
karyotes, have chaperone proteins, which reduces concern about aggregation and mis-folding of
proteins. Finally, unlike phage display, yeast display pairs well with Fluorescence Activated Cell
Sorting (FACS), which is high-throughput, robust, and was well-known by our lab at the time.

















Figure 2.2: Overview of the Yeast Display Technique The yeast display system used to screen our U1A
E19S-based library can be seen here. The main features are the ability to screen a U1A based protein with
affinity tags to ensure display.
process, allowing more nimble and thoughtful adjusting of screening protocols, as well as reduc-
ing the possibility of enrichment of false-positive “cheater” sequences.
2.3.2 Screening strategy
Since the screening technique defines the upper limit of library size, a concurrent step with
the selection of screening method is deciding which residues on a protein to randomize. We were
planning on screening a library made up of variation in one of the four main binding hot-spots
on U1A. Our choices were the β1α1 loop (residues 15, 16, and 19), the β2β3 loop (residues 46–51),
the conserved binding face (notably residues 13 and 56), and the C-Helix (residues 91–94). The
conserved binding face seemed best kept conserved, our hope was that the β1α1 loop was already
somewhat optimized for TAR binding via the E19S mutation, and since the C-Helix place a role
in the second step of the binding process, it was an illogical place to begin selection. Therefore,
we chose to optimize the β2β3 loop.
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The upper limit of yeast transformation is around 5 × 107 transformants, and in order to have a
reasonable expectation of a complete library, the general rule of thumb is to have ~ten-fold more
transformants than possible members of the protein library [111,112]. Mutating all six residues on
the β2β3 loop would lead to an unreasonably large library size (206 = 6.4 × 107), and the argi-
nine at position 47 is known to play an important role in general RNA recruitment [106], simi-
lar to residues 13 and 56. Leaving out R47 meant we had a more reasonable 5-member library
(205 = 3.2 × 106) consisting of residues 46 and 48–51.
2.4 Yeast Display Confirmation
Prior to making the yeast library, we first needed to confirm that yeast were indeed capable of
displaying U1A variants, and that U1A was still able to bind RNA while displayed on the surface
of a yeast cell.
2.4.1 Cloning U1A Variants into Yeast
The components of the yeast display platform are the specially engineeredSacharomyces cere-
visae variant EBY100 and the pCTcon2 plasmid (which encodes the Aga2 protein, cut sites for
cloning a fusion with the Aga2 gene, an Amp-resistance gene for selection in E. coli, and a Trp
syntheis gene for selection and maintenance in S. cerevisae. Both were generously provided for
our use by the Wittrup lab. The yeast are also available via the American Type Culture Collection
ATCC (MYA-4941) and the plasmid is available from AddGene (41843).
Wild-type U1A (wtU1A) and U1A E19S genes were amplified via PCR templated by wtU1A and
U1A E19S in pET plasmids with FWD NheI U1A (5′-ATA TAG CTA GCA TGG CCC AGG TGC
AGC-3′) as a forward primer and REV BamHI U1A (5′-CGG GAT CCT GCG GCC GCA ACC-3′)
as a reverse primer. The pCTcon2 Plasmid was digested using NheI and BamHI (High-Fidelity
versions from New England Bioloabs) and treated with Calf Intestinal Phosphatase (CIP). The
amplicons were digested with BamHI and NheI and purified. The amplicons were then ligated
into the digested pCTcon2 vector using a Quick Ligation kit from New England Biolabs, and this
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ligation transformed into chemically competent 5α E. coli(NEB C2978). The transformation was
plated (following 1 hour of rescue in SOC media at 37 °C) onto LB plates containing 100 μg/mL
Carbenicillin (obtained from GoldBio).
This construct represents, from 5′ to 3′, a sequence encoding the Aga2 protein, Human in-
fluenza hemagglutinin (HA) tag, a GGGGSx2 linker, the U1A variant, and a myc affinity tag (Se-
quence: Section C.1.2 for wtU1A and C.1.3)
Yeast Electroporation
The plasmid DNA was isolated using a standard DNA miniprep kit (from Omega Biotek),
and transformed into EBY100 yeast made electrocompetent using a standard yeast electropora-
tion protocol [113], using a GenePulser (Bio-Rad) and Gene Pulser/Micro Pulser Cuvettes 2 mm
(BioRad). Electroporator was set to 540 V and 25 μF. Transformed yeast were rescued using YPD
media, and plated on SD-CAA plates.
All of the following cloning and yeast transformations in this thesis were performed using
the above protocol unless otherwise noted.
2.4.2 Positive Controls
The transformed yeast were cultured in 250 mL baffled shaker flasks containing 50 mL of SD-
CAA minimal media (5.4 g/L Na2HPO4, 8.6 g/L NaH2PO4 • H2O, 20 g/L dextrose, 6.7 g/L yeast
nitrogen base lacking amino acids, 5 g/L casamino acids, 200 kU/L penicillin, 0.1 g/L strepto-
mycin), which lacks tryptophan, until they had reached mid-log phase, at which point they were
centrifuged and resuspended in 50 mL SG-CAA (5.4 g/L Na2HPO4, 8.6 g/L NaH2PO4 • H2O, 1 g/L
dextrose, 19 g/L D-galactose, 6.7 g/L yeast nitrogen base w/o amino acids, 5 g/L casamino acids,
200 kU/L penicillin, 0.1 g/L streptomycin) media (which induces production of the Aga2 fusion
protein) to a cell density of 1.0 × 107 cells/mL [113]. Simultaneously, yeast containing wtU1A DNA
were re-suspended to a density of 1.0 × 107 cells/mL in SD-CAA. The assumption was that the
uninduced yeast would serve as a proxy for the surface of a yeast cell to ensure that EBY 100 did
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not have any affinity for TAR RNA without our displayed RRM. Yeast were induced for 24–36
hours. The above is the standard yeast induction protocol used throughout this thesis.
To analyze display, 106 yeast cells were centrifuged, the buffer aspirated, and the pellet
washed in a 1.7 mL eppendorf tube with 1 mL of ie-cold Phosphate Buffered Saline (PBS), washed
with 1 mL of ice-cold Phosphate Buffered Saline (PBS) containing 1 mg/mL Bovine Serum Albu-
min (BSA). Cells were resuspended in 1 mL of this PBS-BSA containing a 1:10,000 dilution of
FITC conjugated anti-myc antibody (Abcam ab117599, which was used extensively throughout
this thesis). Additionally, wtU1A samples were incubated with various concentrations of U1hpII
RNA labeled on the 5′ end with a Cyanine-5 fluorophore (Cy-5, RNA ordered from IDT). Follow-
ing 1 hour of incubation rotating at room temperature the cells were pelleted, washed once with
PBS-BSA, and left as pellets on ice after removal of the PBS-BSA.
Melt and Refold RNA
As a general note, before any assay involving RNA (yeast display, FP, ELISA, etc.) the RNA
was melted and refolded. First, the RNA was brought to a lower concentration to prevent dimer
formation by diluting the 100 μM stock into water to a concentration of 10–20 μM depending on
the assay. The RNA was heated for 2 minutes by submersing the tube in boiling water (~95 °C).
Following this two minutes of heating, the tube was immediately plunged into ice.
Flow Cytometry
After <20 minutes (the time needed to transport samples to flow cytometry), cells were re-
suspended in 1 mL PBS-BSA, and analyzed for fluorescein fluorescence via Flow Cytometry
(Beckman-Coulter MoFlo). Results for both antibody binding and RNA binding for wtU1A and
U1A E19S can be seen in Figure 2.3.
Both wtU1A and U1A E19S seemed to be displayed on ~20% of yeast cells, which was in line
with normal display, and the wtU1A seemed to bind U1hpII RNA. The uninduced yeast cell sur-
face bound neither the antibody nor the Cy-5 labelled U1hpII RNA, which was the confirmation
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Figure 2.3: FunctionalDisplay ofU1AVariantsThe histogram inA shows yeast displayingmyc fusions of
wtU1A, E19S, or displaying nothing (negative), demonstrating that U1A variants display reasonably well.
The histogram in B shows yeast displaying wtU1A incubated with various concentrations of fluorescently
labelled U1hpII, and demonstrates that the displayed protein is still functional while displayed on a yeast
cell.
2.5 Library Preparation
2.5.1 Cloning the β2β3 Loop Library
As was alluded to earlier, our decision to target full sequence-space coverage of a limited
region of the protein meant that we needed to perform saturation mutagenesis [111] of positions
46 and 48–51 in the β2β3 loop of U1A E19S. We chose to use NNK codons (N = A/T/C/G, K = G/T)
to generate diversity. There are 4×4×2 = 32 possible NNK combinations, rather than the 43 = 64
possible NNN combinations. There is no loss in sequence diversity, since all 20 proteinogenic
amino acids are coded for by at least one NNK codon, and only one NNK codes for “Stop” (TAG),
which means fewer transformants contain truncated proteins.
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The initial challenge in making our saturation mutagenesis library was the lack of conve-
nient cloning sites near the β2β3 loop. To overcome this, we chose to use the type IIs restriction
enzyme BsaI, which, when properly designed, is able to create DNA fragments which, when lig-
ated, produce a construct without a cloning scar.
AmpR BsaI Removal
In order to use BsaI, we had to first remove the BsaI recognition site from the Ampicillin
resistance region in pCTcon2 (5′-GAGACC-3′→ 5′-GAGCGC-3′), which was performed using a
standard site-directed-mutagenesis protocol and the primers FWD BsaI Out (5′-CAA GGA GGT
GTC GAG C GCC ACC AAC-3′) and Rev BsaI Out (5′-CTC GAC ACC TCC TTG AAG ATG ACA
AAA GCT TGG CC-3′). This “BsaI out AmpR” plasmid is used for all pCTcon2 constructs moving
forward. The plasmid was digested with NheI and BamHI, treated with CIP, and extracted from
a 1% agarose gel after 40 minutes of electrophoresis at 140 V in TBE buffer.
1st Gen Lib Receiving Plasmid
An insert encoding, from 5′ to 3′, an NheI cut site, a BsaI restriction site, and the 3′ portion of
U1A (coding for Arg61 to the C-terminus, 75 residues including themyc tag) was prepared via PCR
using primers FWD U1A BsaI (5′-CAA GGA GGT GTC GAG C GCC ACC AAC-3′) and reverse
U1A BamHI (5′-CGG GAT CCT GCG GCC GCA ACC-3′). The resulting amplicon was digested
with NheI and BamHI, and ligated into the pCTcon2 plasmid described in the previous para-
graph, to make 1st Gen Lib Receiving Plasmid, also described as BsaI U1A plasmid henceforth.
β2β3 Loop Library Amplification and Ligation
Next, the β2β3 library was created amplifying the 5′ portion of U1A E19S (Positions 1- 53) with
5 sites in the β2β3 loop region (Ser46, Ser48, Leu49, Lys50, and Met51) substituted with NNK
codons (or, in this case, the reverse complement of an NNK: MNN). An amplicon was generated
via PCR using primers Fwd U1A NheI and Rev b2- b3 lib (5′-TA TAT GGT CTC GCC CCT MNN
MNN MNN MNN CCG MNN TAC CAG GAT ATC CAG GAT CTG GCC-3′).
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To receive this insert, BsaI U1A Plasmid was digested with NheI and BsaI, treated with CIP,
and extracted from a 1% agarose gel to give pure vector suitable for cloning. The insert and vector
were then combined using a Quick Ligation Kit (NEB) according to the manufacturer’s instruc-
tions. Ligated vector was purified by phenol chloroform extraction (3x), chloroform extraction
(2x), and ethanol precipitation.a
The resulting DNA was used as a template for a second PCR with homologous recombina-
tion primers for cut pCTcon2 HR FP (5′-CTC TGG TGG AGG GCG TAG CGG AGG CGG AGG
GTC GGC TAG C-3′) HR RP (5′-CGA GCT ATT ACA AGT CCT CTT CAG AAA TCA GCT TTT
GTT CGG ATC C-3′) (This pair of primers will be simply referred to as “HR Primers” hence-
forth), which are designed to create an insert with ~40 base pairs of overlap with the pCTcon2
vector, enabling yeast to perform homologous recombination on the two linear pieces of DNA,
removing the need to ligate the DNA. The resulting amplicon contained the randomized β2β3
loop library in a complete U1AE19S gene (“Library Amplicon”, Section C.1.5), and was purified
by gel electrophoresis. The general cloning scheme is shown in Figure 2.4.
2.5.2 Library Transformation
To transform the library, pCTcon2 vector was cut with BamHI and NheI, and gel purified. Five
aliquots containing ~5 μg library amplicon and ~2 μg cut pCTcon2 were prepared, and the DNA
ethanol precipitated. These ethanol precipitated pellets were used to perform five separate yeast
electroporations, which were each rescued in 1 mL 30 °C YPD and immediately combined. Yeast
were allowed to incubate in the YPD at 30 °C for ~60 minutes, followed by a centrifugation (2500 x
g, 5 minutes, 4 °C), removal of YPD, and resuspension in 50 mL liquid SD-CAA. Serial dilutions of
this resuspension were plated onto SD-CAA agar plates, and after 3 days of growth, the number
of colonies was counted to determine the number of transformants. The final determination was
that there were ~6.6 × 106 transformants. While this likely does not represent a complete library,
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Figure 2.4: Cloning Diagram for Diversification of the β2β3 Loop
2.6 Library Screening
2.6.1 General Screening Conditions
The yeast culture containing our β2β3 loop library was prepared by standard galactose induc-
tion (subculture in SD-CAA to a density of ~0.5 × 107) cells/mL, grow to a density of ~2.0 cells/mL,
subculture in SG-CAA to a density of ~1.0 × 107) cells/mL. Grow for 24–36 hours).
To prepare the library for screening the library, ~108 yeast cells were pelleted, washed in 500
μL ice-cold PBS-BSA. As a control, uninduced yeast cells were subjected to the same conditions
as the experimental samples each round to ensure that the library was performing above back-
ground. The library screened was treated with 1:1000 FITC conjugated anti-myc antibody, as well
as varying concentrations of TAR RNA labeled with a 5′Cy-5. Prior to being used in screening the
5′ Cy-5 TAR RNA was melted and refolded (2.4.2). Varying concentrations of E. coli tRNAs were
used as an off-target competitor. E. coli tRNAs were chosen as competitors due to the fact that
they have ~2x the number of residues as the TAR RNA target, and these residues form a variety
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of secondary structures. Presumably, any U1A variants which merely have general affinity for
any RNA, or even general affinity for structured RNA, rather than the desired specificity for TAR
RNA, would preferentially bind the unlabelled tRNAs.
Because FITC and Cy-5 have essentially orthogonal emission profiles it is possible to plot
each flow cytometry event on a graph with FITC and Cy-5 fluorescence visualized on the X and Y
axes, representing cells displaying protein and binding RNA respectively. The ideal case is that
a yeast cell is both displaying a U1A variant, and that it has bound TAR RNA because of this U1A
variant. The display can be seen with FITC fluorescence, RNA binding with Cy-5 fluorescence,
and a yeast cell binding RNA becauseof its displayed protein will be “double-positive,” and appear
in the top-right quadrant of a yeast display plot (clearly seen in Figures 2.5 and 2.7).
2.6.2 Sorting Methods
Each round, we used a MoFlo flow cytometer to sort double positive cells into ~5 mL of SD-
CAA, each time aiming to collect the best-binding ~2% of the cells displaying a U1A variant.
Sorting took around 2 hours for each round. The SD-CAA the cells had been sorted into was
transferred to 50 mL of SD-CAA within an hour of sort completion, and the cells allowed to
grow to confluency (usually 2–3 days of growth). Upon reaching confluence, the cells were sub-
cultured and induced, and the process was repeated.
After each round, we extracted plasmid DNA from an aliquot of the outgrowth using a Zy-
moPrep II extraction kit (Zymo Research). This DNA was transformed into 5α E. coli, and ~10 se-
quences were analyzed. No obvious pattern arose in these first three rounds, and this sequencing
was simply to ensure that we had not already converged upon a sequence. The sequencing data
can be seen in Table 2.1.
2.6.3 Sorting Conditions
Conditions became more stringent as the selection was continued based on a combination of
reducing Cy-5 TAR concentration or incubation time, while raising either incubation tempera-
ture or competitor tRNA concentration. Rounds one and two were performed at 25 °C with 5 μM
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Table 2.1: Sequences of library members in first three rounds of sorting
Position 46 48 49 50 51
wt Ser Ser Leu Lys Met
Round 1
1.1 R R R S Q
1.2 S W T L A
1.3 V H G F A
1.4 P M R R L
1.5 S F T P P
1.6 S L L T D
1.7 A H K V S
1.8 K C V F S
Round 2
2.1 C P C T Y
2.2 T N Y T F
2.3 G P S P H
2.4 V L D Y T
2.5 Q L * A M
2.6 S P * V S
Round 3
3.1 C P C R R
3.2 V L A S C
3.3 P P R R P
3.4 G R R C T
3.5 T Q G L K
3.6 C C A K N
3.7 L L V A S
3.8 S S H Q A
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unlabeled E. coli tRNAs, while round three was performed at physiological temperature (37 °C)
with 50 μM unlabeled tRNAs from E. coli. The concentration of TAR-Cy5 (round 1: 10 μM; round
2: 1 μM; and round 3: 0.5 μM) and incubation time (round 1: 60 min; round 2: 30 min; and round
3: 30 min) were also decreased as rounds increased to enrich the highest affinity interactions.
The variation in conditions over the six rounds screening is shown in Table 2.2. The fluo-
rescence profiles of the populations in each round, along with approximations of which cells
were collected, are shown in Figure 2.5. Rounds 4–6 occur after the diversification discussed in
Section 2.6.4, and represent the C-Helix library.
Table 2.2: Yeast Display Round Conditions
Conditions Round 1 Round 2 Round 3 Round 4 Round 5 Round 6
[TAR-Cy5, nM] 10,000 1,000 500 500 100 10
[tRNA, nM] 4,000 4,000 50,000 50,000 50,000 50,000
incubation time (min) 60 30 30 30 30 30
incubation temp (°C) 25 25 37 37 37 37
yeast screened ~4 × 107 ~6 × 107 ~3 × 107 ~3 × 107 ~3 × 107 ~1 × 107
yeast sorted ~1 × 106 ~ 6 × 105 ~2 × 105 ~5 × 105 ~2 × 106 ~3 × 105
2.6.4 Diversification
The only change in this routine came after round 3, when the already sorted β2β3 loop library
was diversified by adding randomized sequences to an additional region important for binding.
The diversification was performed at one of two locations—The β1α1 loop (positions 15, 16, and
19), or the C-helix (positions 91, 92, and 94). Since each library has 3 randomized codons, they
represent an 8000-fold increase in diversity (203) from the sorted library of unknown size. A
diagram of this diversity can be seen in Figure 2.6.
As before, we used BsaI to ensure that there were no cloning scars. A modified pCTcon2
plasmid, named “2nd Gen Lib Recieving Plasmid”(Sequence: Section C.1.6) , was constructed to
receive the second-generation library using the following methods. A pCTcon2 plasmid contain-
ingwtU1Adownstream of Aga2 and a linker was digested with restriction enzymes MluI and NotI
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Figure 2.5: Yeast Sorted in Rounds 1–6 An approximation of yeast cells display and binding, along with
an approximation of which cells were sorted for the next round. On these two-color graphs cooler colors
represent a higher density of events at that position. We aimed to take ~2% of the yeast displaying an RRM
in each round. Adapted from [109].
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(both from NEB), followed by treatment with Calf Intestine Phosphatase (NEB), and extracted
from a 1% agarose gel to give pure vector suitable for cloning. Then, two oligos, Fwd c-helix re-
cieving (5′-CGC GTC CTA ACC ACA CTA TTT ATA TGA GAC CAC TCT AGA GGT TCC CCG
GTT GC-3′) and Rev c-helix receiving (5′-GGC CGC AAC CGG GGA ACC TCT AGA GTG GTC
TCA TAT AAA TAG TGT GGT TAG GA-3′), were treated with T4 Polynucleotide Kinase (NEB)
according to the manufacturer’s instructions. The phosphorylated oligos were then heated up
to 94 °C for 5 minutes and allowed to room temperature slowly, over 5 minutes. The annealed
oligos were then cloned into the vector using standard methods to create Dual BsaI U1A pCTcon2.
The C-helix library was built by using the DNA extracted from the 3rd round sort and in-
troducing diversity at the C-helix position on the U1A scaffold, while maintaining the selected
diverse β2β3 loops. The U1A mutant genes were amplified by PCR using the primers Fwd U1A
NheI and Rev c-helix lib (5′-T ATA TGG TCT CTT GGC MNN GAT MNN MNN GTC GGT GCG
CGC AT ACT GGA TAC G- 3′). The resulting amplicon was digested with NheI and BsaI.
To receive this insert, 2nd Gen Receiving Plasmid was also digested with NheI and BsaI, and
treated with Calf Intestine Phosphatase (NEB), and extracted from a 1% agarose gel to give pure
vector suitable for cloning. The insert and vector were then combined using a Quick Ligation Kit
(NEB) according to the manufacturer’s instructions. Ligated vector was purified by phenol chlo-
roform extraction (3x), chloroform extraction (2x), and ethanol precipitation. The resulting DNA
was used as a template for a second PCR with HR Primers. The resulting amplicon contained the
β2β3 loop sequences isolated from three rounds of screening with a randomized C-helix region
(Sequence: Section C.1.7), and was electroporated into EBY100.
The β1α1 library was produced using similar methods, but the receiving plasmid was con-
structed to contain a BsaI site upstream of the β1α1 loop sequence. The library was amplified
Rev U1A BamHI primer and a forward primer which randomized the β1α1 region, Fwd b1a1 (5′-
ATA TAG GTC TCT TAT ATC NNK NNK CTC AAT NNK AAG ATC AAG AAG GAT GAG CTC
AAA AAG-3′). The recieving plasmid and amplicon were digested with BsaI and BamHI, and the
insert ligated in. All other cloning methods were identical.
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Again, a visual representation of the diversification process can be seen in Figure 2.6.
3rd round β2β3 library
C-Helix library
β1α1 library
Figure 2.6: Diversification Strategy Having narrowed down our randomized β2β3 loop, we aimed to di-
versify our library at one of areas, but not both simultaneously. Adapted from [114]
The C-Helix library yielded ~2 × 107, and the β1α1 library ~3 × 107 transformants. Though
there was no way to know how many members a “complete” library contained at this stage, this
was deemed sufficient. Both libraries represent an increase in diversity of ~8000-fold (203), so
this represents a complete library if we had ~400 β2β3 sequences remaining.
2.6.5 Screening of Rounds 4–6
Rounds 4–6 were performed as rounds 1–3 were, with the conditions given in Table 2.2. Grati-
fyingly the C-Helix library represented a major improvement in double positive population from
the previous round, despite the now rather stringent sorting conditions with 50 μM E. coli tRNA
acting as competitor. As can be seen in Figure 2.7, the C-Helix library significantly outperformed
the β1α1 library in both rounds 4 and 5, which led to the abandonment of the β1α1 library.
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Figure 2.7: YeastDisplay forRounds 4 and 5We analyzed both the randomized C-helix and β1α1 libraries
in rounds 4 and 5. A shows the β1α1 library and B the C-helix library under round 4 conditions while C
shows the β1α1 library and D shows the C-helix library under round 5 conditions (conditions shown in
Table 2.2. As can be seen, the C-Helix library was superior under both attempts. Adapted from [114])
2.6.6 Sequence Analysis of Round 4
We analyzed sequencing data for both the C-helix and the β1α1 libraries after round 4 (though
not round 5), these sequences are shown in Table 2.3. Though no obvious patterns emerged,
there are some interesting observations to be made in hindsight. The first is the abnormally
high incidence of proline at positions 46 and 51, which would become a signature of the final
library. The other is that even the β1α1 fourth generation library seems to be circling the ultimate
consensus sequence, with sequence 4.a.8 actually having the β2β3 loop consensus sequence.
2.6.7 C-Helix Rationale
I hypothesize that the ultimate success of the C-Helix library over the β1α1 library, despite
the apparent similarity in β2β3 loop sequences, is due to the fact that the C-Helix is the most
dynamic piece of the RRM. In acting as a mobile clamp, it is likely that if it is unable to form
favorable interactions, it simply doesn’t participate at all. Given what we would come to learn
about this binding interaction (described in Chapter 4), it is frankly possible that we were just
giving it the ability to not participate in the binding interaction, and therefore removing possible
steric interference. It is also possible that the dynamism of this element means there are more
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Table 2.3: Yeast sorted in fourth round, both from the C-Helix and β1α1 libraries
β2β3 Loop Position C-Helix Position
46 48 49 50 51 91 92 94
wt Ser Ser Leu Lys Met Ser Asp Ile
4.1 P K R T P N A Q
4.2 * P E Q G Y M F
4.3 P R R Q P E S P
4.4 P T R L P S G E
4.5 S C I I P L Y *
4.6 P A R R F P E P
4.7 R H R R P E P D
4.8 A R A S R T A S
β2β3 Loop Position β1α1 Position
46 48 49 50 51 15 16 19
wt Ser Ser Leu Lys Met Asn Asn Ser
4.a.1 P T R R P S G A
4.a.2 E M I L C R Y G
4.a.3 K Y R T P S G A
4.a.4 P S R R P S Y G
4.a.5 T R M R L G G S
4.a.6 P S R R P G H T
4.a.7 P D I N R P R I
4.a.8 P T R T P G Q Y
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“favorable” possibilities, rather than requiring a specific arrangement (synergistic with the β2β3
loop) to get a “maximally favorable” possibility. In U1hpII, the backbones of S91, D92, and I94
form a complex H-bond network with the A and C residues at the 6th and 7th positions of the
U1hpII loop [110]. Notably, the TAR loop is 6 bases long, indicating that the C-Helix may be able
to engage with this loop. I also posit that in being mobile, the C-helix may be more modular and
independent of the interactions between β2β3 loop and TAR RNA, while the β1α1 loop is likely
to require synergistic maturation concomitantly with the β2β3 loop.
2.7 Properties of Sixth Generation TAR Library
2.7.1 β2β3 Loop Homology
After six rounds of sorting, U1A E19S derived sequences for the sixth generation were ana-
lyzed. Since these were the 6th generation of TAR Binding Protein, a designation of “TBP 6.X”
was given to each protein. A total of 71 sequences were analyzed, and all sequences are included
in Table 2.4.
The sequence logo for the β2β3 loop can be seen in Figure 2.8A.
This logo shows a strong consensus sequence for the β2β3 loop, suggesting that we had
evolved a privileged sequence for TAR recognition. The overall charge character of the con-
sensus sequence β2β3 loop in positions 46–51—PRTRTP (with R47 unmutated)—is cationic, as
RNA-binding proteins are wont to be, but does not have the overwhelming positive charge which
would indicate a non-specific binder. The only position which changed from non-cationic to
cationic is the leucine→arginine mutation at position 48.
Positions 46 and 51, on the other hand show a very strong (100 and 93%, respectively) prefer-
ence for proline—a neutrally charged, somewhat hydrophobic residue notable for major struc-
tural effects—in contrast to the serine and (cationic) lysine present at these positions in the wild-
type U1A protein. The structural consequences of these flanking prolines became clear with
the crystal structure (Figure 4.4), but in the moment the most important conclusion was that we
weren’t merely selecting for positive charge. Position 48 is largely populated by threonine and
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Table 2.4: Sequences from TAR 6G Library
β2β3 Loop Position 46 48 49 50 51 C-Helix Position 91 92 94
wtU1A Ser Ser Leu Lys Met Ser Asp Ile
TBP 6.1 P T R T P P P P
TBP 6.2 P T R T P A R K
TBP 6.3 P T R R P R T R
TBP 6.4 P T R T P K H I
TBP 6.5 P R R T W R H Q
TBP 6.6 P T R T P G R A
TBP 6.7 P Q R T P K R P
TBP 6.8 P T R T P D R T
TBP 6.9 P R R T P R T K
TBP 6.10 P T R R P G R R
TBP 6.11 P T R T P S Q P
TBP 6.12 P T R T P S R G
TBP 6.13 P T R R P R R P
TBP 6.14 P T R T P V P V
TBP 6.15 P R R T P R P P
TBP 6.16 P T R N P T K A
TBP 6.17 P R R T Y A P K
TBP 6.18 P T R T P S K P
TBP 6.19 P T R T P D K R
TBP 6.20 P R R T P R P K
TBP 6.21 P T R T P T K P
TBP 6.22 P T R T P P R P
TBP 6.23 P Y R T P R R A
TBP 6.24 P T R T P G K R
TBP 6.25 P R R T P T N K
TBP 6.26 P R R T P S A V
TBP 6.27 P T R R P S A R
TBP 6.28 P P R R P R P R
TBP 6.29 P R R T Y S R P
TBP 6.30 P T R T P S R P
TBP 6.31 P T R T P R P S
TBP 6.32 P M R R P S H Q
TBP 6.33 P T R T P K C P
TBP 6.34 P R R T P R P Q
TBP 6.35 P T R T P S R V
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β2β3 Loop Position 46 48 49 50 51 C-Helix Position 91 92 94
wtU1A Ser Ser Leu Lys Met Ser Asp Ile
TBP 6.36 P R R T P L L P
TBP 6.37 P R R T P G K R
TBP 6.38 P T R T P L R R
TBP 6.39 P T R T P R Q R
TBP 6.40 P T R V P A R W
TBP 6.41 P T R T P G P P
TBP 6.42 P T R T P E A P
TBP 6.43 P P R T Y L I Q
TBP 6.44 P K R T P L V P
TBP 6.45 P T R T P K T S
TBP 6.46 P M R T P G R A
TBP 6.47 P T R T P W A P
TBP 6.48 P T R T P G R S
TBP 6.49 P R R T Y T R K
TBP 6.50 P T R T P K P P
TBP 6.51 P R R Q P H R R
TBP 6.52 P Y R T P P P R
TBP 6.53 P R R T P T N K
TBP 6.54 P Q R T P R R S
TBP 6.55 P R R T P G W K
TBP 6.56 P H R T P G R Q
TBP 6.57 P T R T P A R A
TBP 6.58 P T R T P S K R
TBP 6.59 P R R T P T P T
TBP 6.60 P T R T P G K R
TBP 6.61 P P R T P A H T
TBP 6.62 P R R T P R T P
TBP 6.63 P T R T P S Q L
TBP 6.64 P T R T P R A S
TBP 6.65 P T R T P S G P
TBP 6.66 P T R T P S P G
TBP 6.67 P T R V P Q R N
TBP 6.68 P T R T P T P G
TBP 6.69 P R R T P G K P
TBP 6.70 P H R T P G R A

































































Figure 2.8: TAR 6G Sequence Logo The sequence logo shows that A the β2β3 loop showed excellent
homology after sorting and B the C-Helix region showed patterns, but no homology
arginine, which means that both the wt and library consensus sequence have an alcohol func-
tionality in position 48 (serine in the wild-type and threonine in the consensus). But there are
two instances of asparagine among the 71 sequences analyzed, one of them in TBP 6.7, the most
avid TAR binding protein we characterized.
2.7.2 C-Helix Homology
The sequence logo for the C-helix, shown in Figure 2.8B, shows that this region is consider-
ably more heterogeneous than the evolved β2β3 loop, but certain themes emerge. In native U1A,
residues 91 and 92 are serine and aspartic acid, respectively. Interestingly, a signficant portion
of the TAR-binding RRMs retain serine at position 91, although arginine, glycine, and threonine
are also prominent. Positions 92 and 94 undergo more dramatic changes. In particular, cationic
residues arginine and lysine are found in a significant number of TAR-binding RRMs, as is pro-
line. Proline, arginine, and lysine are also prominent at position 94, which in the native protein
is known to modulate the conformation of the C-terminal helix. The prominence of proline at
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positions 92 and 94 within the C-terminal helix is interesting and suggests that conformational
rigidity might be favorable at this position, while the fairly prominent glycine at position 91 may
indicate that flexibility may be more favorable in that position. In any case, we would eventually
learn that the C-Helix region was inessential for TAR binding [45], which seemed to contradict
the apparent variation in affinity based on different C-Helix sequences shown in Figure 3.3. The
most plausible explanation is that we simply selected for a C-Helix which stays out of the way of
the β2β3 loop, and doesn’t interfere with bindingrawford.
2.8 Initial Characterization Attempts
Our goal of determining quantitative binding values (i.e. dissociation constants, which will be
expressed generally as KD values in this work) proved challenging. Initially we tried to determine
a KD via Fluorescence Polarization (as had been done for U1A E19S) and Yeast Display. Both failed
to give believable and reliable data, and initial assays were a mix of disheartening and promising.
2.8.1 Fluorescence Polarization
Fluorescence Polarization had been used to good effect to quantify the binding of the origi-
nal engineered synthetic RRMs in the McNaughton Lab, most notably the U1A E19S which had
been the starting point for our scaffold. As such, it seemed a logical choice to analyze these new
putative TAR binders.
Briefly, the protein being analyzed was concentrated to ~1 mM and used to load on a plate, and
was diluted until its concentration ranging from the maximum ~1 mM to ~1 nM. These dilutions
were added to a 384 well plate, and a fixed concentration of RNA (melted and refolded 2.4.2) was
added to each well with a final RNA concentration of 20 nM. Full method given below.
Fluorescence PolarizationMethod
The purified RRM to be analyzed was concentrated using a centricon-4 spin column (Milli-
pore) to a concentration of ~1 mM, as determined using an extinction coefficient of 7450. From
this stock serial dilutions were made using a dilution factor of 1.7 to give 24 different protein
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concentrations. The appropriate fluorescein tagged nucleic acid (Integrated DNA Technologies,
RNase free HPLC purified and shipped as a lyophilized pellet) 110 was thawed from an aliquoted
stock of 10 μM, stored at – 80 °C. This was prepared for fluorescence polarization (FP) in a mas-
ter mix containing 40 nM of indicated nucleic acid and 10% NP-40 in HEPES buffer. Prior to
analysis, the mastermix was heated to 95 °C for two minutes and then plunged into ice to ensure
hairpin formation. 20 μL of the protein dilutions were loaded onto a black flat-bottom 384-well
plate (Corning) before addition of 20 μL of the RNA master mix to give 20 nM final RNA con-
centration. Fluorescence polarization measurements were made using a Perkin-Elmer Victor V
multimode microplate reader. Data was processed using KaleidaGraph (Synergy Software) to
determine RNA dissociation constants by fitting the data to single-site binding isotherm.
Results
We analyzed a member of the pre-diversification from after the 3rd sort, and a library member
from after the 6th sort (TPB 6.2, which would prove to be a middle-of-the-range binder in later
assays). The results, which can be seen in Figure 2.9 were discouraging. TBP 3.1 had an apparent
KD of ~30 μM, 6-fold worse than our starting point, while TBP 6.2 an apparent KD of ~5 μM,
no better than our starting point. With that said, since neither curve seemed to saturate, the
conclusion was that this assay was fundamentally unfit to analyze these particular protein–RNA
interactions.
2.8.2 Characterization via Qualitative Yeast Display
Though it did not ultimately prove to be the best quantitative way to analyze our TBP 6.X
proteins, we had more encouraging results analyzing our TBP 6.X proteins via yeast display. As
was discussed in Section 2.3.1, the ability of yeast display to be used as a standalone analytical
technique is a major advantage to using it as a screening platform. We were simply able to elec-
troporate the isolated plasmid we had used to analyze our sequence back into EBY 100 yeast, and
induce display as we had during our controls (Section 2.4.2).
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KD=35.91 ± 4.971 µM KD= 7.05 ± 1.23 µM
TBP 6.2 Fluorescence Polarization
Figure 2.9: TARBindingProtein 3.1 and6.2FluorescencePolarizationWe attempted to use Fluorescence
Polarization to characterize our library, but did not see any saturation. These data were worrying, because
they indicate no improvement in TAR binding
TAR 6G.XX proteins were analyzed in two batches under two different sets of conditions in
order to give two subtly different pieces of comparison data. The first batch was measured by
their absolute ability to bind TAR RNA while displaying on a yeast cell. The samples were incu-
bated under the same conditions as the 6th generation sort (108 cells, 10 nM labeled TAR, 1:1000
FITC conjugated anti-myc antibody, 37 °C, 30 minutes). The results are shown in Figure 2.10A. A
negative sample under these conditions has >99% of events within the “no display, no binding”
quadrant in the bottom left.
For all but one sample (TBP 6.5), there was clear evidence of RNA binding, even at the rel-
atively low concentrations of TAR we used. However, there was fairly high variations in the
amount of display, making this a difficult technique to apply quantitatively.
Since the ultimate goal was to make a better binder of TAR RNA than U1A E19S, I next took
a series of samples with the explicit goal of comparing their TAR binding to that of U1A E19S.
These were prepared with 6th round conditions, but without any FITC conjugated anti-myc an-
tibody, since I was only looking at RNA binding. We found that U1A E19S displayed on TAR
generates only a very small positive signal at these conditions, but increases somewhat when the
TAR RNA concentration is increased to 10 μM (around the putative KD of U1A E19S).
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Figure 2.10: Qualitative Yeast Display for Characterizing Generation 6 TAR Binding Proteins Shown
inA, an analysis of our library under round 6 conditions showed that there was promising binding activity
in an absolute sense, and B A comparison of the RNA binding activity of our 6th generation library to the
U1A E19S starting point indicated that our new TAR binders were more avid binders of RNA than was our
starting material
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We also found that our TBP 6.X variants had both more Cy-5 positive events, and that these
Cy-5 positive events were brighter (which indicates more RNA binding on a given yeast cell). Ex-
amples are shown in Figure 2.10B. Though the RNA binding analysis was qualititative rather
than quantitative, and lacking display information, was imperfectly controlled, it still indicated
that our members of our 6th generation library bound TAR better than the U1A E19S starting
material did.
2.8.3 Yeast Display KD
Between the two rounds of qualitative yeast display, we attempted (with the help of our lab-
mate Bryce Rogers) to perform a quantitative yeast display assay. It is possible to get a KD from
a yeast display experiment [113] by measuring multiple samples with varying concentrations of
target, and plotting the mean fluorescence (rather than the percent positive) against concentra-
tion of the RNA used in the analysis. In this case, the yeast were incubated with varying amounts
of TAR RNA ranging from 1 nM to 1 μM. We chose two variations—TBP 6.2 and TBP 6.4. These



















[TAR RNA] M [TAR RNA] M
KD = 242.6 ± 23.7 nM
TBP 6.2 TBP 6.4
KD = 80.3 ± 8.6 nM
A. B.
10-10 10-9 10-8 10-7 10-6
Figure 2.11: Quantitative Yeast Display Assays of TBP 6.2 and 6.4 The KD values estimated by a quan-
titative yeast display were promising. Both seemed to be ~100 nM, which would represent two orders
of magnitude improvement over our ~10 μM starting point. Red curve represents the best fit of the Hill
Equation to these data using Kaleidagraph.
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Though this was not perfectly convincing, since the mean fluorescence signal never reaches a
saturation point, fitting the Hill Equation yielded values of ~250 nM and ~80 nM respectively for
TBP 6.2 and 6.4 respectively, with reasonable error. Though not reliable, since the signals did not
saturate, this was encouraging, as it would represent a full order of magnitude improvement over
the putative KD determined via Fluorescence Polarization (setting aside questions of comparing
KD values derived from different assays).
Though both KDs were, at this point putative, we had already performed the qualitative yeast
display from Figure 2.10A that showed excellent absolute binding, and I would soon gather the
data shown in Figure 2.10B, which would show a significant degree of improvement over our U1A
E19S starting point. As such, in the months in which we lacked a reliable quantitative binding
value, these ~100 nM KD values (Figure 2.11) were thought to be more reflective of reality than the
~10 μM KD values from the Fluorescence Polarization assay (Figure 2.9).
2.9 Conclusions
Though it would not become clear until later, the screen described in this chapter was a
great success. For me personally, the work described in this chapter represents the time I spent
learning to be a competent molecular biologist, both technically and in being able to design and
perform experiments. The foundation for much of the rest of my time doing graduate research
was laid here.
For the project at large, the fact is that the reason that our initial characterizations failed was
that the interaction being analyzed was tighter than permissible by the assays we were using to
analyze them, and this would lead me to perform ELISA assays (shown in Section 3.3) with a
precision that I initially didn’t think was possible, and lead us to characterize the tightest binders
of TAR yet known in the work described in Chapter 3.
89
Chapter 3
Characterization of TAR Binding Proteins
3.1 Chapter 3 Introduction
3.1.1 Chapter 3 Summary
Having putatively demonstrated that our 6th generation library contained excellent binders
of TAR RNA, we next needed to establish a convincing and quantitative basis for this claim. An
ELISA protocol was determined to be a good basis for analytical comparison of library members.
When applied stringently to our best binders (TBP 6.6 and TBP 6.7), it was quantitative enough
to warrant proposing a KD in the single-digit nM range. A collaboration with the Laird-Offringa
lab, the most-established quantifiers of protein–RNA interactions, this KD was shown to be in
the range of 500 pM–1 nM. Further characterization established that the best proteins were quite
specific for TAR RNA, and minor changes in the TAR element could abolish binding. A collab-
oration with the Le Grice lab enabled us observe, via SHAPE, the long-range effects this TBP 6.7
interaction had on the HIV-1 5′ untranslated region. Furthermore, our best binder, TBP 6.7, was
shown by ITC to be able to inhibit the tat/TAR interaction, and via an in vitro transcription assay,
was shown to prevent the resulting transcription cascade.
3.1.2 Chapter 3 Attribution
This chapter is adapted from [109].2
I was responsible for the design and performance of the ELISA screen, the quantitative KD
curves, and the analysis of the affinity of various RRMs for variants of TAR RNA (Figures 3.3,
3.4, 3.5, 3.6, 3.7, and 3.9), the ITC analysis (Figure 3.15, with assistance from Alex Chapman, also
a graduate student in the McNaughton Lab), the in vitro transcription assays (Figure 3.17), with
2Crawford, DW, Blakeley, BD, Chen, PH et al. An Evolved RNA Recognition Motif That Suppresses HIV-1
Tat/TAR-Dependent Transcription. ACS Chemical Biology, 11(8):2206–2215, 2016
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assistance from John Anderson of the Wilusz lab in the Dept. of Microbiology at Colorado State
University).
Po-Han Chen, of the Laird-Offringa Lab at the University of Southern California Dept. of
Biochemistry and Molecular Biology, was responsible for the Surface Plasmon Resonance char-
acterization.
SHAPE analysis was performed by Chringma Sherpa, working under Stuart Le Grice at the
National Cancer Institute. Though I was not involved in the performance of these assays, I was
frequently involved in discussing the conclusions, and they add a practical dimension to the work
I performed.
3.1.3 Chapter 3 Background
The work done in Chapter 2 using yeast display to find U1A-derived binders of TAR RNA was
apparently successful. The final rounds of screening indicated good amounts of TAR-binding
yeast even with low concentrations of TAR, and qualitative assays indicated that certain members
of our sorted library bound TAR far better than the E19S starting point. What we lacked was
quantitative binding data, and functional data indicating that our TAR binding proteins could
disrupt the Tat–TAR interaction.
3.2 ELISA Preparation
3.2.1 Assay preliminaries
I decided that an ELISA assay represented the best possibility of successfully developing a
method to quantifiably compare TAR Binding proteins against each other, since ELISA assays
are well-characterized, and use a minimum amount of material. The ELISA format favored by
our lab involved using a streptavidin coated plate, and an anti-FLAG antibody with a conjugated
Horseradish peroxidase (HRP) enzyme.
Since, by definition, fewer materials are used for the immobilized phase of an ELISA exper-
iment, I decided that the easiest element to immobilize would be the TAR RNA. I purchased
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this RNA directly from Integrated DNA Technologies (IDT), and it is quite expensive. This also
worked well, since adding a 5′-biotin modification did not add significant cost, and would allow
the RNA to be immobilized on the streptavidin coated plates commonly used in ELISA.
In order to measure the bindinginteraction, the first task, therefore, was obtaining the
TBP 6.X library members described in Section 2.8.2 as purified proteins. The genes encoding
these proteins needed to be transferred to a purification vector with a His6 tag for purification,
and a FLAG (DYKDDDDK) tag for analysis.
3.2.2 Cloning
I used the pETduet plasmid (digested to only contain a single T7 promoter/terminator) fa-
vored by our lab. I decided to locate fuse both the His6 and th FLAG tag to the C-terminal of
the protein. The rationale for a C-terminal His6 tag was largely inertia: the U1A variants char-
acterized by Brett Blakeley [105, 107] had His6 tags located on their C-termini, and had purified
well. This also seemed a logical location for the FLAG tag for steric reasons. Since the stem-loop
would be the moiety of TAR furthest from the streptavidin coated plates, and the assumed bind-
ing conformation involved the RRM motif contacting the TAR loop with the C-terminal clamped
above the RNA, a C-terminal FLAG tag would likely be more sterically accessible.
The genes were PCR amplified from the pCTcon2 template using U1A NcoI FP (5′-ATA TAC
CAT GGC CCA GGT GCA GC-3′) and U1A His FLAG PacI RP (5′-GTT AAT TAA CTA TTA CTT
GTC GTC ATC GTC TTT GTA GTC GTG ATG ATG GTG ATG ATG TGC GGC CGC AAC C-3′).
This PCR product was digested with NcoI and PacI. To prepare the vector, pETduet was digested
with NcoI and PacI, and treated with CIP. A 5-fold molar excess of insert was ligated into cut
vector, transformed into NEB 5α, and plated. A colony was picked into 5 mL liquid culture the
next day, DNA extracted, and sent for sequencing verification (GeneWiz). Protein and DNA se-
quences for a generic TBP 6.X protein, and all TBP 6.6 and 6.7 constructs used and DNA sequence
can be found in Sections C.2.2–C.2.4.
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3.2.3 Protein Purification
Upon sequence verification, plasmid was transformed into NEB chemically competent BL21
cells (C2527), and plated on LB-Carb. After overnight growth, a single colony was picked into 2
x 5 mL of culture. After overnight growth, DNA was extracted from one culture to be used as a
final sequence verification.
The other culture was used as a starter culture (100X) for protein purification. Cells were
grown in LB-Carb (100 μg/mL carbenicillin) in either 100 mL cultures grown in 250 mL baf-
fled flasks, or 500 mL cultures grown in 1 L Erlenmeyer Flasks. Cells were grown at 37 °C to
OD600 = ~0.6, when they were induced with 1 mM IPTG. Upon induction, they were incubated
at 25 °C for 4–12 hours.
Cells were subsequently collected via centrifugation (5000 × g, 10 min, 4 °C), resuspended
in 30 mL HEPES buffer (10 mM HEPES, pH = 7.4, 50 mM KCl, 30 mM NaCl, 1 mM MgCl2, 1
mM EDTA) containing cOMPLETE protease inhibitor (1 tablet / 30 mL), and frozen (generally
overnight) at -20 °C. Frozen cell suspensions were thawed, and sonicated for 2 minutes. The lysate
was cleared via centrifugation (15000 x g, 25 min, 4 °C), and the supernatant mixed with 400 μL
Ni-NTA agarose resin for 10 minutes (tumbling, 4 °C), and the resin collected by centrifugation
(5000 x g, 10 minutes, 4 °C).
The resin was washed with 30 mL of HEPES buffer containing 20 mM imidazole followed by
10 mL of HEPES buffer containing 50 mM imidazole. Proteins were eluted using 4 mL of HEPES
buffer containing 400 mM imidazole.
Eluted proteins were dialyzed in SnakeSkin Dialysis Tubing with a 10 kDa molecular weight
cutoff (ThermoFisher 88243) against 2 L of HEPES buffer, and subsequently dialyzed against 2 L
of phosphate buffer (20 mM phosphate, pH = 7.4, 150 mM NaCl).
Purified proteins can be seen cleanly on a PAGE gel in Figure 3.1.
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Figure 3.1: PAGE Gel of TBP 6.6 and TBP 6.7 This gel shows that TBP 6.6 and TBP 6.7 purify cleanly
Protein Purification Notes
The second dialysis is in phosphate buffer because initial ELISA experiments did not work
in HEPES buffer. Since the screening was performed in PBS (obviously a phosphate buffer) and
the phosphate buffer described had been working for other lab members’ ELISA experiments, I
decided to perform assays using this buffer, and began dialyzing my purified proteins against it
to ease the transition.
Even though I needed the proteins in phosphate buffer for the ELISA assay, I continued to
use the HEPES buffer for protein purifications. The general makeup of the buffer—Mg+2 ions
and an EDTA chelator in a Good’s buffer—is used to purify many RNA binding proteins [115–117].
The benefit of such a purification environment is less non-specific interaction between positively
charged RRM and cellular nucleic acid, but the downside is that the presence of the chelator
reduces yield in a nickel purification. This is a major downside but is necessary. I once attempted




The general strategy for my ELISA is shown in Figure 3.2. It is a fairly traditional sandwich
ELISA, though it required a great deal of optimization.
Detailed assay notes follow, for anyone who may wish to build upon it.
3.3.1 General ELISA Protocol
Materials
The base for the buffer used in ELISA experiments was the second dialysis buffer (20 mM
Phosphate, pH = 7.4, 150 mM NaCl) from the protein purification. The only practical considera-
tion with doing this is that it is unwise to wash the proteins in a concentration column with this
buffer if there is any possibility that a dialysis bag was leaking, since this will also concentrate
the leaked protein into any samples. The ELISA buffer was 20 mM phosphate, 150 mM NaCl,
pH = 7.4 with 0.05% Tween-20, and 0.1 mg/mL Bovine Serum Albumin (BSA). Generally, 250 mL
of buffer was sufficient, and it was prepared by adding 125 μL of Tween-20 using a small syringe.
The BSA was prepared by dissolving 100 mg of BSA into 10 mL of phosphate buffer, using 2.5 mL
of this stock.
The assay was most successful when performed using streptavidin coated plates with only 5
picomoles (Thermo Scientific cat. 15124) of immobilized biotin, rather than the more commonly
used plates with 10 picomoles (Thermo Scientific cat. 15125).
The best 3,3′,5,5′-Tetramethylbenzidine (TMB), in my experience, is TMB One, from
Promega.
Plate Equilibration
In a typical experiment, the wells to be used (generally 4 rows, for a total of 48 wells, is the
maximum number of wells able to be efficiently utilized) were incubated for 5 minutes with 200
μL ELISA buffer, washed by aspirating the buffer with a Pasteur pipet with vacuum, and incu-






2. FLAG tagged 6th Generation library member
3. HRP conjugated anti-FLAG antibody
4. 3,3´,5,5´-tetramethylbenzidine (TMB)
spectroscopy readout (Absorbance at
650 nM)
HorseradishPeroxidase
Figure 3.2: General ELISASchemeAn illustration of the scheme for the sandwich ELISA used to roughly,
and eventually precisely, characterize the 6th generation TAR binding proteins
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Generally speaking, “washing” refers to incubation for five minutes with 200 μL of ELISA
buffer followed by aspiration. Buffer for washing was typically kept ice-cold, while “incubations”
were at ambient room temperature. Plate was continuously shaking on an oval shaker at ~200
RPM.
The plate was then allowed to “equilibrate” to the buffer by incubating 200 μL of ELISA buffer
for 1 hour. The buffer was aspirated, and the first incubation was begun.
RNA Preparation and Incubation
RNA was melted and refolded (2.4.2). All incubations were performed at 100 μL and 5–10
pmoles of RNA was required to saturate the plate, so the final 1X concentration of RNA needed
was 1.1× 5×10−12moles
100×10−9L
= 55 nM if using the 5 pmol plates, or 110 nM if using 10 pmol plates. Given a
stock concentration of 100 μM, this meant that the final dilution was ~1000-fold. Importantly, the
first dilution, which brought the concentration to 100X (5.5–11 μM), should be done into buffer
without Tween-20 and BSA, and the subsequent 100X dilution done into ELISA buffer shorty
before application to plate.
100 μL of RNA was added to the plate, and allowed to incubate at room temperature for 2–4
hours. The RNA was aspirated from the plate using a Pasteur pipet attached to vacuum. The
pipet was discarded and replaced between removal of different RNAs.
The plate was washed 3 times with ice-cold buffer prior to addition of protein.
Protein Preparation and Incubation
Protein concentrations were analyzed , and proteins were diluted to a 10X concentration in
phosphate buffer not containing Tween-20 or BSA. These 10X protein solutions were distributed
to strips of 300 μL PCR tubes which were arranged to have the same positioning as the ELISA
plate. Using a 12-channel pipettor, immediately prior to incubation, ELISA buffer was added (9
times the volume to bring the 10X protein to 1X), dilution was mixed, and 100 μL added to the
plates in the correct row. For example, if the assay was being performed with 50 nM protein, 25
μL of 500 nM protein would be added to the appropriate PCR tube, and 225 μL of ELISA buffer
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added. The pipettor would then be adjusted to pipet 100 μL in each channel, and the solutions
were applied to the plate.
Incubations were 1 hr. at room temperature, and were followed by 3 washes. If multiple con-
centrations of protein were used, aspiration began with the lowest concentration and continued
to the highest. If switching between proteins or between RNAs, the pasteur pipet was washed by
aspirating ~1 mL of 70% ethanol followed by ~1 mL of ddH2O.
Antibody Incubation
The HRP conjugated anti-FLAG antibody was diluted in Odyssey Blocking Buffer (Li-Cor) at
1:10,000 (0.1 μL/mL), and mixed by rotation for ~10 minutes prior to application to plate. 100 μL
of this mixture were applied to each well, and allowed to incubate at room temperature for 30
minutes. The antibody was removed, with pasteur pipet washed with ethanol and water between
conditions, and the plate washed 4X.
TMB
TMB was allowed to come to room temperature for 30 minutes in a foil-wrapped 15 mL falcon
tube. On the final antibody wash, wells were inspected for any residual liquid, and when dry, 100
μL of TMB added to each well. The plate was wrapped in foil, and allowed to incubate.
Absorbance was measured at 655 nM with a plate reader, and a higher absorbance is assumed
to indicate a higher level of protein/RNA binding.
3.3.2 ELISA results
Initial attempts at ELISA were challenging, but a general protocol emerged using 5′ biotiny-
lated TAR, or 5′ biotinylated U1hPII as the RNA, and incubating with a fixed concentration of
various library members, or wtU1A. Initial “guesses” for a good concentration of protein, ~1 μM,
were too high, and resulted in excessive background signal. The assay began to behave dynam-
ically, and give good negatives when a concentration of 50 nM of protein was used. The results










Figure 3.3: Results of a Single Plate of ELISA Assays using 50 nMU1A Variants The data shown in this
assay represent the first time that wtU1A–U1hpII was used, and the high signal by that pair demonstrated
that the assay was most likely reflecting reality. This validated the use of this assay and led to confidence
in using it to compare the TBP 6th generation mutants, though none of the other mutants on this plate
were particularly avid binders of TAR.
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Though there was still non-specific background, there was also variation in signal. This
concentration-dependent variation indicated that I was in or near the dynamic range of the as-
say. Additionallyk, the fact that the remarkably tight wtU1A–U1hpII interaction was generating
high signal indicating that the assay was reflecting reality.
This assay, with 50 nM wtU1A or library member applied to immobilized TAR or U1hpII,
was used to measure the relative TAR binding activity of library members, as well as to ensure
that they did not bind U1hpII. Data was normalized to a positive control on each plate (wtU1A–
U1hpII) in order to compare different assays. The results of these normalized ELISAs are shown
in Figure 3.4. All but one library member (TBP 6.1) appreciably bound TAR at 50 M, and did not
bind U1hpII significantly above background. These data are shown in Figure 3.4.
A.
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Figure 3.4: ELISA Survey of 6th Generation TAR Binding Proteins Shown in A is ELISA analysis of
selected 6th generation TAR Binding Proteins. These data are the result of combining data from assays
performed on different days, with the data from each day normalized to the wtU1A–U1hpII interaction.
These data were then normalized to the highest normalized signal, that of TBP 6.7, which was given a
value of “1.” B Crystal Structure of U1A protein highlighting the mutations identified in the best apparent
TBPs: TBP 6.6 and TBP 6.7 (adapted from [109])
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Additionally, E. coli containing only empty pET plasmid were taken through the protein pu-
rification protocol as outlined in Section 3.2.3, concentrated to a normal degree (generally ~10-
fold), and used in the ELISA experiment to ensure that our signal was not coming from non-
specific interactions with trace E. coli proteins.
As a final qualitative check to be absolutely sure that the excellent results we were seeing were
the result of the yeast display and selection, the most avid binder (TBP 6.7) would be compared
to this pET “purification,” and library foundation U1A E19S. As is clear from Figure 3.5, the fact



















Figure 3.5: ELISA Signal of TBP 6.7 vs. U1A E19S for TAR Binding The most straightforward way to
demonstrate the degree of improvement from the output of a library screen is to compare the scaffold and
end-product head-to-head. We can see a remarkable change in TAR affinity from U1A E19S to TBP 6.7
Two particularly avid binders—TBP 6.6 and (especially) the aforementioned TBP 6.7—
would become the basis for extensive future study.
3.3.3 Quantitative ELISAs
Though the ELISA assay seemed robust in comparing proteins to each other, it was initially
unable to give us any absolute idea of the KD value range for our TBP 6.X proteins. That would
change while I was in the process of evaluating the approximate dynamic range of the ELISA
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assay for the best binder to date (TBP 6.6). In so doing, it appeared that there was a hint of a
binding curve present (seen in Figure 3.6A), with a desaturation and saturation point. I repeated
the assay the next day, and used more concentrations in the apparent transition from unsaturated
to saturated signal (corresponding to single digit nM). To my delight, when I plotted these new
data a clear sigmoidal binding curve emerged (Figure 3.6b). Fitting with the Hill equation gave a
KD of ~5 nM.
I repeated the experiment for TBP 6.6 and, also for TBP 6.7, with all concentrations in trip-
licate. This confirmed the results for TBP 6.6, and established TBP 6.7 as having comparable
affinity. These curves can be seen in Figure 3.7, and established final dissociation constants, by
our analysis, of KD = ~6 nM for TBP 6.6 and KD = ~7 nM for TBP 6.7.
















KD= 5.34 ± 0.39 nM







Log10 [TBP 6.6, nM]
A B
Figure 3.6: Initial Binding Curve Generated by ELISA A A semi-quantitative ELISA of TBP 6.6 showed
promise, so I chose to B try again with more data points, and found that there was a believable binding
curve
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) TBP 6.6KD = 7.3 nM +/- 0.7 nM
TBP 6.7
KD = 5.9 nM +/- 0.4 nM
Figure 3.7: FinalizedQuantitativeELISA-basedBindingCurvesThe ELISA assay behaved quantitatively,
unusual for a qualitative assay. When fit to the Hill Equation, the data seemed to indicate binding with




With the repeatable data indicating that TBP 6.6 and TBP 6.7 were binding TAR with a dis-
sociation value in the single-digit nM range. These values would represent the tightest binders
of TAR RNA to date. In order to corroborate this extraordinary finding, I sent the proteins to the
lab of Ite Laird-Offringa for analysis via Surface Plasmon Resonance (SPR).
The TBP 6.6 was sent for SPR analysis as the same C-terminal His-FLAG fusion protein used
in ELISA analysis (Section 3.2.2). TBP 6.7 was, for final analysis, analyzed without the FLAG tag.
This variant was prepared by PCR amplifying the TBP 6.7 C-term His-FLAG construct with the
U1A-NcoI FP (5′-ATA TAC CAT GGC CCA GGT GCA GC-3′) and TBP 6.7-His RP (5′-GTT AAT
TAA CTA TTA GTG ATG ATG GTG ATG ATG TGC GGC CGC AAC C-3′), cut with NcoI and
PacI, ligated into pET plasmid, and purified as described in Section 3.2.3.
It is worth noting that concentrations of TBP 6.6 and TBP 6.7 were determined via A280 us-
ing a Nanodrop prior to shipping proteins. Initial SPR experiments were performed using this
concentration as a given. A second experiment was performed on the TBP 6.7 in which concen-
tration was determined by gel at the Laird-Offringa lab at USC, after shipment of protein. Due
to differences in measurement and instability during shipment, this resulted in an ~2-fold lower
concentration than was determined prior to shipment. In Table 3.2 this is referred to as “TBP 6.7
(Corrected Concentration).”
3.4.2 SPR Experiment
SPR was performed by Po Han Chen, in the Laird-Offringa lab at the University of Southern
California. Though I was not involved in the performance of the assays, I selected and purified
the proteins involved, and the results both corroborated and informed my own research.
A streptavidin-coated sensor chip (Sensor chip SA, GE Healthcare) was used to coat 25 re-
sponse units (RU) of 5′-biotinylated U1hpII on flow cell 1, and 25 RU of TAR on flow cell 3, leav-
ing flow cells 2 and 4 blank for background correction. Proteins were serially diluted in running
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buffer (10 mM Tris-HCl, pH = 8, 150 mM NaCl, 5% glycerol, 62.6 μg/mL bovine serum albumin,
1 mM dithiothreitol, 0.05% surfactant P20, and 125 μg/mL yeast tRNA) to the concentrations in-
dicated (Fig. 4D) and injected at 20 °C with a flow rate of 50 uL/ min over all surfaces consec-
utively. In each of three independent experiments, triplicate injections were fully randomized
and interspersed with buffer injections to allow double referencing. After each protein injection
the surface was regenerated with a 1-min 2 M NaCl injection, followed by a buffer injection. Data
was processed using Scrubber and analyzed using CLAMP XP2 and a simple 1:1 Langmuir inter-
action model with a correction for mass transport. Association and dissociation rates are listed
in Table S2. U1A RRM1 was injected for comparison, using the conditions described above. The
biotinylated RNA was from the same stock as that used in the ELISA, demonstrating that RNA
was viable.
3.4.3 SPR Analysis
A benefit of SPR is that it is able to give full kinetic information. A complete analysis with
the ka, the kd, and the KD for TBP 6.6–TAR, TBP 6.7–TAR, and U1A–U1hpII is shown in. Full
statistical information for the initial, uncorrected experimental values, can be found in Table 3.1.
The interesting contrast between TBP 6.6 and TBP 6.7 can only be seen in this kinetic data. Their




So a binding interaction is, intuitively, tighter if the complex forms faster, or dissociates











Table 3.1: Statistical Values of SPR for TBP 6.6 and TBP 6.7 and wtU1A for TAR and U1hpII RNAs
TBP 6.6 and TAR RNA
experiment 1 experiment 2 experiment 3
ka 1.16 × 107 1.23 × 107 1.42 × 107
kd 1.91 × 10-2 1.38 × 10-2 1.39 × 10-2
KD (M) 1.65 × 10-9 1.12 × 10-9 9.79 × 10-10
average SEM SD
ka 1.27 × 107 7.58 × 105 1.31 × 106
kd 1.56 × 10-2 1.76 × 10-3 3.04 × 10-3
KD (M) 1.25 × 10-9 2.03 × 10-10 3.51489 × 10-10
TBP 6.7 and TAR RNA
experiment 1 experiment 2 experiment 3
ka 1.81 × 107 4.64 × 107 2.32 × 107
kd 9.01 × 10-3 2.31 × 10-2 1.30 × 10-2
KD (M) 4.98 × 10-10 4.98 × 10-10 5.60 × 10-10
average SEM SD
ka 2.92 × 107 8.72 × 106 1.51 × 107
kd 1.50 × 10-2 4.20 × 10-3 7.28 × 10-3
KD (M) 5.19 × 10-10 2.06 × 10-11 3.55991 × 10-11
wtU1A and U1hpII
experiment 1 experiment 2 experiment 3
ka 1.21 × 107 7.13 × 106 1.38 × 107
kd 5.41 × 10-4 3.60 × 10-4 3.64 × 10-4
KD (M) 4.47 × 10-11 5.05 × 10-11 2.64 × 10-11
average SEM SD
ka 1.10 × 107 2.00 × 106 3.47 × 106
kd 4.22 × 10-4 5.97 × 10-5 1.03 × 10-4
KD (M) 4.05 × 10-11 7.27 × 10-12 1.25876 × 10-11
106
According to these data, which are the best head-to-head comparison between the two, the
TBP 6.7 is ~5-fold slower to form, but also ~5-fold slower to dissociate. Notably, given equal KDs,
slower kinetics are preferable in a pharmacological sense, since a slower on/off rate means that
an effector molecule stays with its target. Additionally, slower kinetics generally indicate better
pharmacological specificity [118]. In a more general sense, the fact that the kinetics vary between
TBP 6.6 and TBP 6.7 indicates that they have slightly different modes of binding.
Figure Analysis
The SPR binding curves can be seen in Figure 3.8 and demonstrate the excellent binding of
TBP 6.6 and 6.7 to TAR RNA.
Figure 3.8: SPR Binding Curves of TBP 6.6, TBP 6.7 and wtU1A against TAR and U1hpII The binding
and un-binding curves from the SPR experiment performed in the Laird-Offringa lab (adapted from [109]
The interaction between TBP 6.6 or TBP 6.7 and TAR mirrors the excellent affinity of U1A for
U1hpII, while both the TBPs and U1A show little to no affinity for the off-target surface.
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The final measurement of TBP 6.7–TAR binding, done with a corrected concentration to
bring the values in line with normal Laird-Offringa lab concentration protocols, found that the
interaction between TBP 6.7 and TAR was not low nM, but ~500 pM, a success beyond our wildest
expectations. These data can be found in Table 3.2.
Table 3.2: Kinetic and Equilibrium Values of SPR for TBP 6.6, TBP 6.7, and wtU1A for TAR RNA and
U1hpII RNA
TBP 6.7–TAR
TBP 6.6–TAR TBP 6.7–TAR (Adjusted Concentration) U1A–U1hpII
KD 1.3 ± 0.2 nM 1.5 ± 0.3 nM 0.50 ± 0.02 nM 0.041 ± 0.007 nM
ka 1.3 ± 0.1 × 107 5.6 ± 0.7 × 106 2.9 ± 0.9 × 107 1.1 ± 0.2 × 107
kd 1.6 ± 0.2 × 10-2 8.0 ± 0.9 × 10-3 1.5 ± 0.4 × 10-2 4.2 ± 0.6 × 10-4
3.5 Characterization of TAR Binding Selectivity
Binding selectivity, and the requirements for TAR RNA recognition, was further character-
ized by ELISA using a variety of TAR derived RNAs. The protocol was as described in Sec-
tion 3.3.1, but with a standard protein concentration of 20 nM, rather the the 50 nM used in initial
characterization. We used a TAR-derived RNA hairpin, designated hairpin 1 (hp1) that lacks the
UCU bulge (Figure 3.9), and three TAR-derived RNAs designated hairpins 2, 3, and 4 (hp2, hp3,
and hp4), which have two consecutive mutations in the apical loop (structures shown in Fig-
ure 3.9A, with mFold analyses shown in Figure 3.10 and Table 3.3.
The most dramatic change in binding was observed when we removed the UCU bulge in
TAR (hp1). When we performed an ELISA using this immobilized RNA, essentially no binding
was observed with either TBP 6.6 or TBP 6.7 (Figure 3.9,). This finding is important because the
native TAR-binding protein (Tat) largely recognizes the UCU bulge. Thus, if our proteins occupy




TAR hp1 hp2 hp3 hp4 hp5 hp6 BIVTAR
Figure 3.9: Affinity of TBP 6.6 and TBP 6.7 for Modified TAR TBP 6.6 and 6.7 show different affini-
ties, via ELISA assays, for TAR derived hairpins with a variety of modifications, shown in A made to the
stem-bulge, loop, or stem with the intention of probing binding mechanism. We also tested the affin-
ity of TBP 6.6 using a different subtype of TAR, from the Bovine Immunodeficiency Virus (BIV-TAR).B
shows the reduction in binding from these various changes. Of note is hp4, a loop mutation which greatly
reduces binding to TBP 6.7, but not TBP 6.6 (adapted from [109]
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Dramatically decreased binding was also observed when the first two loop nucleotides (5′-
CU-3′) were mutated to 5′-GA-3′ (hp2). Less dramatic, but significant, changes in affinity were
observed when we mutated other loop residues. When the last two loop nucleotides (5′-GA-3′)
are mutated to 5′-CU-3′ in hp4, although no appreciable loss in affinity was observed for TBP 6.6,
significantly lower binding was observed for the complex involving this RNA and TBP 6.7 (Fig-
ure 3.9B, blue bar). In contrast, mutating the central nucleotides (5′-GG-3′) to 5′-CC-3′ did not
appreciably alter affinity for either protein (Figure 3.9B, green bar).
The ability of synthetic RRMs to recognize specific loop nucleotides begs the question: are
nucleotides in the top of the stem (which link the bulge and loop) recognized by U1A-derived pro-
teins? To probe this, we assessed binding of mutants hp5 and hp6, which have mutated residues
in the top of the stem. Both mutations significantly decreased affinity to TBP 6.6 and TBP 6.7,
suggesting that the uppermost stem nucleotides directly participate in complex formation. Ad-
ditionally, we also tested binding to the TAR sequence from the bovine immunodeficiency virus
(BIV TAR)(53). This RNA is structurally similar to HIV TAR but differs in the sequence and size
of the loop (4 bases in BIV TAR, versus 6 bases in HIV-1 TAR) and in the nature of the stem bulge.
We found that neither TBP 6.6 nor TBP 6.7 had appreciable affinity for this RNA .
This allowed us to make certain guesses about the nature of the interaction between TAR
and TBP 6.6 or TBP 6.7, though they would remain guesses for a while longer. It was clear, based
on the differences in binding to hp4 and the different kinetic profiles, that the two high-affinity
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proteins had different modes of binding, and that the binding was sensitive to alterations in TAR,
and therefore specific.
TAR hp1 hp2 hp3
hp6 BIV-TARhp4 hp5
Figure 3.10: mFold Calculations of Hairpins Used to Analyze Selectivity We wanted to be sure that
our tests were still being done with folded RNA, and mFold calulations indicate that given our melting
and refolding protocol, there was little danger of the RNA being unfolded. Folding energies are given in
Table 3.3
3.6 SHAPE Analysis
I was also fortunate to have the assistance of Chringma Sherpa and Stuart Le Grice at the
National Cancer Institute, who were able to perform selective 2′hydroxyl acylation analyzed by
primer extension (SHAPE) analysis on the interaction of TBP 6.6 and 6.7 with the HIV 5′ UTR.
SHAPE is a complicated assay, but can be generally described as using the accessibility of the
2′-OH on RNA as a proxy for conformational flexibility at a given base, and changes in conforma-
tional flexibility upon binding with protein are used as an indicator of where the protein binds.
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3.6.1 SHAPE Context
We predicted that TBP binding to TAR would make the TAR region on the HIV 5′ UTR
less amenable to chemical modification. We studied binding in the context of the 362-nt 5′-
UTR because this RNA is highly structured, harboring the TAR and polyA hairpins, the primer
binding site (PBS), packaging signal (Ψ), dimer linkage sequence (DLS), and major 5′ splice site
(5′ss). [119, 120]. These multiple cis-acting elements bind different ligands and support long-
range interand intramolecular interaction(s) that facilitate genome transcription, translation,
RNA dimerization/packaging, and splicing. Therefore, TBP binding to the 5′-UTR provides a
direct and biologically relevant measure of potential off-target effects.
3.6.2 SHAPE RNA Prep
The 5′-UTR RNA exists in monomeric and dimeric forms [121–124], and because SHAPE mea-
sures ensemble-average reactivity, folding conditions were optimized to prepare a homogeneous
monomeric RNA Figure 3.11A.
Figure 3.11: RNA Folding Conditions and Baseline Reactivities for SHAPE In A we an see the clear
difference in size on a PAGE gel of monomeric vs. dimeric HIV 5′ UTR, and in B the baseline SHAPE
reactivities of the HIV 5′UTR. Adapted from [109].
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To prepare monomeric RNA, the 362 nt long NL4-3 5′ UTR RNA was prepared by in vitro
transcription using the MegaShortScript kit (Ambion/Life Technologies) according to manufac-
turers’ recommendations. DNA template used in the transcription reaction was generated by
PCR from a proviral pNL4-3 plasmid using high fidelity platinum Taq DNA polymerase (Invit-
rogen) and forward and reverse primers “T7L” (5′-TAATACGACTCACTATAGGTCTCTCTG-3′)
and “369R” (5′-GCTTAATACCGACGCTCTCGC-3′) respectively. The forward primer was de-
signed to introduce T7 promoter sequence at the 5′ end of the 5′UTR. The RNA was then treated
with Turbo DNase I for 1 hour at 37 °C, heated at 85 °C for 2 min and run on a denaturing gel (5%
polyacrylamide (19:1)), 1x TBE, 7M urea) at constant temperature (45°C, 30W max). The 5′ UTR
band was then excised, electro-eluted at 200 V for 2 hours at 4 °C, ethanol precipitated and stored
at -20 °C in TE buffer (10 mM Tris, pH = 7.6; 0.1 mM EDTA) prior to use.
3.6.3 SHAPEMethod
In 5 different tubes, 40 pmoles of RNA in a total volume of 10 µl was refolded by heating
to 85 °C for 2 minutes, followed by slow cooling to 25 °C for 15 minutes (ramp rate 0.1°C/sec).
Meanwhile, two-fold serial dilutions of U1A mutant protein (20 picomoles/µl, 10 picomoles /µl ,
5 picomoles /µl , 2.5 picomoles /µl) were made in the protein storage buffer (20 mM phosphate,
pH = 7.4, 150 mM NaCl containing 10% glycerol). The volume in each tube was brought to 284
µl by adding 274 µl of nuclease free water (Invitrogen). 16 µl of each protein dilution or 16 µl of
protein storage buffer alone was incubated with the folded RNA at 37 °C for 10 mins. 144 µl of
each RNA-protein mixture was aliquoted into two tubes labeled as “NMIA+” and “NMIA-”. RNA
in the “NMIA+” tubes was chemically modified by incubation with 16 µl of 30 nM NMIA in an-
hydrous DMSO at 37 °C for 20 minutes. To the “NMIA-” tubes, 16 µl of anhydrous DMSO was
added and these tubes were also incubated at 37 °C for 20 minutes. Protein in both the “NMIA+”
and “NMIA-” tubes was removed by phenol-chloroform extraction. For this, 140 µl of water fol-
lowed by 300 µl of phenol:chloroform:iso-amyl alcohol mixture pH 6.8 (Ambion) was added to
each tube and spun at 14000 rpm at 4 °C for 5 mins. 250 µl of the aqueous phase was recovered
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and ethanol precipitated. The RNA pellet was suspended in 12 µl nuclease free water. 3 pico-
moles of each RNA were then used to generate cDNA library for each RNA. Subsequent cDNA
processing/fractionation and SHAPE data analysis were conducted as previously described [125].
To check the homogeneity of the RNA samples, 20 µl of the SHAPE reaction mix containing
16 µl of protein storage buffer alone was sampled out just before the addition of NMIA and frac-
tionated on a native gel [4% polyacrylamide (19:1), 1x TBE] at constant voltage of 200V at 4 °C for
5.5 hours. RNA bands were visualized by SYBR Green II RNA Gel Stain (Life Technologies).
3.6.4 SHAPE Results
Averaged SHAPE reactivity values from three independent experiments were color-coded
onto the proposed pseudoknot monomeric 5′-UTR structure [122,123] as the algorithm of the soft-
ware commonly used for RNA secondary structure prediction (RNAStructure) cannot be used to
predict pseudoknot structures. As shown in Figure 3.11B, data for the 5′-UTR RNA in the absence
of protein are at slight variance with the proposed pseudoknot structure.
Such discrepancy in HIV-1 monomeric RNA secondary structure, which was previously re-
ported [123], may reflect differences in folding conditions and tertiary interactions. SHAPE anal-
ysis was performed at different RNA:TBP ratios (1:1, 1:2, 1:4, and 1:8), and appreciable changes in
acylation sensitivity were observed only when either protein was present in a 4- or 8-fold molar
excess (Figure 3.12, Figure 3.14). Reactivity values were color-coded (Figure 3.14A for TBP 6.6 and
Figure 3.14 for TBP 6.7) and plotted as a function of nucleotide position (Figure 3.14B for TBP 6.6
and Figure 3.14D for TBP 6.7). For the determination of which nucleotides were conformation-
ally flexible or constrained by TBP binding, reactivity values in the absence of the protein were
subtracted from those in its presence, and the resulting difference values were plotted as a func-
tion of nucleotide position (Figure 3.14C for TBP 6.6 and Figure 3.14F for TBP 6.7). Following
the previously reported quantitative SHAPE difference cut-offs, 60 nucleotides with a reactiv-
ity difference > +1 were designated as conformationally more flexible and those with a reactivity
difference < −1 were assigned as conformationally more constrained.
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Figure 3.12: SHAPE Data Using 4:1 Protein:RNA A,B TBP 6.6–TAR or C,DTBP 6.7–TAR show some
changes, but were less active than the 8:1 data shown in Figure 3.14. B and D show the reactivity of each
base position, while A and C transpose this reactivity onto a map of the HIV 5′-UTR. Adapted from [109].
3.6.5 Qualitative Binding
One reviewer complaint about our affinity measurements is that they were all performed
in the context a solid scaffold (both ELISA and SPR require immobilzied target). In the course
of performing the SHAPE assay, qualitative gel-shift assays were performed which demonstrate
binding outside the presence of a scaffolding. These data can be seen in Figure 3.13.
3.6.6 SHAPE Data
A common feature of TBP 6.6 and 6.7 complexes was increased acylation at several important
positions of the TAR hairpin. Protein binding destabilized the local helix at nucleotides U 12
, U 13 , A 14 , G 15 for TBP 6.6 and U 13 , and A 14 for TBP 6.7. Nucleotide C 23 of the UCU
loop (which was deleted in the hp1 mutant) was also rendered more flexible in the presence of
TBP 6.6. Interestingly, of all TAR mutants tested for reduced binding to TBP 6.6 and 6.7 by ELISA
(Figure 3.9), the hp1 mutant most significantly disrupts the interaction. Therefore, the SHAPE
and ELISA assays collectively implicate UCU loop nucleotide C 23 in TBP 6.6 binding. TBP 6.7
significantly constrained nucleotide C18 located at the base stem implying C18 as an important
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TBP 6.7 Binding to Full HIV 5′ - UTR
Molar Excess of TBP 6.7
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TBP 6.7 Binding to TAR – Poly(A)
Molar Excess of TBP 6.7
Monomeric HIV
TAR – Poly(A)
Figure 3.13: TBP 6.7 Binding TAR via Gel Shift Assay In both the full HIV 5′-UTR and the isolated TAR–
Poly(A) element, appreciable shifts are seen with a 32-fold excess of TBP 6.7. This shift occurs in the full
5′-UTR in both the monomeric and dimeric forms. It is clear that this is not degradation, as all shifts
appear to involve increasing mass. This qualitative data shows binding occurring in the absence of a solid
support. Adapted from [109].
contact site for the protein. Conversely, no TAR nucleotide was rendered more constrained by
TBP 6.6 binding, suggesting it may bind to an already constrained (base-paired) region, e.g., the
upper stem, which was shown to be important for binding by ELISA (Figure 3.9). Therefore, both
TBP 6.6 and TBP 6.7 proteins induce significant, yet distinctly different, conformational changes
in TAR, suggesting they interact differently.
No significant changes in acylation sensitivity were observed outside the TAR region for
TBP 6.6, indicative of a local interaction. In contrast, TBP 6.7 significantly increased conforma-
tional flexibility at nucleotides C58, A73, A74, U94, G99, U100, U131, C159, U176, G178, C179, A192,
A211, G212, C219, C238, C267, and U295. TBP 6.7 also significantly constrained nucleotide C 292 in
the SL2 loop (the major 5′-splice site). SL2 residues were shown to mediate long-range contact
with residues at the base of SL1 and upstream of the U5 region 56 in the dimeric UTR. Therefore,
by decreasing reactivity of the SL2 loop residue, TBP 6.7 could shift the equilibrium toward the
dimeric UTR conformer.
Furthermore, we rule out nonspecific protein−RNA interactions driving the conformational
flexibility observed outside the TAR hairpin of the 5′-UTR as TBP 6.7 strongly discriminates
against (a) BIV TAR, a highly homologous relative of HIV-1 TAR (Figure 3.9) and (b) 5000-fold
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Figure 3.14: SHAPE Data Using 8:1 Protein:RNA With a protein:RNA ratio of 8:1 A,B,C TBP 6.6 or D,E,F
TBP 6.7. The SHAPE profile of the 5′UTR was significantly altered. The TAR regions in both were heavily
impacted, but TBP 6.7 seemed to alter reactivity on residues far (in sequence space) from the TAR element.
B and E show the reactivity of each base position in TAR, while A and D transpose this reactivity onto
a map of the HIV 5′-UTR. C and F interpret these data as nucleotide positions which are more or less
constrained. Adapted from [109].
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excess of competitor tRNA (Figure 2.5). Therefore, we propose that TBP 6.7 binding to TAR in
the context of the 5′-UTR induces long-range alterations in overall topology that are more pro-
nounced than those promoted by TBP 6.6. Stated differently, secondary consequences of TBP 6.7
binding to TAR on global 5′-UTR topology cannot be ruled out. This notion is supported by
recent work that identified small-molecule ligands specific for TAR, where changes in SHAPE
reactivity profiles where observed distal to the ligand binding site [126].
Thus, we believe that differences in the nature of the primary interaction between TPB 6.6–
TAR and TPB 6.7–TAR, and the structural consequences thereof, might explain why TPB 6.7
selectively induces long-range topological changes. These differences might also explain why,
despite having equal affinity toward TAR RNA, the two TAR-binding proteins have different bio-
logical activity. As shown subsequently in the manuscript, TBP 6.7 prevents Tat–TAR interaction
and inhibits transcription from the TAR region whereas TBP 6.6 does not (shown in Figure 3.15).
3.7 Disrupting the Tat–TAR Interaction
The synthetic proteins described in this work recognize TAR RNA with excellent affinity and
exquisite selectivity. Though this is an achievement in-and-of itself, any potential therapeutic
and many basic research utilities of these new proteins rests on their ability to inhibit a pro-
tein−RNA interaction involving the trans-activator of transcription (Tat) protein and TAR RNA.
In binding to TAR, Tat alters the transcription complex, recruits the positive transcription elon-
gation complex (PTEFb) of cellular CDK9 and cyclin T1, resulting in an increase in the produc-
tion of full-length viral RNA [127]. Reagents that inhibit the Tat–TAR complex can suppress the
transcription of full-length HIV RNA, leading to suppression or abrogation of HIV protein ex-
pression and production of virus [127].
To determine if our new TAR-binding proteins inhibit an interaction with Tat, we utilized a
previously described Tat peptide comprising a portion of the full length Tat protein known to
bind RNA (N-RKKRRQRRRRPPQSQTHQVSLSKQPTSQPRGDPTGPKE-C) [128].
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3.7.1 ELISA
I initially attempted to use ELISA (as in Section 3.3) to determine if TBP 6.7 could disrupt or
inhibit the Tat–TAR complex; however, the high theoretical charge of this Tat peptide N-RKK
RRQRRRPPQGSQTHQVSLSKQPTSQPRGDPTGPKE-C; theoretical charge = +9) complicated
these experiments. I found that Tat peptide adsorbed onto the plates whether or not biotinylated
TAR was also immobilized (presumably through nonselective interactions with streptavidin) and
could not be easily removed. Despite many attempted variants on the ELISA protocol, this sim-
ple fact of the Tat peptide always binding the plate meant that these attempts were not succesful.
3.7.2 ITC
To overcome the fact that our principal immobilized surface assay was ineffective, we used
a solution phase experiment—isothermal titration calorimetry (ITC)—to characterize the inter-
action and the effect our TAR-binding proteins have on complex formation.
ITC was performed using a MicroCal iTC200 calorimeter maintained at 25 °C. TBP 6.6 and
TBP 6.7 were expressed with C-terminal His tags, and purified by as described above (Sec-
tion 3.2.3). Purified proteins were dialyzed overnight in phosphate buffer (20 mM sodium phos-
phate, pH = 7.4, 150 mM NaCl). Truncated HIV Tat peptide was ordered (Genscript Corp), and
resuspended in this phosphate buffer. HIV TAR RNA was placed in the sample cell at concentra-
tions ~6 µM, and ~60 µM Tat peptide was injected in 2.49 µL increments (16 injections total), with
an initial injection of 0.4 µL, at 180 second intervals using a stirring speed of 750 rpm. Displace-
ment experiments were performed by titrating 65.3 µM Tat peptide into a pre-formed 1:1 complex
of TAR and TBP 6.7 (6.1 µM each), or a pre-formed 1:2 complex of TAR and TBP 6.6 (6.1 µM TAR
and 13.8 µM TBP 6.6). Pre-formed complexes were used in order to reduce the complexity of the
system to manageable levels: a displacement assay (with the TBP displacing Tat peptide) would
have unpredictable heats of formation/dissolution, and mixing of the Tat and TBPs would be a
complicated three-body system. Therefore, we pre-complexed the Tat and TBP in order to best
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represent the most realistic cellular scenario where TBP 6.7 would prevent the Tat–TAR interac-
tion rather than break it up.
Data were analyzed using Origin7.0 (MicroCal, ITC200) using a one set of sites binding model
for fitting. All data were reference subtracted by subtracting the mean heat of dilution from each
data point.
Figure 3.15 shows that TBP 6.7, but not TBP 6.6 block formation of the Tat–TAR complex.
Presumably, this discrepancy relates to their apparently different modes of binding (given the
differences in kinetics via SPR, and the differences in binding to TAR mutants). It could be as
simple as the slower off-rate of the TBP 6.7 leaving the TAR free for TAT binding. It could also
be that the different modes of binding by TBP may leave the mode of binding for TAT accessible
for one, but not the other, or it could be that TBP 6.6 somehow recruits TAT peptide.
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Figure 3.15: Disruption of Tat–TAR interactionMeasured by ITC The RNA binding region of TAT pep-
tide binds TAR RNA, but this binding does not occur if TAR is pre-complexed with TBP 6.7. Interestingly,
pre-complexing with TBP 6.6 seems to have the opposite effect, possibly because the TBP 6.6 makes the
TAR bulge more accessible, or because the TBP 6.6 recruits TAT peptide. Adapted from [109].
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3.8 Suppression of Tat–TAR-Dependent Transcription by a
Synthetic TAR-Binding Protein
I performed an in vitro transcription assay to quantify the suppression of Tat/TAR-dependent
transcription of a portion of the HIV-1 genomic DNA which includes the TAR element [129–131]. I
performed this in vitro transcription assay with HeLa cell nuclear extract in the presence of all the
elements needed for Tat/TAR-dependent transcription, with and without TBP 6.7. An overview
of the expected effects on cellular processes is shown in Figure 3.16.
A DNA fragment (-477 to +568) containing the HIV 5′ LTR was PCR amplified from the plas-
mid pLAI.BS (a gift from the Goyce lab) using PLAI FP (5′-TCTAGAACTAGTGGATCTTAG
-3′) and PLAI RP (5′-GCTACAACCATCCCTTCAGAC-3′). An in vitro transcription reaction was
performed in a 40 μL reaction containing 18 μL of HeLa nuclear extract in 20 mM HEPES, 80 mM
KCL 3 mM MgCl 2 , 2 mM DTT 10 μM ZnCl 2 , 15 U rRNasin, 1 microg creatine kinase, 10 mM
creatine phosphate, 250 microM of GTP, ATP, and CTP, 50 microM UTP, and 10 microCi [α- 32
P]-UTP. Reactions contained the PCR amplicon template (Sequence: Section C.2.7), Tat Protein
(Sequence: Section C.2.6), and C-Terminal His6 tagged TBP 6.7 (Sequence: Section C.2.3) were
included in the concentrations given in Table 3.4.
Table 3.4: Reagent concentrations for TAT/TAR Dependent Transcription Assay
Reaction [Template] [Tat Peptide] [TBP 6.7]
1 10 nM 2 μM —
2 10 nM 2 μM 2 μM
3 10 nM 2 μM 0.2 μM
The reactions were incubated for 5 hours at 37 °C, and quenched by addition of 200 μL HSCB
buffer (25 mM Tris-HCL, pH = 7.5, 400 mM NaCl). Following reaction stop 60 μg of glycogen was
added to each reaction as a carrier, as was 1 μL of a 60 base radio-labelled RNA which functioned
as a loading control. Proteins were extracted using phenol/chloroform/isoamyl alcohol, and nu-























Figure 3.16: Biochemical Overview of Transription Assay Tat/TAR-dependent transcription results in
production of mRNA copies of the HIV-1 genome. This transcription is blocked by the addition of TBP 6.7.
RNA loading dye, melted and refolded at 95 °C (to denature and prevent dimerization), and sep-
arated via PAGE. PAGE gels were developed using a phosphor imaging screen and a Typhoon
imager.
A ~500 bp transcript was determined to be the key template-dependent transcript, and was
quantified using ImageQuant software from GE Healthcare. The ~60 base spikant band was used
to confirm that no significant variations occurred during the Phenol-Chloroform extraction and
ethanol precipitation.
Gratifyingly, we observed a concentration-dependent suppression of Tat/TAR-dependent
transcription in the presence of TBP 6.7. At the highest concentration of TBP 6.7 tested (2 μM),






Figure 3.17: TBP 6.7 inhibition of TAT/TAR based Transcription TBP 6.7 was able to inhibit TAT/TAR
based transcription in a concentration dependent manner. 2 μM of TBP 6.7 was able to all but turn off
transcription, and 0.2 μM reduces transcription as can be seen in A a gel, and B the quantification of the
transcription band. Adapted from [109].
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3.9 Conclusions
The work described in this chapter marks the culmination of years of work in the Mc-
Naughton Lab, starting with Brett Blakeley’s low-throughput screens of U1A point mutants. It
also represents a major step forward for the field of RNA-binding proteins in general. The ability
to engineer a protein which binds an RNA to bind a class of RNAs is useful, but engineering a
protein which binds an RNA to bind a different RNA is even more so. There are very few such
instances of a protein being engineered to have altered, rather than broadened specific for a target,
especially for RNA binding proteins. TBP 6.7 especially fits this bill quite well, with its excellent
(~500 pM) affinity for TAR (the tightest TAR-binding molecule, to my knowledge), while having
negligible affinity for U1hpII.
The success of the protein in the functional transcription assay, as well as its ability to affect
the entire bundled HIV 5′-UTR bode well for the possibility of using this protein (or peptides
derived from it, see Chapter 5) to affect the HIV life cycle.
Our success in engineering and characterizing a binder with such excellent affinity was be-
yond our expectations. While we were excited and intrigued by the alterations to RNA binding
based on the mutated TAR variants we used (Figure 3.9), we would ultimately require a crystal
structure in order to truly understand the novel binding interaction we had developed.
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Chapter 4
Crystallization of TBP 6.7 and TAR
4.1 Chapter 4 Introduction
4.1.1 Chapter 4 Summary
After yeast display affinity maturation (Chapter 2), and extensive characterization (Chap-
ter 3), we determined that TBP 6.7 had excellent affinity for TAR and performed well in functional
assays. Yet the chemical determinants of this interaction remained largely unknown. To learn
about these determinants, we began a collaboration with Ivan Belashov in Joseph Wedekind’s
lab at the University of Rochester. I performed some basic confirmation that TBP 6.7 still bound
TAR when it was changed back to the canonical U1A scaffold which would be used to find a crys-
tal structure, and Ivan was able to obtain a crystal structure. This crystal structure illuminates
the interaction between TBP 6.7 and TAR far beyond the crude mutagenesis data we gathered
in Figure 3.9. Notably, we learned that rather than binding the single-stranded loop (as in the
U1A–U1hpII interaction), TBP 6.7 binds TAR via the major groove of the double-stranded stem.
4.1.2 Chapter 4 Attribution
This chapter is adapted from [45].3
All crystallization research in this chapter performed by Ivan Belashov and Professor Joseph
Wedekind of the University of Rochester Medical Center. My role was frequently active, but
advisory, generally involving discussion regarding my typical methods of protein and RNA han-
dling.
Molecular Dynamics simulations by Chapin E. Cavender and Professor David H. Mathews,
also at the University of Rochester.
3Belashov, IA, Crawford, DW, Cavender, CE et al. Structure of HIV TAR in complex with a Lab-Evolved RRM
provides insight into duplex RNA recognition and synthesis of a constrained peptide that impairs transcription.
Nucleic Acids Res, 154:766–15, 2018
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I assisted with cloning of certain constructs, and performed initial checks to make sure that
variants being used in crystallization studies maintained their ability to bind TAR (shown in
Figure 4.1).
4.1.3 Chapter 4 Background
In Chapter 3, I and my collaborators had quantified the binding of TBP 6.7 to TAR. Addition-
ally, we learned a great deal about the long-range effects of TBP 6.7 on the HIV-1 5′-UTR, and
had determined that TBP 6.7 was able to disrupt the Tat–TAR interaction, and inhibit Tat/TAR-
dependent transcription. Despite this knowledge of the effects of TBP 6.7 on TAR, our knowledge
of the mechanism of interaction was limited to supposition based on the crude mutagenesis data
shown in Figure 3.9. To obtain a crystal structure to better understand this interaction, we began
a collaboration with the Wedekind Lab at the University of Rochester, hoping they could solve
a crystal structure.
4.2 PreliminaryWork
Though U1A was well-known to the Wedekind lab, there were some differences between the
version they were accustomed to working with, and our own (our original wtU1A construct was
a gift from the Laird-Offringa lab). The differences were relatively minor. Our lab’s version has
short linker sequences at the N- and C- termini and chemically minor changes at positions 75
(ours has a tyrosine, theirs a phenylalanine) and 88 (our version has an arginine, theirs a lysine),
far from the putative binding face. These differences are highlighted in Figure 4.1A. No expla-
nation was found for these small differences, and as they ultimately seemed to matter very little,
no particular effort was made to find one.
To make sure that crystallization efforts were not doomed to failure from the start, I used
ELISA to analyze the effects of removing the terminal linker sequences as well as the point mu-
tations. As can be seen in Figure 4.1B, the truncations didn’t affect binding appreciably, and the
R88K only resulted in a minor difference. The Y75F mutation was more drastic, but given that
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the binding is near saturation when the concentration is raised to a concentration of 100 nM, it






















Figure 4.1: ELISA Assays to Analyze Variation Between U1A Scaffolds A The changes in U1A sequence
between the construct in the McNaughton Lab and the Wedekind Lab needed to be analyzed.B The U1A
version used by the Wedekind lab proved to be somewhat, but only somewhat, less avid when those mu-
tations were added to TBP 6.7
4.3 Crystallization
Ivan Belashov was able to successfully crystallize, and solve the structure, of a TBP 6.7–TAR




TBP 6.7 was purified by Ivan Belashov in the Wedekind Lab in a similar manner to its purifi-
cation in the McNaughton Lab.
TBP 6.7 was identified by the McNaughton Lab [109]. TBP 6.7 DNA was prepared as a syn-
thetic gene (GeneScript Inc) comprising the human U1A sequence, yeast-display mutants [109],
and Y31H/Q36R integrated for crystallization . After sub-cloning into pET28a(+) (Novagen) the
crystallization [132]. After sub-cloning into pET28a(+) (Novagen) the thrombin site was modified
by PCR to utilize TEV protease to cleave the N-terminal linker (ENLYFQ/G).
Point mutations were incorporated using the Q5 Site Directed Mutagenesis kit as described
by the manufacturer (NEB) with primers from IDT. Protein expression in E. coli BL21(DE3) (NEB)
was induced by 0.5 mM IPTG in LB at 20 °C. Cells were harvested after 4 h and pellets were frozen
in N2(l). Cells were thawed in a cell lysis buffer (CLB): 0.05 M Na-HEPES pH 7.5, 0.5 M NaCl, 0.02
M imidazole pH = 8.0, 0.0005 M EDTA, 0.005 M β-Mercaptoethanol and 0.01% (v/v) Brij35; the
cell slurry was made 2 mg ml-1 in lysozyme (VWR).
After 20 min, cells were sonicated and the clarified supernatant was applied in batch to Ni-
NTA resin (Pierce) equilibrated with CLB. After 2 h of nutation at 4 °C, resin was poured into a 1.5
cm × 10 cm gravity-flow column (CrystalCruz), washed with 40 column volumes of CLB, and two
column volumes of wash buffer (WB): 0.05 M Na-HEPES pH 7.0, 0.3 M NaCl, 0.04 M imidazole
pH 7.5, 0.005 M EDTA, 0.005 M β-ME and 0.01% (v/v) Brij35. Elution was in 3 ml fractions using
elution buffer (EB): 0.15 M NaCl and 0.2 M imidazole pH 7.5. Fractions with 280 nm absorption
were pooled and diluted with EB to a final imidazole concentration <0.02 M. TEV [133] was added
(1:100 TEV:TBP) and the mixture was incubated at 4 °C. After 16 h, the reaction was incubated in
batch with pre-equilibrated Ni-NTA, and supernatant was collected. Protein was loaded with an
ÄKTA Pure (GE Lifesciences) at 0.5 ml min-1 onto a 5 ml HiTrap SP FF column (GE), followed by
a linear gradient comprising: 0.15–0.85 M NaCl, 0.05 M Na-HEPES pH 7.0, 0.0025 M EDTA and
0.00025 M β-ME; TBP 6.7 elutes at ~70% as a sharp peak. The concentrated protein is polished
on a HiPrep (16/60) Sephacryl S-300 HR column (GE Lifesciences). TBP 6.7 (Mr of 11.5 kDa) ex-
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hibits higher retention than predicted by its Mr, eluting at or >1 CV. The yield is 2–3 mg/L of cells.
Mutants were purified similarly.
4.3.2 Crystallization and X-Ray Data Collection
TAR RNA, produced by chemical synthesis, and purified by denaturing gel electrophoresis
(Dharmacon), was suspended in 0.01 M Na-HEPES pH 7.5 to a concentration of 0.4 mM and
heated at 65 °C. After 3 min, the RNA was diluted 10-fold with folding buffer (0.01 M Na-HEPES
pH 7.5, 0.05 M NaCl and 0.002 M MgCl2) and incubated at 65 °C for 2 min. The RNA was cooled
overnight to room temperature. TBP 6.7 was titrated drop-wise into folded RNA at a 1.2:1 molar
ratio (48 μM protein to equal volume of 40 μM RNA) with vortexing.
The mixture was incubated at room temperature for 0.5 h and concentrated to 10–12 mg ml-1
based on 280 nm absorption using a Nanosep 3K Omega spin-filter (PALL); the final complex
was 0.2 μm filtered (Millex, EMD). Crystals were prepared by vapor diffusion in which an equal
volume of well solution (0.05 M Na-cacodylate pH 7.0, 0.1 M NaCl, 0.002 M (NH4)2SO4 and 17%
(w/v) of PEG-MME 5K) was added to 1.5 μl of TAR–TBP 6.7 complex with equilibration over 1 ml
of well solution at 20 °C. Crystals grew within 72 h producing a half-octagon habit that reached
0.12 mm × 0.07 mm × 0.04 mm in 1 week. Cryo-protection was by serial transfer into well solu-
tion supplemented with 5–20% (v/v) glycerol followed by snap cooling in N2(l). X-ray data were
recorded at the Stanford Synchrotron Radiation Lightsource Table 4.1.
4.3.3 Phase Determination, Refinement and Analysis
The structure was determined by molecular replacement in PHENIX [134, 135] start-
ing from U1A RRM1 [102] devoid of RNA. The initial TBP 6.7 model was generated by
Phenix.autobuild [134], although TAR required manual building in Coot [136] with interven-
ing cycles of Phenix.refine [134]. This iterative approach converged on Rcryst/Rwork/Rfree values of
19.1%/18.9%/22.1% to 1.80 Å resolution (Table 4.1). An unbiased electron density map envelops all
TAR nucleotides and the TBP 6.7 core (Figure 4.2A) indicating the quality of the refined structure.
Reduced-bias omit maps demonstrate atomistic features that define placement of R47, R49* and
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Table 4.1: X-ray Diffraction and Refinement Statistics of TBP 6.7–TAR Co-crystal
Data collection
Space group P43212 
Cell constants 
a = b, c (Å) 40.4, 284.6 
α = β = γ (°) 90.0 
Resolution (Å) 38.90–1.80 
(1.83–1.80) 
Rp.i.m. (%) 2.6 (45.1) 
CC1/2 (%) 98.7 (69.2) 
I/σ(I) 19.9 (1.8) 
Complete (%) 99.4 (91.8) 
Redundancy 8.8 (7.9) 
Refinement 
Resolution (Å) 37.2–1.80 
No. reflections 23 297 










Bonds (Å) 0.005 
Angles (°) 0.759 




Coord. error (Å) 0.21 
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R52 side-chain rotamers and opposing bases (Figure 4.2B-D). These features are representative
of the high-quality model that defines the TBP 6.7–TAR interface. The accompanying quality
indicators (Table 4.1) provide confidence that the coordinates accurately describe the molecular
details of protein-mediated TAR recognition. All cartoons, schematic diagrams and movies de-
rived from coordinates were produced in PYMOL (Schrödinger, LLC). Cα superposition and Sc
analysis were performed in CCP4 [137, 138].
4.3.4 Molecular Dynamics (MD) Simulations
MD simulations were conducted on the TBP 6.7–TAR complex, the TAR-(β2β3 loop) peptide
comprising residues L41 to F59 (Figure 5.1), and isolated TAR RNA. The Amber 14 simulation
package [142] was used to solvate crystallographic coordinates, or subsets thereof, in a box of
OPC water [143] with 150 mM KCl. Starting coordinates were energy minimized using 500 steps
each of steepest descent and conjugate gradient minimization with 25 kcal mol-1 Å-2 positional
restraints on solute atoms. Then, 10 cycles of alternating between minimization with decreasing
positional restraints on the solute atoms and NVT dynamics were performed. After 250 ns of
NPT equilibration, production dynamics simulations were performed using the AMBER ff14SB
( [144–146]) force field in the NPT ensemble with periodic boundary conditions, a time step of
2 fs, and a direct space cutoff of 10.0 Å for nonbonded interactions. Bond lengths for covalent
bonds involving hydrogen were constrained using the RATTLE algorithm [147]. Temperature
was maintained at 300 K using a Langevin thermostat with a collision frequency of 1 ps-1, and
pressure was maintained at 1 atm using a Monte Carlo barostat. Simulations were performed on
Nvidia Tesla K20X GPU cards. Six trajectories each of TAR–TBP 6.7, TAR–(β2β3 loop) peptide,
and free TAR were each run for 4 μs for an aggregate time of 72 μs. For simulations of TAR–(β2β3
loop) peptide, the distance between the terminal carbon atoms of the β2β3 loop was restrained
using a harmonic restraint with a force constant of 250 kcal mol-1 Å-2 (roughly the strength of a
covalent bond) to mimic peptide cyclization. Analysis of simulation interactions was performed
using custom tools developed using the LOOS software [147].
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Figure 4.2: ElectronDensityMapofTBP 6.7–TARCrystal StructureAAn unbiased, composite iterative-
build omit map [139] at 1.80 Å resolution contoured at 1.25σ. To differentiate the chains, the electron density
surrounding the final refined coordinates of TBP 6.7 (blue bonds) is colored red, whereas that enveloping
TAR (purple bonds) is green. The protein main-chain electron density is continuous from E5 to A95 with
side-chain rotamers and carbonyl oxygens discernible for most amino acids. All nucleotides of the TAR
27-mer are well defined with obvious sugar puckers and base orientations about the N-glycosidic link-
age. BReduced bias simulated-annealing-omit (mFo–DFc) electron density map [140,141] calculated from
phases of the refined coordinates, but excluding atoms from the side-chain of R52 and base of Gua36; here
and below, the map contour level is 3.0 σ and the final refined coordinates are depicted as ball-and-stick
models. C Simulated-annealing-omit electron density map calculated from phases of the refined coordi-
nates, but excluding atoms from the side-chain of R49* and the base of Gua28. D Simulated-annealing-
omit electron density map calculated from phases of the final refined coordinates, but excluding atoms
from the side-chain of R47 and the base of Gua26. E,F,G show the absence of symmetry contacts between
TBP 6.7–TAR units. From [45].
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4.4 Structural Analysis of the HIV TAR-TBP 6.7 Complex
4.4.1 Comparison to Previous Structures
To define the molecular details by which TBP 6.7 recognizes TAR, we determined the co-
crystal structure (Table 4.1, Figure 4.2, and Section 4.3.2). In complex with TBP 6.7, TAR exhibits
several architectural features consistent with solution studies of small ligands bound to the RNA.
Hallmarks include stems S1a and S1b interrupted by the major-groove Uri23•Ade27-Uri38 triplex,
flanked by a bulge that extrudes Cyt24 and Uri25 from its core (Figure 4.4A–D and Supplemen-
tary Movie S1). These characteristics are consistent with NMR analyses [55, 56] and persist on a
μs timescale in our MD simulations (Figure 4.3A).
Figure 4.3: Fractional Occupancy and Molecular Dynamic Simulations for TAR-TBP 6.7 Complex
Here and elsewhere, the fractional occupancy is reported for specific interactions indicated in the accom-
panying diagram (derived from the crystal structure). Hydrogen bonds are depicted as thin broken lines.
Fractional occupancy (left) is the fraction of simulation frames—sampled at 1 ns intervals —in which a
specific hydrogen bond is occupied. Bars represent mean fractional occupancy over the six MD trajecto-
ries ± SEM. Hydrogen bond occupancy is determined using a heavy-atom distance cutoff of 3.5 Å and an
angle cutoff of 45° from linear. For each interaction, a time series of the occupancy during a given simula-
tion (depicted as a colored line, right) shows a dot if the interaction is present. A color-coded key for each
simulation type is shown at the top. In all cases, the molecules were pre-equilibrated for 250 ns. From [45],
which also includes supplementary movie files.
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Conversely, MD simulations conducted on apo-state TAR showed rapid dissolution of the
triple (Table 4.3A, and Supplementary Movie S3 from [45]) concurring with ligand-free NMR
analyses ( [148–152]). Another hallmark of TAR is that the apical hexaloop interconverts between
minor and major conformations [153]. In the latter, Uri31, Gua32 and Ade35 are flexible with ade-
nine extruded [69,152–154]. This is again mostly consistent with our co-crystal structure wherein
Ade35 projects away from the hexaloop, whereas Gua32 and Uri31 stack on Cyt30 (Figure 4.4). Al-
though unrepresented in solution ensembles of TAR-peptide complexes [55,56], the TAR/TBP 6.7
co-crystal structure exhibits a canonical cross-loop Cyt30-Gua34 pair (Figure 4.4C, E) supported
by chemical modification experiments, NMR assignments, sequence conservation, and cyclin-
T1 binding requirements [39, 68, 69, 155–157]. MD simulations indicate that Cyt30/Gua34 pairing
is stable Figure 4.3, although transient dissolution and spontaneous reformation are seen for the
TBP 6.7-bound and apo states. Nonetheless, the interaction appears to be a stable feature of the
RNA conformational landscape (Supplementary Movie S2 from [45]). In one trajectory, Ade35
makes an excursion into the apical loop to displace Gua34 and interact with Cyt30 (Figure 4.3B,
right, purple lines of trajectory four), agreeing with a low population state observed by NMR [153].
A likely site of conformational variation is extruded base Gua33, which forms a crystal contact
with Cyt24 of the bulged loop from a neighboring molecule (Figure 4.2E, F). Neither base stacks
appreciably inside the apical loop or bulged loop core on the timescale of MD simulations (Sup-
plementary Movies S2 and S3 from [45]) and this contact does not influence TBP 6.7 binding.
Figure 4.4
Comparison of the TBP 6.7 fold to that of U1A reveals that the evolved protein adopts the same
mixed βαββαβ, architecture as parental RRM1 (Figure 4.4 A,F). A Cα superposition produced a
modest rmsd of 1.1 Å, but local conformational differences are apparent. The greatest variations
include the β2β3 loop (46–51, rmsd 3.9 Å) and the C-terminus (91–95, rmsd 3.6 Å), which were each
subjected to saturation mutagenesis to achieve TAR binding [109]. When oriented similarly it is
evident that TBP 6.7 and U1A engage their RNA targets in extraordinarily different ways (Fig-










































































































































Figure 4.4: Overview of TAR Binding Protein 6.7–TAR complex Ribbon and schematic diagrams de-
picting the HIV-1 TAR–TBP 6.7 complex of this investigation and parental U1hpII-U1A. A Global view of
the co-crystal structure depicting the TBP 6.7 RRM domain (blue) engaging TAR RNA (purple) in upper
helical stem S1b. Arginines of the β2β3 loop that provide the principal determinants of TAR binding are
depicted as ball-and-stick models (orange); similar depictions are provided for conserved RRM amino
acids known as RNP2 (Y13) and RNP1 (R52, Q54 and F56). B Global view of the structure in A rotated +90°,
providing a view looking through the apical loop and down the helical axis. The TBP 6.7 β2β3 loop pen-
etrates deeply into the TAR major groove. C Schematic diagram depicting interactions between TBP 6.7
and TAR based on the co-crystal structure. Henceforth asterisks (*) indicate lab-evolved TBP 6.7 residues
(see Figure 2.8). DClose-up of the TAR Uri23•Ade27-Uri38 major-groove base triple and the central bulge
that interrupts stems S1a and S1b. Dashed lines joining ball-and-stick models represent putative hydrogen
bonds unless noted otherwise. E Close-up view of the apical hexaloop and interface with the S1b closing
base pair. F Global view of the U1hpII-U1A complex [102] oriented and colored as in A. U1A binds U1hpII
primarily within the single-stranded region of the upper loop. From [45].
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stranded loop of U1hpII between Ade66 and Cyt72 [102]. Despite fundamentally different modes
of engagement, TBP 6.7 buries 1555 Å2 in its protein–RNA interface, which is only 278 Å2 less than
the U1A–U1hpII complex. Importantly, the co-crystal structure reveals that numerous contacts
to TAR originate in the β2β3 loop (Figure 4.4A–C), which yielded a clear consensus during se-
lection that departs from U1A (Figure 2.1. Unexpectedly, the evolved C-terminus of TBP 6.7 is
devoid of TAR contacts, implying that the minimal lab-evolved β2β3 loop is operative in the new
mode of RNA binding, at least in this context.
4.4.2 TBP 6.7 Uses the RNPMotif to Recognize Double-Stranded RNA
Because TBP 6.7 maintains the classical RRM fold, we asked if it uses the conserved RNP
motifs to bind double-stranded S1b of TAR, since these amino acids were unaltered in our ap-
proach [109]. This point is especially significant because RNP residues function classically in
single-stranded RNA recognition [100]. In the U1A–U1hpII complex, RNA bases stack upon aro-
matic RNP side chains to provide affinity and recognition ( [62,100,102,158,159]); Y13 of RNP2 and
F56 of RNP1 stack on bases Cyt70 and Ade71 (Figure 4.4F and Supplementary Figure S3A). In con-
trast, Y13 of TBP 6.7 stacks on Ade35, but F56 does not engage TAR due to a lack of bulged bases
flanking S1b (Figure 4.4A and Supplementary Figure S3B). Conversely, the Q54 amide of U1A
RNP1 approaches the 2′-OH of Gua69 in U1hpII without interacting, whereas Q54 Nδ of TBP 6.7
hydrogen bonds to the 2′-OH of Gua34 in TAR (Figure 4.5A,B), consistent with its RNA readout
role in other RRMs [100]. Finally, R52 of RNP1 recognizes the Hoogsteen edge of loop-closing
pair Gua76-Cyt65 in U1hpII, as well as Gua36 in TAR (Figure 4.53C,D). The former interaction is
the only instance of arginine-mediated base readout by U1A, although its simultaneous recogni-
tion of Ade66 N1 yields a non-optimal, inclined guanidinium-guanine interaction. A key finding
is that TBP 6.7 still utilizes a subset of RNP amino acids to bind TAR, but affinity and specificity
appear to arise primarily from the lab-evolved β2β3 loop, distinguishing it from U1A and other
RRMs [100].
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Figure 4.5: The RNP Motif in the TBP 6.7–TAR Complex The conserved RNP residues, a feature gen-
erally understood to be involved in single-stranded RNA binding participating in duplex interactions A
View of the U1A RRM1 β-sheet face showing Y13 of RNP2 forming a π-stack with Cyt70 of the cognate
U1hpII stemloop. F56 of RNP1 π stacks similarly with Ade71; Q54 of RNP1 makes no RNA contacts [102]. B
View of TBP 6.7 (oriented as in A) wherein Y13 π stacks with Ade35; F56 makes no TAR contacts, but the
Q54 amide hydrogen bonds to both the 2´-OH of Gua34 and the side-chain amide of Q48. C View of the
U1A β2-β3 loop in which R52 of RNP1 uses its guanidinium group to read the N1 imino of Ade66 and the
Hoogsteen edge of Gua76 located in the closing base pair of the U1hpII upper stem. The latter interaction
is the only discernible site of duplex recognition by U1A. D View of the TBP 6.7 β2β3 loop oriented as in
C to illustrate R52 recognition of the Gua36 Hoogsteen edge in stem S1b of TAR. From [45].
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4.5 Thermodynamic Analysis
Thermodynamic analysis of the TAR/TBP 6.7 complex reveals that binding is enthalpy-
driven (ΔH of −25 ± 0.2 kcal mol-1) with an unfavorable entropy (−TΔS of 13.5 ± 0.2 kcal mol-1)
that yields a KD,App of 2.5 ± 0.1 nM (Table 4.2, Figure 4.7A). Analysis of the co-crystal structure
suggested that binding interactions can be parsed into four groups: (i) arginines in the β2β3 loop
that read guanine to impart specificity; (ii) β2β3 loop residues that interact with phosphate or 2′-
OH groups; (iii) evolved protein–protein interactions that stabilize the β2β3 loop; and (iv) inter-
actions outside the β2β3 loop. To test the energetic contributions of each, TBP 6.7 point mutants
































Figure 4.6: Detailed View of the β2β3 loop in the TBP 6.7–TAR Complex Close-up views of key interac-
tions between the evolved β2β3 hairpin loop of TBP 6.7 and HIV-1 TAR based on the co-crystal structure.
ΔG° values from ITC analysis of R-to-A mutations are taken from Supplementary Table S1. A R52 forms
two hydrogen bonds to the Hoogsteen edge of Gua36; for clarity, some evolved amino acids in the β2β3
loop are omitted. B R49* forms a hydrogen bond with N7 of Gua28 and a salt-bridge to its non-bridging
phosphate oxygen. C R47 forms two hydrogen bonds with the Hoogsteen edge of Gua26, as well as hydro-
gen bond and salt-bridge interactions to the Uri23 phosphate. Cation–π interactions and buried surface
areas for each arginine are described in Figure 4.8. From [45].
4.5.1 Contributions of R52
Of the arginines in the β2β3 loop (Figure 2.1), R52 makes the fewest TAR contacts, making it
straightforward to evaluate its binding contributions. Its guanidinium moiety donates hydrogen
bonds from NH1 and NH2 to atoms N7 and O6 of Gua36 (Figure 4.6A and Supplementary Movie
S4 from [45]), while forming a cation–π interaction with Gua34 of the apical loop (Figure 4.8A).
Accordingly, the R52A mutation reduced binding by a factor of 116 (ΔΔG° of +2.8 kcal mol-1) (Ta-
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ble 4.2 and Figure 4.7B). R49* is the only arginine in the β2β3 loop that resulted from yeast display
(Figure 2.2). This side-chain makes an equal number of contacts to TAR compared to R52, but
the modes of interaction are different. The guanidinium group not only makes a hydrogen bond
that recognizes N7 of Gua28, but also forms a salt-bridge to the nucleotide’s pro-Rp oxygen while
engaging in a cation–π contact to Ade27 (Figure 4.6, Figure 4.8 and Supplementary Movie S4
from [45]). Accordingly, R49A* yielded a larger ΔΔG° of +3.2 kcal mol-1, corresponding to a loss
in binding by a factor of 233 (Table 4.2 and Figure 4.7C).
Table 4.2: Thermodynamic Parameters for TAR-TBP 6.7 Binding at 20 °C
Sample KD,App n ΔH° −TΔS° ΔG° ΔΔG°1 Krel2
TBP nM number
sites
kcal mol-1 kcal mol-1 kcal mol-1 kcal mol-1
TBP6.7 2.5 ± 0.13 0.99 ± 0.02 −25.0 ± 0.2 13.5 ± 0.2 −11.6 ± 0.03 0 1
P46A 11.7 ± 2.5 0.97 ± 0.05 −22.7 ± 0.2 12.1 ± 0.1 −10.6 ± 0.1 1 4.7
R47A 1516 ± 163 0.96 ± 0.2 −7.5 ± 1.1 0.3 ± 1.1 −7.8 ± 0.1 3.84 606.4
R47K 818 ± 61 0.91 ± 0.02 −10.5 ± 1.1 2.3 ± 1.1 −8.2 ± 0.03 3.4 327.2
Q48A 5.5 ± 1.0 1.00 ± 0.01 −22.6 ± 2.2 11.5 ± 2.1 −11.1 ± 0.1 0.5 2.2
Q48T 3.6 ± 1.9 1.00 ± 0.04 −25.7 ± 0.1 14.4 ± 0.2 −11.4 ± 0.3 0.2 1.4
R49A 583 ± 21 0.93 ± 0.1 −13.8 ± 0.7 5.5 ± 0.6 −8.4 ± 0.02 3.2 233.2
T50A 49.8 ± 19.1 1.00 ± 0.1 −21.6 ± 6.6 6.32 ± 1.9 −9.8 ± 0.2 1.8 19.9
P51A 10.8 ± 2.1 0.95 ± 0.05 −23.1 ± 0.1 12.4 ± 0.0 −10.7 ± 0.1 0.9 4.3
R52A 290 ± 57 1.00 ± 0.01 −14.3 ± 0.3 5.5 ± 0.2 −8.8 ± 0.08 2.8 116
Q54A 7.2 ± 2.4 1.05 ± 0.05 −21.9 ± 2.0 10.9 ± 1.8 −11.0 ± 0.2 0.6 2.9
ΔC-term 12.0 ± 3.0 1.01 ± 0.01 −24.7 ± 2.7 14.1 ± 2.5 −10.6 ± 0.2 1 4.8
TBP6.7-
TAR2AP5
7.9 ± 0.2 1.00 ± 0.02 −25.9 ± 1.6 15.0 ± 1.6 −10.9 ± 0.01 0.7 3.2
1 The difference of [ΔG° mutant − ΔG° TBP 6.7]
2 Defined as the ratio of [mutant KD,App]/[wild-type KD,App] TBP6.7.
3 Duplicate measurements were made for TBP6.7 wild-type and mutants with the exception of R49*A, which was
measured in triplicate. Standard deviations of the mean are reported.
4 Considered an estimate due to the low c-value associated with the measurement.
5 Represents wild-type TBP6.7 injected into TAR RNA labeled at position 24 with 2-aminopurine (2AP).
4.5.2 Vital Contributions of R47A
Although R47 is present in the U1A sequence (Figure 2.1), it does not contact U1hpII RNA
[102]. In contrast, R47 of TBP 6.7 makes the most extensive number of contacts with TAR forming
an ‘arginine fork’ [160] wherein NH1 and NH2 hydrogen bond to O6 and N7 of Gua26, while Nϵ
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Figure 4.7: ITCPlots ofTBP6.7MutantsTitrated intoTARThe full isotherms and raw ITC data showing
the interactions between varietions of TBP 6.7 and TAR. From [45].
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Figure 4.8: Schematic diagram of cation-π contacts between HIV-1 TAR bases and guanidinium
groups contributed by the TBP 6.7 β2-β3 loop The figure cation-π interactions between the β2β3 loop
and TAR.AR52 positions its Cζ atom near the π cloud of the Gua34, B) R49* positions its Cζ atom near the
π cloud of the Ade27 imidazole ring, C R47 positions its Cζ atom near the π cloud of the Ade27 imidazole
ring, and D R47 positions its Cζ atom near the π cloud of the Uri23 pyrimidine ring. From [45].
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and NH2 hydrogen bond and salt-bridge to Uri23 O5′ and its pro-Rp oxygen (Figure 4.6C). The
R47 guanidinium is sandwiched simultaneously between bases from Ade22 and Uri23 to form
cation-π stacks (Figure 4.8C,D). As anticipated, R47A produced a large ΔΔG° of ~+3.8 kcal mol-1
corresponding to a loss in binding by a factor >600 (Table 4.2 and Figure 4.7D). The magnitude of
this loss makes it tenuous to relate specific energetic contributions to the structure. An estimated
324 Å2 of buried area is ablated by this mutation—nearly double that of R52A (Figure 4.8). For a
more conservative change, we examined R47K, which gave a ΔΔG° of +3.4 kcal mol-1 correspond-
ing to factor of 327 in lost binding (Table 4.2 and Figure 4.7E). K47 could theoretically preserve
salt bridge formation between its Nϵ and the Uri23 phosphate, as well as cation-π stacking, but
hydrogen bonding to Gua26 and O5′ of U23 seem unlikely. From this analysis it is clear that R47
is of paramount importance for TAR binding, and that the positive charge of lysine is insufficient
to attain optimal readout.
Our collective mutagenesis results support the crystallographic observations, revealing three
tiers of TAR recognition corresponding to explicit modes of arginine readout with distinct free-
energy profiles. MD simulations of the TAR–TBP 6.7 complex support the dynamics of the
observed arginine–TAR interactions with higher maintenance of binding occupancy in more
solvent-excluded regions Figure 4.9.
The simulations not only illustrate the feasibility of interactions to TAR in the context of full-
length TBP 6.7, but also in the context of a minimal β2β3 loop peptide. An analysis of the other
classes of interactions (ii) through (iv) (Section 4.5) demonstrated the roles of other evolved β2β3
loop residues in TAR recognition, their maintenance of a loop conformation productive for RNA
binding, and the dispensability of the lab-evolved C-terminus for TAR readout. The co-crystal
structure also provides a strong rationale for the binding affinities of various TAR mutants that
were generated previously by the McNaughton Lab to probe sites of TBP 6.7 interaction with TAR
RNA mutants [109].
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Figure 4.9: Fractional Occupancy Fractional occupancy (left) is the fraction of simulation frames, sam-
pled at 1 ns intervals, in which a specific interaction is occupied. Bars represent mean fractional occupancy
over six trajectories ± SEM. Hydrogen bond occupancy is determined using a heavy-atom distance cutoff
of 3.5 Å and an angle cutoff of 45° from linear. Cation-π occupancy is determined using a distance cutoff of
4.5 Å between the centroids of the planar atoms of the nucleobase and those of the arginine guanidinium
group, and an angle cutoff of 45° between the normal vectors of the planes defined by these atoms. For
each interaction, a time series of the occupancy (right) shows a dot if the interaction is present. Associ-
ated graphed interactions are drawn as ball-and-stick models derived from corresponding regions of the
co-crystal structure in which protein bonds are blue and RNA bonds are purple. Hydrogen bonds and salt
bridges are depicted as thin broken lines; cation-π interactions are depicted as thick dashed lines. A The
average occupancies of interactions to R52. These plots demonstrate that the interactions are dynamic,
with a number of events showing loss and reformation of interactions across each of the simulations. B
Average occupancy of interactions to R49*. C Average occupancy of interactions to R47. D Average occu-
pancies of Q48* and Q54 interactions. E Average occupancies of van der Waals contacts between P46* to
F56, and P51 to S19*. The van der Waals contact was set to a maximum C-C cutoff of 4.2 Å based on ex-
perimental distributions [161]. The van der Waals contacts are depicted here as semi-transparent surfaces
for relevant groups of atoms; N/A means not applicable because the P51-S19* interaction is absent in the




The results of the work described in this chapter have a number of important implications.
The most obvious implication is the advanced understanding of the mechanisms of binding be-
tween TBP 6.7 and TAR, as well as the advanced general understanding of binding possibilities
of binding between an RRM and a structured RNA.
The most notable implication of the advanced understanding of the specific mode of binding
between TBP 6.7 and TAR is the prominence of the β2β3 loop in this binding interaction, making
up ~⅔ of the buried surface area in the co-crystal. Most directly, this prominence inspires the
peptide-based work in Chapter 5. Furthermore, there are less predictable, but obvious benefits of
having an actual crystal structure of TAR (rather than the NMR based structures used to develop
this work), not to mention a protein binding to it. Given that efforts toward a true cure for HIV
infection would likely be based on some kind of transcriptional activation and suppression of
HIV proviral transcription, the ability to affect and manipulate the TAR element is of utmost
importance [162, 163].
In an abstract sense, this crystal structure represents a solution to this problem, that is to say:
a particular set of molecular interactions that lead to binding of TAR. Knowledge of this set of
interactions will surely inform the design or discovery of future TAR binders. This could mean
that the direct contacts—notably the arginine trio discussed in Section 4.5—could be adapted.
It could also mean less obvious motifs, such as P46 and P51 which make no direct contact, but
P46 seems to guide residue F56 (on the RNP face) into place, and P51 affects S19 (itself a mutated
residue).
Of more general interest is the fundamental mode of binding demonstrated by TBP 6.7,
namely the double-stranded RNA binding based on major-groove recognition. The RRM class
is generally, though not exclusively, made up of binders to single-stranded RNA. The fact of a new
example of a dsRNA binding protein is itself noteworthy.
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I hesitate to make concrete predictions, but it is inconceivable that this new, detailed data
set won’t be useful in the broader goals of developing binders to the TAR element, and general
engineering of the RRM fold.
4.6.2 Relationship to PriorWork
Of particular interest to me is the fact that the C-helix has no obvious importance given that
there are no apparent contacts between this region and TAR (seen in Figure 4.4), and the deletion
of this region results in only a modest (~4.8-fold) decrease in affinity (shown in the ΔC-term data
point in Table 4.2). Though unexpected (after all, the C-helix demonstrated better binding via
yeast display than the β1α1 loop library in Figure 2.7, and in the ELISA data collected in Figure 3.4
there were clear differences in binding based solely on differing sequences in the C-helix. My
explanation given in Section 2.6.7, that we may have been exerting selection pressure toward
a C-helix which stays out of the way (rather than making any positive contributions), remains
sound. I also posit that differences seen in the C-helix are more meaningful, perhaps as a cordon
or stabilizer, in the context of solid-phase analysis (yeast display, ELISA, SPR) than they are in
solution phase (ITC).
Realistically, the crystal structure shown in Figure 4.4 supersedes the mutagenesis data shown
in Figure 3.9, but to me, of course, there is interest in the way the crystal structure explains the
mutagenesis data. For instance, hp1, in which the UCU bulge is deleted (positions 23–25 on TAR)
abolishes binding because the three vital arginines (R47, R49, and R52) are spatially distributed
to accommodate this bulge, and R47 makes close contact with U23 on TAR. Obviously, these
interactions can no longer occur in the bulgeless hp1. Realistically, this also makes most obvious
case for the lack of binding to BIV TAR.
Of interest for a different reason are the case of hp2 (C30G/U31A)—which abolishes
binding—and hp4 (G34C/A35U)—which results in reduced but not abolished binding to TBP 6.7,
but does not significantly reduce binding to TBP 6.6. These changes may be most meaningful
not due to any disruption between TBP 6.7 and TAR (though that is possible due to possible dis-
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ruption of the G34-R52 cation-π interaction), but due to the fact that they disrupt the cross-loop
base-pair which forms between C30 and G34 during TAR/TBP 6.7 binding. Ultimately, the hp2
and hp4 mutations were made with the assumption that they would not drastically alter the dy-
namics of TAR itself, but disruption to binding from these changes is in fact due to changes in
TAR dynamics since the contacts between protein and RNA in these regions is minimal.
The apical loop mutations in hp3 (G32C/G33C) have little effect on TAR binding by TBP 6.7,
and the crystal structure confirms the lack of contact between these apical bases and TBP 6.7. The
stem mutants, hp5 (C29U/G36A) and hp6 (G28A/C37U/C29U/G36A), which decrease but don’t
abolish binding to TBP 6.7, are explained by the fact that R49 on TBP 6.7 recognizes the phosphate
backbone of G28, as well as N7 on the nucleobase, both of which are still present on the A28 of
hp5 and hp6. The contact between TBP 6.7 and TAR is a cation-π interaction between R49 on
TBP 6.7 and G27 on TAR. This general interaction can still take place between R49 and the A27
on hp6.
Finally, the ultimate validation of our work, and the fundamental assumption that our “semi-
design” strategy would be effective, was given in Section 4.4.1 in the comparison of the crystal
structures of TBP 6.7 and the U1A from which it is derived. The rationale for using the U1A RRM
as a scaffold was that the RNA-binding function of this RRM derived from its basic fold, and
that it would be possible to maintain this basic function while changing the object of binding by
making small, targeted mutations. Ultimately, there is a fundamental difference in function be-
tween U1A and TBP 6.7: high affinity and specificity binding to U1hpII RNA via a single-stranded
RNA binding mode vs. high affinity and specificity binding to TAR RNA via a double-stranded
RNA binding mode. But despite this fundamental alteration, both proteins maintain the canon-
ical βαββαβ RRM fold, and a Cα superposition of TBP 6.7 and U1A has a RMSD of only 1.1 Å.
This validation of a successful alteration in binding properties with minimal impact on overall
structure is a triumph for the method of semi-design.
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Chapter 5
Peptide Derivatives of TBP 6.7
5.1 Chapter 5 Introduction
5.1.1 Chapter 5 Summary
The co-crystal structure of the TBP 6.7–TAR complex revealed that the majority of the inter-
action (~⅔ of the buried surface) between the TBP 6.7 and TAR occurred at the β2β3 loop. We
were intrigued by the possibility that this relatively small region of the protein may be indepen-
dently sufficient for TAR binding, as it would have permeability and in vivo stability advantages
over the full-length protein. Constrained peptides consisting of either the full β–turn–β motif,
or only the loop residues, were synthesized and analyzed. The peptide binding to TAR was mea-
sured via a Fluorescence assay, and found to bind TAR with a KD of 1.8 ± 0.5 μM. Furthermore this
peptide was found to inhibit TAT/TAR-dependent transcription of the HIV DNA genome. When
fused to a SUMO domain, the β2β3 motif selectively binds TAR over (CUG)10 RNA as measured
by ELISA. When displayed on bacteria (as an eCPX fusion) or yeast (as an Aga2 fusion), the pep-
tide binds TAR. These successful fusion experiments indicate the possibility of being able to
perform high-throughput screens in order to discover peptides with even better affinity for TAR,
or other disease-relevant RNAs.
5.1.2 Attribution
This chapter is adapted from [45].4
ELISA (Figure 5.7), yeast display (Figure 5.9), and transcription assays (Figures 5.5 and 5.6)
performed by myself.
4Belashov, IA, Crawford, DW, Cavender, CE et al. Structure of HIV TAR in complex with a Lab-Evolved RRM
provides insight into duplex RNA recognition and synthesis of a constrained peptide that impairs transcription.
Nucleic Acids Res, 154:766–15, 2018
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Bacterial display (Figure 5.8) performed by myself, with some assistance from Patrick Beard-
slee.
Polarization assay, the ITC data summarized in Table 4.2 and Figure 5.3B, performed by Ivan
Belashov at the University of Rochester.
Molecular Dynamics simulations by Chapin E. Cavender and Professor David H. Mathews,
also at the University of Rochester.
Peptide synthesis by Peng Dai, of the Pentelute Lab at the Massachusetts Institute of Tech-
nology.
5.1.3 Background
As described in Chapter 2, the decision to base the primary U1A-based library on the β2β3
loop was due to the large degree of contact between this loop and the RNA in the U1A–U1hpII
interaction. We suspected that the β2β3 loop in the TBP 6.7–TAR interaction also accounted
for disproportionate amount of the contact between protein and RNA. The co-crystal structure
(described in Chapter 4) confirmed that the β2β3 loop accounted for ~⅔ of the buried surface
area. This raised a question: could peptides based on the β2β3 loop (constrained to mimic the
conformation on the TBP 6.7 protein) bind TAR on their own?
5.2 Synthesis of Constrained Peptide
Peptides were synthesized by Peng Dai in Bradley Pentelute’s lab at the Massachusetts Insti-
tute of Technology.
Note: In the following text the NH2 terminus and CONH2 terminus will be designated, respectively,
with the traditional “N” and “C” used for natural proteins, with the understanding that these designations
correspond to the slightly different termini of a synthetic peptide.
The peptides were constrained by flanking the sequence in cysteines and forming a perma-
nent perfluoroaryl covalent linkage between the thiol groups. The sequences used were either
the full β–turn–β motif including the β2β3 loop (N-CLDILVPRQRTPRGQAFVIFC-C) for pep-
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tide 1 or simply the β2β3 loop itself for peptide 1s (N-CVPRQRTPRGQAC-C). Structures of peptide 1
(the constrained β–turn–β peptide), and peptide 1s (the constrained loop only) are shown in Fig-
ure 5.1 with Liquid Chromatography–Mass Spec (LC-MS) analysis of the final products.
L44D42















Figure 5.1: Structures and LC-MSAnalysis of Constrained Peptides A Peptide 1 analysis showing a total
ion current (TIC) chromatogram and the mass spectrum corresponding to the maxima point of the TIC
peak (inset). B Peptide 1s analysis showing a total ion current (TIC) chromatogram and the mass spectrum
corresponding to the maxima point of the TIC peak (inset). From [45].
5.2.1 General reagent information for synthesis of constrained peptide 1 and
peptide 1s
1-[Bis(dimethylamino)-methylene]-1H-1,2,3-triazolo[4,5-b] pyridinium 3-oxide hexafluo-
rophosphate (HATU) and Fmoc-L-amino acids were purchased from Chem-Impex International
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(Wood Dale, IL). H-Rink Amide ChemMatrix resin was obtained from PCAS BioMatrix Inc.
(Quebec, Canada). Peptide synthesis-grade N,N′-dimethylformamide (DMF), dichloromethane
(CH2Cl2), diethyl ether and HPLC-grade acetonitrile were obtained from VWR International
(Philadelphia, PA). Decafluorobiphenyl was from Oakwood Chemicals (West Columbia, SC).
5.2.2 Synthesis of Constrained peptide 1 and peptide 1s
Peptide 1 (N-CLDILVPRQRTPRGQAFVIC-C) and peptide 1s (N-CVPRQRTPRGQAC-C) con-
taining two free cysteines (Figure 5.1) were each synthesized on a 0.1 mmol scale on H-Rink Amide
ChemMatrix resin. Solid-phase peptide synthesis was carried out on a synthesizer for automated
flow peptide synthesis [164]. After completion, the resin was washed thoroughly with CH2Cl2
and dried under vacuum. The resin was transferred to a 50-ml plastic tube and the peptide was
cleaved simultaneously from the resin while the side-chain was deprotected by treatment with
2.5% (v/v) water, 2.5% (v/v) 1,2-ethanedithiol and 1% (v/v) triisopropylsilane in neat trifluoroacetic
acid (TFA) for 2 h at room temperature. The resulting peptide-containing solution was triturated
and washed 2× with cold diethyl ether (pre-chilled at −80 °C). A gummy-like solid was dissolved
in 50% H2O:50% acetonitrile containing 0.1% TFA and lyophilized to yield the crude peptide.
The peptide was reacted with decafluorobiphenyl in DMF for macrocyclization (43,44). The re-
action mixture in DMF was quenched by water containing 0.5% TFA for 1:10 dilution, filtered
and then purified by Reverse Phase HPLC (RP-HPLC). The solvent compositions for RP-HPLC
purification were water with 0.1% TFA (solvent A) and acetonitrile with 0.1% TFA (solvent B).
The diluted crude mixture was injected directly into an Agilent 1260 Infinity Automated LC/MS
Purification System with a semi-preparative Agilent Zorbax 300SB C3 Reverse Phase-HPLC col-
umn (21.2 mm × 250 mm, 7 μm) operated with a linear gradient of 5−65% B over 82 min at a 4
ml min-1 flow rate. Fraction purity was assessed by LC–MS. Fractions containing pure, cyclized
peptide were combined and lyophilized.
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5.2.3 LC-MS Analysis of Constrained peptides
LC-MS chromatograms and associated mass spectra were acquired using an Agilent 6520
ESI-Q-TOF mass spectrometer. Mobile phases used for LC–MS analysis were: solvent C (0.1%
formic acid in water) and solvent D (0.1% formic acid in acetonitrile). LC utilized a Zorbax 300SB
C3 column (2.1 mm × 150 mm, 5 μm) with a column temperature set at 40°C and a flow rate of
0.8 ml min-1. The gradient was: 0–2 min 5% D; 2–14 min 5–95% D; and 14–15 min 95% D. MS
conditions were: positive electrospray ionization (ESI) extended dynamic mode in mass range
300–3000 m/z; temperature of drying gas equals 350°C; flow rate of drying gas equals 11 l min-1;
pressure of nebulizer gas equals 60 psi; the capillary, fragmentor, and octupole rf voltages were
set at 4000, 175 and 750 V. LC–MS characterization of each peptide product is shown in Figure 5.1.
5.3 Preparation of TBP 6.7, SUMO, and SUMO-β2β3 Fusions for
ELISA or Transcription
Protein and DNA sequences for TBP 6.7, SUMO, and SUMO fusions are provided in Sec-
tion C.4. Briefly, plasmids containing indicated DNA sequences were constructed according the
cloning procedure outlined in Section 3.2.2.
Cells were grown to confluence overnight in 5 mL cultures, and used to inoculate 0.5 L cul-
tures of LB (Fisher) containing 100 μg ml-1 carbenicillin (GoldBio Technology) to an OD600 of ~0.6
and induced with 1 mM IPTG (Thermo Scientific) at 25 °C for 4–12 h. Cells were harvested by cen-
trifugation (5000 × g, 10 min, 4 °C), resuspended in phosphate buffer (20 mM phosphate, pH 7.4,
0.15 M NaCl) prepared with cOmplete ULTRA Protease Inhibitor Tablets (Roche) and stored at
−20 °C. For lysis, frozen cell suspensions were thawed and sonicated for 2 min. The lysate was
cleared by centrifugation (9000 × g, 20 min, 4 °C) and the supernatant was mixed with 0.75 ml
of Ni-NTA agarose (Fisher) for 10 min. The resin was sedimented by low-speed centrifugation
for 5 min. Resin was washed with 30 ml of phosphate buffer containing 0.02 M imidazole, fol-
lowed by a 10 ml wash with phosphate buffer containing 0.05 M imidazole. Proteins were eluted
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using 2 ml of phosphate buffer containing 0.4 M imidazole. Eluted protein was dialyzed in 10K
MWCO dialysis tubing (Thermo Scientific) against 2 L of phosphate buffer for ~12 hours, and
then against a fresh 2 L of phosphate buffer for 4–6 hours. Purified proteins were quantified by
absorbance at 280 nm using the calculated extinction coefficient. TBP 6.7 was prepared in an
identical manner except that purification and initial dialysis were performed in HEPES buffer
(10 mM HEPES, pH = 7.4, 50 mM KCl, 30 mM NaCl, 1 mM MgCl2 and 1 mM EDTA).
5.4 Fluorescence Emission Analysis of TARbinding to peptide 1
5.4.1 Fluorescence Emission Assay
Due to the large quantities of material required by ITC, a fluorescence emission assay [165]
was used to measure binding of peptide 1 to TAR.
Fluorescence measurements were conducted at 24 °C by titrating concentrated peptide in
FL buffer (0.050 M HEPES, pH 7.5, 0.050 M NaCl, 0.050 M KCl and 0.002 M MgCl2) into 500 μL
100 nM TAR RNA 31-mer labeled with 2-aminopurine (2AP) at position 24 (5′-CGG CAG AU(2AP)
UGA GCC UGG GAG CUC UCU GCC G-3′) known as (2AP)-TAR hereafter. The 2AP-RNA was
purified by denaturing PAGE and folded as described (above). The excitation wavelength for
2AP was 320 nm and changes in emission were recorded at 390 nm as described [165] using a
Fluoromax-3 fluorometer (Horiba Scientific). Data were fit to a one-site binding model, as de-
scribed for TBP 6.7 binding to (2AP)-TAR (Figure 5.3).
5.4.2 Fluorescence Emission Results
The results of this assay indicate that peptide 1 binds TAR fairly well, with KD = 1.8 ± 0.5 μM,
the binding curve can be seen in Figure 5.2.
One concern of this assay was whether the substitution of TAR for (2AP)-TAR was valid, espe-
cially since the substitution occurs in the critical bulge. This concern was alleviated by measur-






















KD,App = 1.8 ± 0.5 μM
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Figure 5.2: FluorescenceAssayMeasuring Binding of peptide 1 to TARThe fluorescence assay measured
binding to (2AP)-TAR of a peptide 1, with b showing the binding curve and the apparent KD of 1.8 ± 0.5 μM.
A similar assay showing binding of TBP 6.7 to (2AP)-TAR can be seen in Figure 5.3. From [45].
that though the use of (2AP) in place of the C at position 24 may have an effect, there is still fairly
avid binding when measured by the fluorescence emission assay. with KD = 10.8 ± 2.6 nM.
Additionally, these results were validated by an ITC experiment using TBP 6.7 and (2AP)-
TAR, where it was found that, when measured by ITC, TBP 6.7 bound (2AP)-TAR with ~3-fold
loss in affinity vs. normal TAR RNA (Figure 5.3B, Table 4.2), which indicates that the binding
interaction between peptide 1 and TAR may in fact be tighter than measured.
Overall, these data indicate that our minimal β2β3 peptides appreciably bind TAR.
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Figure 5.3: Fluorescence Assay Measuring Binding of TBP 6.7 to TAR Binding of (2AP)-TAR a via fluo-
rescence assay with the binding curve shown. This was compared to b binding of TBP 6.7 to (2AP-TAR)
as measured by ITC at 20 °C shown in b and c at 24 °C. Since this apparent KD is ~10-fold worse than the
binding of TBP 6.7 to TAR, it is possible that the 2AP affects binding, and peptide 1 may bind TAR with
greater affinity than is shown by this assay. From [45].
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5.5 ITC Inhibition Assays
I also tried to perform a similar experiment to that shown in Figure 3.15. The hope was that
peptide 1s would be able to disrupt the Tat–TAR binding interaction, and that that disruption in
the interaction would be measurable via ITC.
5.5.1 ITC Inhibition Assay Methods
Assay Overview
These assays were performed in a similar manner to the assays described in Section 3.7.2.
The same Tat peptide was used (N-RKKRRQRRRPPQGSQTHQVSLSKQPTSQPRGDPTGP
KE-C), and the same TAR RNA (5′-GGC AGA UCU GAG CCU GGG AGC UCU CUG CC-3′).
Experiments were performed at a variety of concentrations (3 μM or 10 μM TAR RNA), but the
sample cell always contained either TAR RNA or TAR RNA pre-complexed with peptide 1s, and
the syringe always contained Tat peptide at 10x the concentration of the TAR RNA (20 μM, 30
μM, 100 μM).
Material Preparation
Since peptide 1s was given to me as a lyophilized powder, I simply weighed out small aliquots
of ~1 mg and was thus able to suspend the peptide 1s, RNA, and Tat peptide in the same buffer
(20 mM phosphate, pH = 7.4, 150 mM NaCl). Stocks were made at 1 mM of each. Though this
does not, of course, take into account any leftover salts from peptide or nucleic acid synthesis,
it did not seem to cause any obvious buffer mismatches. TAR RNA was also subjected to the
melt-and-refold protocol described in Section 2.4.2, which is essential to its proper behavior in
ITC.
Experimental Conditions
Tat peptide was either titrated into TAR RNA, or TAR RNA pre-incubated with a 2x or 10x
molar excess of peptide 1s or SUMO-β2β3 fusion. Pre-incubations occurred in volumes of ~400μL
in 1.7 mL eppendorf tubes, rotating at 4 °C for 30–60 minutes.
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ITC Conditions
ITC experiments were conducted using an ITC200 (MicroCal) using a 350 μL cell volume
and a 75 μL syringe volume. All experiments consisted of 16 injections, an initial 0.4 μL injection
and 15 injections of 4.98 μL. After a 60 second initial delay, injections occurred at 180 second
intervals. Experiments were performed with a cell temperature of 25 °C, and a reference power
of 2–5 μcal/sec.
Data were analyzed using Origin 7.0 (MicroCal, ITC200) using a “one set of sites binding
model” for fitting. All data were reference subtracted by subtracting the mean heat of dilution
from each data point.
ITC Results
Results of these ITC experiments can be seen in Figure 5.4, with full thermodynamic param-
eters given in 5.1.
Table 5.1: Thermodynamic Parameters for ITC, at 25 °C, of Tat Peptide Titrated into TAR RNA, with and
without pre-complexing of β2β3 SUMO and peptide 1s
Sample KD,App n ΔH° ΔS° Krel
nM number of sites kcal mol-1 cal mol-1 deg-1
100 μM Tat into 10 μM TAR
No Peptide 75.2 ± 14.7 1.47 ± 0.11 -7.7 ± 0.9 6.60 1
20 μM SUMO β2β3 101.8 ± 29.2 1.32 ± 0.02 -8.3 ± 0.2 4.22 0.74
100 μM peptide 1s 255 ± 49.8 1.34 ± 0.02 -8.6 ± 0.2 1.20 0.29
30 μM Tat into 3 μM TAR
No Peptide 16.1 ± 7.57 1.30 ± 0.0218 -9.0 ± 0.2 5.57 1
30 μM peptide 1s 93.4 ± 41.4 0.63 ± 0.03 -9.4 ± 0.6 0.71 0.17
Though the data was not deemed sufficiently reliable to include in the final journal article
due to the high error, and lack of clear saturation in most ITC curves (because of this, it is possible
that the KD, app differences shown in Figure 5.4A are due simply to minor differences in heats of
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100 μM Tat into 10 μM TAR





20 μM SUMO-β2β3 100 μM peptide1s
30 μM peptide1s
100 μM Tat into
10 μM TAR
30 μM Tat into
3 μM TAR
" + 20 μM
SUMO-β2β3
" + 100 μM
peptide1s
KD = 75.2 ± 14.7 nM
KD = 16.1 ± 7.6 nM
KD = 93.4 ± 41.4 nM
KD = 101.8 ± 14.7 nM KD = 255 ± 49.8 nM
" + 30 μM
peptide1s
Figure 5.4: Inhibition of Tat–TARComplex Formation by SUMOβ2β3 loop and peptide 1s asmeasured
by ITCShown in A are ITC data representing titration of 100 μM Tat peptide into 10 μM TAR RNA with
either no peptide, 20 μM β2β3-SUMO, or 100 μM peptide 1s. B shows the three binding curves overlaid.
Shown in C are ITC data representing titration of 100 μM Tat peptide into 10 μM TAR RNA without and
with 30 μM peptide 1s. D shows both binding curves overlaid.
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dilution at saturation). The data do indicate that sufficiently high concentrations of peptide 1s
can affect the ability of Tat peptide to bind TAR RNA. I feel it is worth including here, as it is
somewhat corroborated by the more reliable (and more biochemically relevant) data shown in
Section 5.6. This possible displacement via ITC is, incidentally most clear when 30 μMpeptide
is used with 3 μMTAR RNA (Figure 5.4C,D), similar to the conditions used in the transcription.
5.6 Transcription Assay
5.6.1 Transcription Assay Methods
We then tested the ability of the shorter peptide 1s (shown in Figure 5.1C) to target TAR using
a known functional assay, the same transcription assay using HeLa Nuclear extract described
in Section 3.8. The only major difference from the protocol described there is that rather than
stopping the reactions with HSCB buffer and subsequently adding a loading control, the radio-
labelled loading control (a purified RNA strand of either 180 or 350 nt) was mixed into the stop
solution, which removed a potential source of error.
Each experiment consisted of 7 reactions (described in the caption of Figure 5.5. The count
value of the ~500 nt band associated with Tat/TAR-dependent transcription was measured as a
ratio of the count value of the control band, with the background subtracted based on densitom-
etry values for areas adjacent to each band. This Tat/TAR band:control band ratio is considered
the “absolute transcription.” This value works well for comparing transcription levels within
an experiment, but since there is so much variation in absolute magnitudes of transcription and
spike band activity between experiments, it is not a valid comparison over multiple experiments,
and performing three full experiments simultaneously is unrealistic. As such, the final value (the
“transcript rel.” y-axis value in Figure 5.6A) for each data point is given as the ratio of the absolute
transcription value for each reaction and the uninhabited template + tat reaction. This relation-
ship is illustrated in the following equations
Transcipt (absolute) = Densitometry500ntband
Densitometry120ntband
Transcript (rel.) = Transcript(absolute)Reaction
Transcript(absolute)Reaction(Template+Tat)
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To give some idea of the background levels of transcription which occur in this experiment,
and the variation between experiments, the uncropped gel from Figure 5.6B can be seen in Fig-
ure 5.5A, and another example gel is seen in Figure 5.5B. Visible on these gels is a ~180 nt band
which, given its presence in all samples, is apparently a product of non-specific transcription.
The fact that this band correlates very well to the control band is good confirmation that both
peptide 1s and TBP 6.7 operate by reducing Tat/TAR-dependent transcription, rather than being
general transcriptional inhibitors.
5.6.2 Statistical Analysis
Unpaired, two-tailed t tests were performed with a Welch correction on data obtained from
three separate transcription assays comparing untreated to inhibitor-treated conditions (Fig-
ure 5.6). The analysis was performed using Prism (GraphPad Software). The t values were: 4.82
(2) for 100 μM peptide 1, 5.83 (2) for 10 μM peptide 1, 4.07 (2) for 2 μM peptide 1; and 8.55 (2) for 10 μM
TBP 6.7. Parenthetical values indicate degrees of freedom.
5.6.3 Results
The statistical summary of three separate experiments, as well as a cropped-for-readability
gel, is shown in Figure 5.6.
Efficient transcription from the HIV-1 5′-LTR requires an unfettered TAR–Tat interaction. As-
says were conducted in HeLa nuclear extract to provide the endogenous transcription machin-
ery, and exogenous Tat (Prospec Cat. No. hiv-129 417, Lot P1TATCB) was required for efficacious
production of the ฀500 base transcript. Reactions lacking plasmid template and Tat, or without
Tat, generated low levels of product (Figure 5.6, lanes I and II). In contrast, reactions containing
template and exogenous Tat generated comparatively high levels of transcription product (Fig-
ure 5.6, lane III). When template, exogenous Tat, and various concentrations of peptide 1s (100, 20
or 2 μM) were added, we observed concentration-dependent decreases in transcript production
(Figure 5.6, lanes IV–VI). Statistically significant reduction occurred at 100 and 20 μM concen-






































































- product (~500 nt)
- control (120 nt)
B
Figure 5.5: Transcription Assay Full Gels Two complete gels of independent transcription assays Fig-
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Figure 5.6: TAT/TARTranscriptionAssaywith peptide 1s In an in vitro transcription assay using HeLa nu-
clear extract peptide 1s is able to inhibit TAT/TAR Dependent Transcription A with statistical significance
at 100 μM and 10 μM, and near statistical significance at 2 μM. B shows a cropped-for-clarity version of
the gel from Figure 5.5. From [45].
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5.6.4 Transcription Assay Summary
The addition of 100, 20 or 2 μM of peptide 1s (Figure 5.1B) resulted in approximately 70%, 65%
or 40% suppression of transcription product (Figure 5.6, lanes 4–6 and Figure 5.5). Consistent
with our previous findings [109], 10 μM TBP 6.7 inhibits TAR–Tat-dependent transcription (Fig-
ure 5.6, lane VII and Figure 5.6, lane 7). The results imply that peptide 1s mimics the β2β3 loop of
TBP 6.7 and serves as a minimal TAR recognition peptide capable of restricting an essential viral
activity.
5.7 SUMO Fusions of the TBP 6.7 β2β3 Loop
Once it was established that peptides derived from the β2β3 loop of TBP 6.7 could serve as
TAR binders and as functional inhibitors Tat/TAR-dependent transcription, I attempted to create
a platform that could be used to synthesize these peptides recombinantly in E. coli. The efficacy
of these fusions was analyzed via ELISA.
5.7.1 ELISA Protocol
ELISA was performed with a condensed version of the protocol described in Section 3.3.1
involving a co-incubation of protein and RNA.
The solid-state scaffold was a clear, 5 picomole well-1 streptavidin-coated 96-well plates
(Pierce). The plate was pre-incubated for 1 h with wash buffer (20 mM phosphate pH 7.4, 150
mM NaCl, 0.05% Tween-20 and 0.1 mg ml-1 BSA). During pre-incubation 100 μl of TAR (5′-GGC
AGA UCU GAG CCU GGG AGC UCU CUG CC-3′) or CUG10 (5′-CCG CUG CUG CUG CUG
CUG CUG CUG CUG CUG CUG GGC-3′) RNA modified with a 5′-biotin (IDT) was incubated
in 100 μl of buffer with 1 μM of either SUMO-β2β3 variant or SUMO for 1 h, rotating at 4 °C. The
pre-incubation buffer was removed from the ELISA plate and the RNA–protein mixture was in-
cubated on the plate for 2 h. Wells were then washed 3× with 200 μl of wash buffer with shaking
for 5 min. Next, a 1:10,000 dilution of HRP-conjugated anti-FLAG antibody (Abcam, ab2493) was
made with Odyssey Blocking Buffer (Li-Cor) and 100 μl was incubated in each well for 30 min
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at 25 °C; each well was then washed 4×. Colorimetry was developed for 20 min using 100 μl of
TMB-One substrate (Promega). Absorbance was measured at 655 nm on a plate reader. ELISA
experiments were repeated in triplicate.
5.7.2 ELISA Results
The results of the ELISA comparing the binding of SUMO-β2β3 to TAR and (CUG)10 are
shown in Figure 5.7A. As expected, a SUMO domain without attached peptide shows compara-
tively low levels of binding. In contrast, SUMO-β2β3 binds TAR, and does so with greater affinity
than it binds (CUG)10 (Figure 5.7). The results collectively demonstrate that the lab-evolved β2β3




























Figure 5.7: ELISA Data Showing Binding of SUMO Fusions of the TBP 6.7 β2β3 Loop, and associated
Arg → Ala mutantA A SUMO-β2β3 loop fusion binds TAR, but not (CUG)10 and B Shows the affects of
loop mutations on this binding. Interestingly, the keystone R47 seems to be the most readily removable of
any of the trio. Adapted from From [45].
The results comparing the evolved β2β3 to arginine mutations of the same are more puzzling
(See Figure 5.7B). Removing the keystone R47 residue and replacing it with an alanine has only
minimal effect on TAR binding. In fact, replacing any of the three important β2β3 Arg residues
has only a minimal effect on binding. This is in contradiction to the ITC data, in which replacing
any of these residues has deleterious effects on binding, with TBP 6.7 R47A essentially losing
binding ability (Figure 4.7, Table 4.2).
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My own supposition is that since the R47 residue was not randomized in the selection experi-
ment, yet is absolutely key to binding TAR, the β2β3 loop evolved largely to position this arginine.
As I discuss frequently, the challenge of engineering RNA binders is that there is only a lim-
ited diversity of function (charge/charge, cation/π, π/π, hydrogen bonding), and that specificity
must come from placement. It is possible that only in the context of the full RRM is the R47A so
perfectly placed, and that in the less sterically-hindered and more flexible context of the β2β3
peptides, the other Arg residues are able to form their own binding interaction network, albeit
a less effective one. If this is the case, it is likely that a double or triple Ala for Arg substitution
would abolish binding.
One important caveat is that these ELISA data were performed at the very edge of the capabil-
ity of the assay, and that the absolute absorbances of ~0.15 are ~30-fold lower than the absolute
absorbances of the ELISA assays discussed in Section 3.3.1, either due to significantly reduced
absolute binding or (my own hypothesis) decreased availability of the FLAG tag for binding the
HRP-conjugated anti-FLAG antibody. With that said, recent unpublished data based on eCPX
bacterial display (similar to the data discussed in Section 5.8.1) indicate that peptide binding is
not abolished by the loss of any given arginine.
5.8 Surface Display Assays
To test the ability of the peptide to express and function in a context in which it could later
be subjected to screening, we fused the full β–turn–β motif to either eCPX (for display on E. coli,
or Aga2 (for display on S. cerevisae).
The yeast display assay using Aga2 is discussed at length in Section 2.4.2. The bacterial dis-
play assay was performed using a system developed in the Daugherty lab [166, 167]. The system
utilizes a fusion to a modification of outer membrane protein X (ompX), an E. coli membrane
protein amenable to fusion. The version used for fusion proteins here is a modified version,
enhanced circularly permuted membrane protein X (eCPX), which is amenable to fusions, re-
sulting in display of ~105 copies of the fused peptide or protein on the surface of an E. coli cell.
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The version of eCPX used here is the result of refinement by Angeline Ta in the McNaughton
Lab, and includes a multiple-cloning site which enables easy fusion with both the eCPX protein
and a myc tag
5.8.1 Bacterial Display
The full β2β3 loop peptide sequence of TBP 6.7, analogous to peptide 1 (N-LDILVPRQRTPR
GQAFVIF-C) was cloned into the pB33-eCPX construct [166, 167] using restriction enzymes NdeI
and XhoI (NEB), downstream of an in-frame myc tag (full sequence given in Section C.4.5and
transformed into 5-α competent E. coli cells (NEB). The eCPX-β2β3-loop plasmid DNA was puri-
fied by miniprep (Omega) and ฀200 ng were used to electroporate E. coli MC1061 F− cells (Luci-
gen) in 1 mm electroporation cuvettes (Fisher). Cells were grown in 50 ml LB (Fisher) contain-
ing 12.5 μg ml-1 chloramphenicol (GoldBio Technology) at 37 °C to an OD600 of 0.5 and induced
overnight with 0.1% arabinose at 25 °C. ~5 × 108 cells were pelleted (7300 × g) for 5 min at 4 °C, then
washed with ice-cold CellGro PBS 1x (Corning). Cells were incubated with 100 nM Cy5-labeled
TAR RNA (IDT) (treated as in Section 2.4.2) and 1:10,000-fold diluted FITC-conjugated anti-cMyc
antibody (Abcam), cells were incubated, rotating, at 4 °C in 1 ml PBS for 1 h. Cells were pelleted
and washed once with ice-cold PBS. RNA-binding (Cy5 fluorescence) and display (FITC fluores-
cence) were measured using a CyAn ADP flow cytometer (Beckman-Coulter). All flow data were
analyzed and plotted using FlowJo 10.3.
5.8.2 Yeast Display
The β2β3 loop peptide was cloned into Aga2 by cutting pCTcon2 with NheI and BamHI with-
out CIP treatment, and gel extracting the cut plasmid. The β2β3 sequence was inserted by order-
ing primers which, upon annealing, form overhangs complementary to the cut vector, and mix-
ing them at a 50:1 ratio with the cut vector under the conditions of a Quick Ligase Kit (NEB). The
sequence is given in Section C.4.4, and is the full β2β3 loop, including the β-strands (analogous
to peptide 1).
165
Transformation and induction of β2β3 loop displaying yeast were performed according to
the protocol in Section 2.4.2. As in previous yeast display assays, surface display was measured
with FITC conjugated anti-myc antibody from Abcam, and RNA binding measured using Cy-5
labelled TAR in concentrations ranging from 1–1000 nM.
5.8.3 Display Assay Results
As can be seen in Figure 5.8A, the β2β3 loop is displayed on the surface of E. coli, though not
spectacularly. Insofar as it doesdisplay, it appears to be binding TAR. A comparison of Figure 5.8A
to Figure 5.8B indicates that this binding is not due to some innate property of the surface of the























































Figure 5.8: Flow Cytometry Analysis of Bacterial Displaying a β2β3 loop Bacterial display of TBP 6.7
β2β3 loop shows binding to TAR that directly correlates with display, indicating that any bacteria which
display the β2β3 loop are able to bind TAR, and bacteria that do not express the β2β3 loop do not. From [45].
The results of the analogous yeast display experiment are shown in Figure 5.9A, and indicate
that the β2β3 loop displays on yeast better than it displays on bacteria. This is still somewhat
poor display, and certainly worse than the naked Aga2 control displays. Figure 5.9B shows that
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this displayed loop binds TAR well, and that this improved binding persists even at the extremely
low concentration of 1 nM.
1 μM TAR 100 nM TAR 10 nM TAR 1 nM TAR
Aga2 control






Figure 5.9: Flow Cytometry Analysis of Yeast Displaying a β2β3 loop Display of the β2β3 peptide on
yeast results in clear binding of TAR over background across a wide range of conentrations (1–1000 nM).
This binding of TAR over background does not occur on yeast displaying only the Aga2 protein which the
β2β3 loop peptide is fused to (See Figure 2.3.1).
The possibilities of surface display are obvious. Though there is clearly space to thoughtfully
engineer variants of peptides based on the TBP 6.7 β2β3 loop, if past (e.g Chapter 2) is prologue,
the best chance of success will come in using high-throughput methods to select for novel RNA-
binders. As such, though these initial surface display results are qualified successes, they are also
quite clearly important. Along with the SUMO fusions discussed in Section 5.7, these display
assays represent the possibility of synthesizing, characterizing, and engineering RNA binding
peptides with all the ease of recombinant protein synthesis and all the power of high-throughput
screening.
5.9 Conclusions
The work described in this chapter represents a culmination and expansion of the work done
in Chapters 2-4. From a basic research perspective, the work done in this chapter represents a
distillation of sorts. We began the affinity maturation process with the assumption that opti-
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mizing the β2β3 of the U1A RRM would be a necessary component of optimizing a protein of
~100 residues in order to bind TAR. The data here show that, to a reasonable approximation, an
optimized β2β3 loop of ~10 residues is sufficient for binding TAR.
Furthermore, this simplified peptide is at least somewhat transferrable to expression and se-
lection platforms. The peptide expresses, and demonstrates TAR binding activity across a variety
of assays (e.g. ITC, ELISA, Flow Cytometry) and within diverse milieus (e.g. β–turn–β peptide,
isolated loop peptide, SUMO fusion, membrane protein fusion). This flexible, minimal func-
tionality indicates that we not only succeeded in finding an extraordinary TAR-binding protein,
but a possibly transferrable, modular motif for binding TAR.
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Chapter 6
Conclusions and Future Directions
Here at the end of the story of the development of binders for TAR RNA, let’s take a look back
at the initial goals of this project, and a look forward at what the next steps might be.
6.1 Project Background and Goals
The work in this thesis was inspired by the recent explosion in understanding of the many
roles of cellular RNA, both as a linear sequence and as functional, structured elements. RNA
sits in the center of the Central Dogma of Molecular Biology [15], and plays a role in regulating
every step from gene regulation [25] to mRNA translation [168] (Figure 1.2). Furthermore, the
well-known canonical roles of tRNA and rRNA in facilitating the formation of the peptide bond
make up an overwhelming majority of the RNA in a cell (Table 1.1).
Even as the extraordinary variety of RNA function becomes apparent, the fact that such a
huge majority of the RNA in a cell is “untouchable” rRNA and tRNA, combined with the limited
chemical diversity of RNA (only 4 bases which are of similar chemical character) make targeting
a specific RNA a major challenge.
There are already a variety of methods for targeting arbitrary single-stranded RNA (most
notably modular, engineerable PUF proteins, Section 1.15), but targeting structured RNA remains
a challenge. The structured RNA that primarily concerns this thesis is the TAR element of HIV-1,
a structured RNA that plays an important role as a miRNA [46], and, through its association with
the HIV-1 Tat protein, as a transcriptional activator [40–42].
This project had both a concrete and abstract goal. The concrete goal was difficult, but
straightforward: generate a binder for the structured and functional TAR element of HIV us-
ing modern protein engineering tools.
The abstract goal was that in so doing we might learn some general information about
protein–RNA interactions. This was really an abstract hope, since any successes in this realm
169
would be informed by the progress of the concrete project, not planned from the outset. In both
of these goals we succeeded beyond any expectation at the outset. A brief visual summation of
the project is shown in Figure 6.1
6.2 Achievement of Project Goals
6.2.1 Develop a Protein-Based Binder of TAR RNA
Affinity Maturation Assumptions
In the concrete goal of finding a binder for TAR RNA, our plan of “semi-design” operated on
the assumption that the U1A RRM would serve as a scaffold, and that the broadened specificity of
the U1A E19S variant could be a starting point for truly altered specificity. We hoped that targeted
changes to the U1A scaffold could unlock new, specific interactions for a different RNA target,
while maintaining the RRM fold that Nature has found so successful at binding a variety of RNA
structures [99].
Library Screening
We chose to use the yeast display technique to analyze our library, and randomized the β2β3
loop (for six rounds) and the C-helix (for three rounds) regions of the U1A protein. After these
six rounds of selection, we seemed to achieve that goal, with our final round of screening having
notable levels of RNA binding even at extremely low concentrations of TAR RNA, and high con-
centrations of competitor tRNA Figure 2.5. The final library showed excellent convergence to a
consensus sequence in the β2β3 loop (Figure 2.8. This represents the first use of yeast display to
select for an RNA binding protein for a specific RNA.
Protein Characterization
When we characterized the resulting proteins, by a variety of techniques, we found that our
best binder (TBP 6.7) binds TAR with exceptional affinity (KD = ~500 pM, Figure 3.8), an order of
magnitude better than our initial hopes of finding a binder with KD =~ 10 nM.
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In addition to its high affinity, TBP 6.7 is exquisitely selective for TAR. There is minimal left-
over affinity for U1hpII (the original cognate RNA of U1A), and the ability of TBP 6.7 to bind TAR
was reasonably sensitive to mutation (Figure 3.9). To our delight, this protein also seemed to per-
form well in biochemically relevant competition and transcription assays, inhibiting Tat/TAR-
dependent transcription (Figure 3.17).
6.2.2 Advance Understanding of Protein–RNA Binding
Our collaborators at the University of Rochester were able to obtain a co-crystal structure of
the TBP 6.7–TAR complex (PDB:6cmn, Figure 4.4). This crystal structure was groundbreaking
for a variety of reasons. The primary reason is that it represents the first full crystal structure
of the frequently targeted TAR element. In a more general sense, it represents one of a very
few examples of a crystal structure involving a synthetic protein/RNA interaction. Among the
most notable findings are the seemingly dichotomous understandings that the basic structure of
TBP 6.7 is extremely similar to that of the U1A protein it is derived from (confirming our “semi-
design” hypothesis), while themode of binding is fundamentally altered (TBP 6.7 binds the major
groove, rather than the single-stranded loop as in the U1A–U1hpII interaction).
My own work has been focused on creation and characterization of properties. This crystal
structure, which elucidates how the TAR/TBP 6.7 interaction occurs, rather than simply char-
acterizing the interaction, certainly represents achievement of this abstract goal of advancing
understanding protein–RNA bindng. In a broader sense, I hope that the work by myself and
my wonderful collaborators will be a source of inspiration and direction for the field. Given the
detail and novelty of the TBP 6.7–TAR interaction, I have little doubt in that outcome.
6.2.3 Develop a Peptide Based Binder of TAR RNA
In fact, the first success of this abstract goal of providing new insight into protein/RNA inter-
action actually comes to fruition within this thesis. The revelation of the importance of the β2β3
loop in the crystal structure inspired the creation and analysis of short peptide derivatives of the
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β2β3 loop of this protein. These peptides demonstrated reasonable affinity (KD = 1.8 μM, Fig-
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Figure 6.1: Project Summary The included selections from various figures throughout this thesis sum-
marize the milestones and successes along the path to achieving our goal of finding a binder to the HIV-1
TAR element, and the advances made possible by achieving that concrete goal.
6.3 Future Directions
6.3.1 Optimization of Peptide Derivatives of TBP 6.7
Given the general knowledge gained in this work, the future directions are endless, but there
are a few clear areas of possibility. The first is the thoughtful refinement of the peptides derived
from the β2β3 loop of TBP 6.7. The fact is that the peptides studied in this thesis were extracted
from the context of a full-length protein. Though they are already functional in their current
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form, there was no particular effort to optimize them for independent existence as isolated pep-
tides, and doing so will be an obvious first step.
The “strand” of the project most within my own skill set and knowledge base is in protein
engineering to determine the modularity of these peptides.
β-strand Optimization
Given that peptide 1s, which consists only of the β2β3 loop absent the connecting β-strands,
is still active via ITC (Section 5.5) and in vitro transcription (Section 5.6) the most logical place to
start optimizing the peptide would be to β-strands using motifs found in Nature, using canonical
amino acids. A good source of inspiration here is the lab of Niels Andersen, which has published
many papers detailing the use of aryl-aryl interactions (functionally similar to the π-stacking
interactions that stabilize protein–RNA interactions) on opposing strands to make ultra-stable
β-turn-β motifs. It is likely possible to combine the loop sequence with optimized β-strands in-
spired by stable motifs found in thermophilic organisms, see [169] and [170] for an idea of what
these strands could consist of.
Some work has already been done in this area by my colleague Patrick Beardslee. The tested
peptides were made using β-strands stabilized by cation-π interactions, directly inspired by work
from Marcey Waters’ lab [171].
Non-canonical Peptides
In addition to the use of optimized peptides based on the canonical amino acids, the β-
strands could be optimized using non-canonical amino acids, especially used as capping (such
as in [172]). In point of fact, peptide 1 and peptide 1s, used extensively in Chapter 5, represent a
version of this strategy, since they are forced into a cyclic conformation using a small molecule.
6.3.2 Optimized Surface Display
Finally, any modified peptides should be placed into a position where the same powerful
library screening tools we used to select a TAR binding protein could be used to select for a
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TAR binding peptide. This would be the most important application of stabilized β-strands using
canonical amino acids, since it would allow more stable variation in the loop structure. The cy-
clization strategies used to make the synthetic peptides could also be applied to surface display
in order to make more rigid structures (see Section B.2 for some initial attempts).
6.3.3 Optimized Recombinant Expression
Any TAR binding peptides discovered through surface display screening would be best an-
alyzed with a simple recombinant platform to stabilize the peptide loop. The method and data
shown in Section 5.7 are a first step, but certainly don’t represent a comprehensive engineering
program, especially given the low ELISA signal. Experimenting with different linker lengths and
fusion domains is an obvious next step.
6.4 Progress Toward a Binding Code
The knowledge of the TBP 6.7–TAR co-crystal structure might well be an important step in
the dream of building a comprehensive code for binding structured RNA. Though any sugges-
tions in this section is, by definition, speculation, there is a general strategy that could be em-
ployed, and general hot-spots of interest on the protein.
Going back to basics (Section 1.10), an RNA binder needs to
• Embrace the broad chemical characteristics of RNA
• Accommodate, or guide into accommodation, the general structure of the RNA molecule
in question
• Make specific, base-dependent interactions to generate selectivity
For a universal structured RNA to exist it would be be necessary that there be some modular-
ity, though what form it takes would be impossible to know a priori. My own hypothesis is that
there will be a “flow-chart” of sorts, based on the three characteristics discussed above.
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At the first level of the flow chart (corresponding to points 1 and 2) would be very general
properties such as size, degree of helicity, and degree of screw-axis distortion. For example, a
miRNA (with repeated internal loops) would be different than TAR (with a single bulge), and
they would both be different than a pseodoknot-containing RNA element. These differences in
structure would likely mean different classesof RNA binding protein. As such, this work probably
means generally less to the goal of binding the SL1 element of the HIV-1 dimerization initiation
site (DIS), which is a pseudoknot, than it does to the goal of binding the SL2 element, which is
a short stem-loop with a single base bulge (see Figure 3.11 for a close look at this portion of the
HIV-1 genome).
6.4.1 Structural Considerations
The second half of point 2, accommodating general structure, could be understood to some
degree based on deviations from the specific TAR/TBP 6.7 interaction. The best way to determine
the beginnings of a code is likely the use of compensatory mutants.
To some degree, this has already been tried. For instance, hp5 and hp6 in Figure 3.9 were
designed to make it easier for the loop-adjacent stem residues on TAR to de-hybridize. If the
mode of binding for TBP 6.7–TAR was similar to that of U1A–U1hpII (single-stranded binding to
the large loop), this would have minimally disrupted, or even improved binding. As it is, these
mutations decrease TBP 6.7 binding drastically, but do not abolish it to the degree of the ΔUCU
in hp1. This was our first clue that the binding modes were, indeed, different, and we would learn
that TBP 6.7 largely contacts the major groove of the 8 paired residues between the loop and the
bulge, which means that it is sensitive to changes in these residues.
I would propose learning the extent of this double-stranded binding activity, since it seems
based on broad structural shape (the TBP 6.7 β2β3 is generally twisted on its axis compared to
the β2β3 loop of wtU1A, and somewhat narrowed), which is seemingly caused by the two intro-
duced proline mutations, especially P51. I assume that a ΔC39ΔG36 TAR would probably not
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bind TBP 6.7, but shortening (narrowing?) the β2β3 loop in compensation (I would propose a
ΔQ54 mutant) might restore it.
Likewise, extending the helical region to the point where the loop no longer impacted TBP 6.7
binding could also be illuminating, and would be the real beginnings of a code for “bulge-helix”
regions of RNA. My own guess is that adding 2–3 extra base pairs beyond the C29·G36 region
would abolish binding. This binding could potentially be restored to some degree, and the
means of doing so would be illustrative. Possible means of restoration could be the addition
of a residue to the loop near position 54, or mutating Q54 (which participates in a single H-bond
interaction with the backbone of G34) to a residue which would facilitate non-specific interac-
tions lysine (good for cation-anion interactions) or a threonine (able to facilitate H-bonds or π-
stacking).
Obviously, there are wild-cards that probably cannot be accounted for in a quest for a reduc-
tive system. For TAR, notably, the reduction in binding seen in hp2 and hp4 in Figure 3.9 had
less to do with contacts between TAR and TBP 6.7, and more to do with the abolishment of the
cross-loop base pair between C30 and G34 which stabilizes the TBP 6.7–TAR interaction. But it
could still be possible to get to “good-enough” based on the TBP 6.7–TAR interaction.
6.4.2 Base Interactions
More difficult to conceptualize is adapting the pieces of the TBP 6.7–TAR interaction that cor-
respond to point 3 – specific interactions to base pairs. What is interesting about this set of inter-
actions is that it was not, as we had assumed, merely a matter of introducing the correct residues
to make the contact, but in placing existing residues. Of the three vital arginine residues—R47,
R49, and R52—only R49 was introduced via affinity maturation.
As such, it seems to me that it won’t simply be a matter of replacing or moving single arginine
mutations, but in making and screening a series of small, targeted libraries. As an example, I’ll
discuss modifying the role of R47, which contacts three separate bases, most notably two H-bonds
to G26.
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The simplest conceptualization is modifying the binding to a G26C/C39G double mutation.
I would make a series of small, easy to screen libraries based on randomizing R47 and two other
residues, notably positions 46+48 and 45+49. Randomizing 3 positions results in a small library
of 203 = 8000 variations, which is easily screened many times over, and more importantly is less
likely to fundamentally alter the binding mode, which should enable step-by-step alteration of
binding interaction (rather than the wholesale change in binding mode represented by the affinity
maturation in Chapter 2), which could feasibly become a set of rationally understood binding
interactions, and therefore predictably adaptable.
A rationally designed binder for the SL2 stem-loop element on the HIV-1 DIS may be far in
the future, but a rationally designed binder for a slight variation of the TAR element (for instance,
as a result of HIV-1 mutation in response to the pressure exerted by a TAR-binding pharmaceuti-
cal) might not be such a pipe dream. Again, the beauty of the TAR binding solution represented
by TBP 6.7 was the combination of new binding residues and the altered placement of the old
ones. A full understanding of how these placements occurred would be a remarkable tool.
6.4.3 Conclusions
Though the field is probably decades from the dream of a simple, modular “code” for struc-
tured RNA binding, I believe it is possible. The limited chemical and structural diversity of RNA
may make targeting a single RNA difficult, but it also means that though the array of targets may
be vast, it is also finite. There are a limited number of structural motifs, and a limited (and pre-
dictable) number of base-pairing interactions. My dearest hope is that the work discussed in
this thesis, and the future directions discussed in this chapter, will enable advances in the fun-
damental understanding of the ways in which proteins interact with RNA.
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Appendix A
Helical Grafting of E6AP
A.1 Background
A.1.1 Significance
One of the more interesting aspects of viral infection is the capacity for the infection to lead
to secondary side-effects, especially cancer. One of the more common examples of this phe-
nomenon is the causal link between infection with Human Papillomavirus (HPV) and cervical
cancer; nearly all (99.7%) of the 470,000 yearly cases of cervical cancer are caused by HPV in-
fection, but HPV infection is also associated with ~¼ of other mucosal cancers such as those of
the mouth, tonsils, and throat [173–175]. There is now a vaccine for the most dangerous forms of
HPV (and it is so effective that Australia is set to all-but eliminate new cases of cervical cancer
by 2020 [176]), but there will still be ongoing need for treatment, and the problem is of general
biochemical interest.
The two proteins most frequently involved in HPV-associated cervical cancer are the coop-
erative viral oncoproteins E6 and E7, which both affect tumor suppression pathways. E6 affects
the p53 tumor suppressor, and E7 affects the retinoblastoma (pRb) suppressor. The research in
this section focuses solely on E6.
A.1.2 The E6/E6AP/p53 Ternary Complex
Though the viral protein E6 has at least some p53-independent oncogenic activity [177], its pri-
mary means of oncogenesis is by association with p53 by way of an association with E6 associated
protein (E6AP) [178], which is also known as Ubiquitin-protein ligase E3A (UBE3A). As the name
indicates, E6AP is a ubiquitin ligase, and part of the proteasome. Roughly speaking, E6 is able
to bind p53 when it is also binding E6AP, but is not able to bind p53 when it is not binding E6AP.
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For a detailed expansion of this interaction see [173], which is an excellent review of the role the
various regions of E6 and E6AP play in HPV-associated cancers.
For the purposes of this research, the only region of E6AP that matters is the the short epitope
that which binds E6. This epitope is a region ~15 residues in length which is largely α-helical in
character. E6 binds this short epitope on E6AP independently of p53, and neither E6 nor E6AP
bind p53 independently, but the E6/E6AP complex is able to bind p53 to form the E6/E6AP/p53
ternary complex. For the remainder of this chapter, the abbreviation “E6AP” will be assumed to
refer to the E6 binding epitope of E6AP, rather than the full protein. A crystal structure of this
interaction, the formal logic of the E6/E6AP/p53 ternary complex and the consequences of this












Figure A.1: Crystal Structure and Cartoon of E6/E6AP/p53 Complex The crystal structure in A ( [179],
PDB: 4xr8) shows the E6/E6AP/p53 ternary complex. The cartoon in B is a reductive explanation of the
biochemical consequences. In brief, E6 can independently bind E6AP, and the E6/E6AP/p53 ternary com-
plex occurs if and only if E6 is binding E6AP. The formation of the ternary complex trigger the oncogenic
pathway. Note that this is true only in a biochemical setting when the full-length E6AP protein is present.
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A.1.3 The E6/E6AP Binding Interaction
The HPV E6 protein is capable of binding human E6AP protein (UBE3A) even without the
presence of p53. This interaction occurs on a leucine-rich α-helical region located on positions
403–414, with the sequence N-LTLQELLGEER-C). Both the leucine-rich helix and the unstruc-
tured 3-residue C-terminal tail play an important role in binding to the E6 binding cleft. As such,
both hydrophobic and electrostatic contacts are important for this binding interaction
A B
Figure A.2: Detail of the E6/E6AP Binding Interaction The cartoons in A show the α-helical region of
E6AP binding to its cleft in E6. The surface view in B shows the same, with leucines highlighted in teal.
Red surface = negative charge, blue surface = positive charge. Note the tight pocket around Arg414 of E6AP.
A.1.4 Research Goals
Long-term Goal
The ultimate goal of this research was to create a molecule which could disrupt the formation
of this ternary complex. The assumption was that such a molecule might take the form of a short
peptide, possibly modified to stabilize a helix, with methods conceptually similar to classic pep-
tide stapling [180]. The peptide would be based on the E6AP binding epitope. Given that a free
E6AP binding epitope could plausibly disrupt the interaction between E6 and full-length E6AP,
a direct analogue would be acceptable, but ideally the inhibiting peptide would be engineered
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thoughtfully, and through high-throughput screening, to have greater affinity for E6 than the
wild-type E6AP.
Short-term Goal
The inherent challenge of that stated aim is the difficulty of screening a large number of
peptide variants, especially when those peptide variants are likely to require modification to fold
into the necessary shape (in this case, an α-helix). As such, my proximal goal was to build and
characterize a platform which would enable rapid study of the E6/E6AP interaction, and high-
throughput screening of same. Additionally, the platform must be expandable to include the
study and screening of the interactions of the ternary system—the interactions between E6,
E6AP (or engineered variant of E6AP), and p53.
A.2 Helical Grafting Strategy
A.2.1 Helical Stabilization
The primary engineering challenge is the creation of a molecule which is a hybrid of sorts
between a peptide and a protein. It needs to be small, but it also needs to be stable, structured,
and expressible by E. coli and yeast. This can best be described as a stabilized helix.
The McNaughton Lab has already developed a system for stabilizing helices. The basis for
this system is grafting long helical sequences onto domains which stabilize extended α-helices.
We have primarily used this to stabilize variants of the trastuzimab, an HIV entry inhibitor pep-
tide based on the HIV HIV gp41 C-peptide helix. This was first done by grafting the peptide
sequence onto the ~150 residue pleckstrin homology (PH) domain GLUE [181], and has been
demonstrated with other PH domains [182]. More recently, the PH domain ELMO has been used
to facilitate high-throughput screening via yeast display of C-helix sequences with improved
binding in an HIV-entry analogue system [183]. These helical peptide mimics inhibit HIV in-
fectivity, and are readily purified or displayed on yeast [181–183].
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Our helix-stabilizing domain du jour is Sac7d, a hyperthermophilic chromosome binding pro-
tein [184]. Sac7d is also the basis for the anti-immunoglobulin proteins known as affitins [185],
and my general strategy was to graft the helical sequence of E6AP onto Sac7d.
A.2.2 Screening SystemDesign
Yeast Display of Sac7d-E6AP
I planned to use yeast display as my screening system due to both my familiarity (Chapters 2
and 5) and our lab’s prior success in using it to perform affinity maturation of helical sequences
[183]. As such, I planned to use the Sac7d-E6AP with the myc tag on the C-terminal. This was
a difficult decision, but my rationale was that the C-terminal of E6AP was already disordered,
so a linker and a small tag shouldn’t interfere with folding. Confirmation of display would be
easily established using the C-terminal myc tag (as in Section 2.3.1) with more certainty than an
N-terminal myc tag. Successful display would then serve as a good indication that the fusion
protein would be amenable to expression and purification in E. coli.
The DNA and protein sequence of Sac7d-E6AP for yeast display can be found in Section C.5.2,
and a graphical overview of the yeast display system, with the various fluorescent readouts can
be found in Figure A.3.
Yeast Display of E6AP Peptide
I also wondered if the Aga2 protein itself might not be a credible helix stabilizer, and as such,
decided to also create a fusion of E6AP without any connection to the Aga2 protein on its N-
terminal and the myc tag on its C-terminal other than the short linkers generally involved in
yeast display.
Such a system would have the disadvantage of being less helically stable—even if the wild-
type E6AP is a stable helix, the possibility exists that a mutation which is beneficial for binding
would destabilize the helix into disorder, while a stabilized helix may be more tolerant to mu-
tations that are beneficial for binding, but detrimental to helix formation. The advantage of a
non-fusion E6AP would be the lack of the steric bulk of the Sac7d protein, as well as toleration
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of the possibility that non-helical folds may be important for the docking and binding process,
even if the end result of this binding process is a helix.
A.2.3 Purification of sfGFP-E6
A secondary challenge which needed to be addressed was the second half of the interaction—
the E6 protein. Though there was no plan to use this as a basis for a library, and though it is
a reasonably large (~150 residues) structured protein, it does not purify well due to extensive
aggregation [173], and is not detectable via flow cytometry.
The aggregation problem had been at least partially solved by the substitution of four cys-
teine residues (C80, C97, C111, C140) for serine. The resulting protein is known as E6 4C/4S
(any mention of E6 henceforth can be assumed to be this variant), and is less prone to aggrega-
tion [186], but still functional in in vitro assays [187], and was used to determine a crystal structure
of the complex [179]. My concern was that this variant of the protein was generally expressed as
a fusion with glutaione-s-transferase [186], which would add a great deal of bulk, and would not
solve the issue of invisibility via flow cytometry.
My proposed solution to both of these problems was to fuse E6 to super-folder Green
Fluorescent Protein (sfGFP), a highly stable variant of GFP [188]. This domain would serve to









Figure A.3: Proposed Yeast Display System for Measuring Binding of E6 to E6AP The proposed yeast
display system to measure binding of sfGFP-E6 to Sac7d-E6AP is shown (though it would also be used
with yeast displaying E6AP peptide not fused to Sac7d). Fluorescent readouts came from either FITC
(conjugated to anti-myc antibody) or sfGFP (fused to E6).
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A.3 Grafting Strategy
The grafting strategy was developed to maximize helical stabilization and minimize steric
hindrance. Since the E6AP is bound to E6 on all sides, I could not graft the helical face of E6AP
onto the portion of the Sac7d helix which is directly stabilized by the β-face. I also wanted to en-
sure that these β-sheets would not cause a steric clash with E6 upon binding of E6AP. I used the
“align” command in PyMol 2.0 (Schrödinger) on the backbones of the helical portion of Sac7d
and E6AP using in order to decide where to graft the E6AP helix onto the Sac7d helix. An illus-
tration of the final graft can be seen in Figure A.4.
A
B
Figure A.4: E6/E6AP complex vs. E6/Sac7d-E6AP Complex Views of A the crystal structure of the
E6/E6AP complex and B the same with the E6AP helix grafted to Sac7d. E6 in purple, E6AP in red, Sac7d
in gray. Care was taken to minimize possible steric clashes between E6 and Sac7d.
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My final decision was to graft the E6AP helix starting at position 61 on Sac7d (the residue
at position 60 is from wtSac7d, while the residue at position 61 is from E6AP, sequence in Sec-
tion C.5.2).
A.4 Materials Preparation and General Methods
A.4.1 Cloning
Cloning was performed as described in 2.4.1.. Any proteins for expression were ligated into a
pETduet vector cut from BamHI to KpnI (thereby making the vector a pET vector with a single
T7 promoter and terminator). Using the BamHI cloning site enabled use of the N-terminal His6
tag on pETduet, which seemed desirable given the importance of the C-terminal E6AP sequence
being studied. All sequences available in Section C.5.
Sac7d and Sac7d-E6AP
All Sac7d-containing proteins in this work had a standard L33T mutation, which turns off the
antibody-binding property of the protein used in affitins [189]. Sac7d fusions were prepared by
PCR, with Sac7d overlap, the entire E6AP sequence (N-ELTLQELLGEEER-C), and the appro-
priate stop codons and cloning sites.
E6AP for Yeast Display
The construct containing E6AP Peptide-myc (E6AP for Yeast Display) was prepared by direct
insertion. Two overlapping oligos, E6AP FWD (5′-CTAGCGAGCTGACTAAACAAGAACTTC
TGGGCGAGGAGCGCG-3′) and E6AP Rev (5′-GATCCGCGCTCCTCGCCCAGAAGTTCTTG
TTTAGTCAGCTCG-3′) were ligated into pCTcon2 digested with NheI and BamHI (but not CIP
treated), using a 50:1 ratio of insert to vector.
sfGFP-E6
The insert for the construct containing sfGFP-E6 was created via overlap PCR. Initial PCR
created an sfGFP amplicon with E6 overlap at the 3′ end, as well as an E6 amplicon with sfGFP
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overlap at the 5′ end. The two amplicons were given ten cycles of PCR without primers, followed
by addition of FP from the sfGFP amplification and the RP from the E6 amplification. The re-
sulting amplicon was digested with NcoI and KpnI and ligated into pETduet.
p53 Core
The construct for p53 Core was generated by PCR using an IDT gBlock as a template. I used
the same BamHI and KpnI cut sites as I did for the rest of the constructs in this chapter. The
sequence I purified is canonically positions 94–292 of p53. Though the protein was never used in
an assay, it purified well from BL21 E. coli with normal induction (0.5 mM IPTG, 16 hours, 25 °C).
The DNA and protein sequences can be found in Section C.5.8.
A.4.2 Protein Purification
Proteins were purified using a standard nickel/His6 protocol, as described in Section 3.2.3,
and quantified by absorbance at 280 nM. Sac7d, Sac7d-E6AP, and sfGFP purified without issue
and remained stable for at least two weeks following purification. The purification of sfGFP-E6
proved more problematic, as can be seen in Figure A.5.
Finalized conditions for this the induction are: initiation of induction at OD600 = 0.6 with 0.5
mM IPTG, induced for 16 hours at 30 °C with 1 L of LB in a 2 L erlenmeyer flask, shaking at 250
rpm. As can be seen in Figure A.6, the protein purifies at usable purity under these conditions,
and remains stable for a usable amount of time.
A.4.3 Protein Purification Assay Consequences
One note that pertains especially to ITC (Section A.6) is that Sac7d and Sac7d-E6AP would
typically come out of dialysis at a concentration of ~10–100 μM, and would require concentration
after dialysis and before ITC. This is probably inconsequential for the yeast display assays (Sec-
tion A.5,Figure A.9), but it is a problem for ITC. Though this shouldn’t lead to a buffer mismatch,

















55 kDa sfGFP-E6 – 49.4 kDa
sfGFP – 30.5 kDa
E6 – 18.7 kDa
40 kDa
10 kDa
Sac7d(-E6AP) – 10 kDa
Figure A.5: Initial Purifications of Sac7d(-E6AP) and sfGPF(-E6) This protein gel, run about a week af-
ter protein purification as a quantitation control demonstrates the tendency of the sfGFP-E6 protein to
degrade over a short period of time.
A.4.4 Yeast Preparation
Yeast were transformed via electroporation (as in 2.4.1), and induced via normal galactose
induction (as in Section 2.4.2). Inductions were kept short, never longer than 24 hours, and were
performed at room temperature (~25 °C). Induced yeast were kept at 4 °C for 1–3 days prior to
flow cytometry.
Flow cytometry was performed on a CyAn ADP, unless otherwise specified. Following in-
cubation conditions listed with the relevant data, cells were washed once and left as pellets on
ice. Flow cytometry was performed by re-suspending the pellets in 1 mL of PBS-BSA. Front and
side scatter were used to gate healthy cells (typically >90% of the total), and the fluorescence of
50,000 healthy yeast cells was measured.
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sfGFP-E6 – 49.4 kDa
sfGFP – 30.5 kDa










Figure A.6: Final sfGFP-E6 Purification PAGE gel run ~1 day after purification demonstrates that under
the right conditions the sfGFP-E6 fusion purifies reasonably cleanly, and is stable over short time periods.
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A.5 Yeast Display Assays
A.5.1 Sac7d-E6AP and E6AP Display on Yeast
In order to analyze the efficacy of our system for measuring binding between displayed Sac7d-
E6AP or E6AP and E6, I first had to ensure that they displayed on yeast, and that the sfGFP
fluorophore proposed to track E6 binding did not generate a false-positive signal.
I incubated ~106 induced yeast in PBS-BSA with a 1:1000 dilution of FITC conjugated anti-myc
antibody or (abcam ab117599) 10 μM sfGFP for 45 minutes rotating at 4 °C. Cells were washed once
and measured for FITC/GFP fluorescence with a CyAn ADP flow cytometer. Figure A.7 shows
these results.
A.5.2 Initial Tests of sfGFP-E6 binding to Displayed E6AP
After establishing that the proteins of interest would display, and had only minimal affinity
for sfGFP (Figure A.7), I decided to determine whether the Sac7d-E6AP and E6AP peptide would
bind sfGFP-E6. Yeast cells were again induced for 24 hours, and I initially set up the experiment
in a similar fashion to a normal yeast display experiment—500 μL of PBS-BSA for 45 minutes at
4 °C with 5 μM protein (as well as the usual display checks with FITC conjugated antibody and
negative controls). The results of this experiment are shown in Figure A.8.
It was obvious that something was occuring, and I had both reason to be hopeful and skepti-
cal. The hopeful signs were that neither the yeast displaying Sac7d (without any E6AP fusion)
seemed to have any appreciable affinity for the sfGFP-E6, while both means of displaying E6AP
did. However, the yeast displaying Aga2 alone had comparable signal to the two E6AP display-
ing samples. Given future results, my hypothesis is that the Aga2 control yeast are displaying
more copies of the Aga1/Aga2 pair, and that these Aga pairs are more sterically accessible. Given
that the pair is held together by disulfide bonds (see Figures 2.2 and A.3), it is possible that the
cysteine-rich E6 protein has some affinity for the Aga1/Aga2 proteins (or possibly mis-folded
copies), which are held together by disulfide bonds. This effect would intuitively be especially
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Figure A.7: Initial Confirmation of Sac7d-E6AP and E6AP Display on Yeast The initial experiment
checking for display of Sac7d-E6AP and E6AP A demonstrated that both the fusion and the isolated pep-
tide display well on yeast, with 52.4% of the yeast in the Sac7d-E6AP sample and 58.8 % of the E6AP peptide
displaying their proteins, which compared well to the positive Aga2 control (74.3% positive) (cutoff indi-
cated by dotted line). Under the same conditions, an uninduced sample of yeast bearing the Sac7d-E6AP
plasmid were <1% positive. Additionally, I needed to ensure that sfGFP did not generate a positive sig-
nal even absent the E6. As can be seen in B, it does not, with only 3.8% of Sac7d-E6AP and 2.8% of Aga2
displaying cells generating a positive signal.
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Uninduced AgaII Sac7d Sac7d - E6AP E6AP
FigureA.8: E6BindingbyDisplayedE6AP, 45min. Incubation Initial experimentAhistograms of sfGFP
fluorescence showed no obvious positive population, but did display a “shoulder” from the negative pop-
ulations. The bar graph in B shows the % positives resulting from these populations.
A.5.3 sfGFP-E6/E6AP Binding with Longer Incubation Times
Given that I suspected that E6/E6AP binding was occurring (and the results were not simply
the result of artifacts), and that these binding events took the form of a “shoulder,” I wondered if
binding was beginning to occur, but had not yet achieved an equilibrium after <1 hour.
To test this, I tried a longer incubation. I still used normal incubation conditions—106 cells
in 300 μL of PBS-BSA, with either 10 μM sfGFP-E6, 30 μM sfGFP, or 1:1000 FITC-conjugated anti-
myc antibody—but I incubated them for 20 hours at 4 °C. Negatives and binding controls were
normal, and the sfGFP-E6 binding data can be seen in Figure A.9.
Though these data are not conclusive, they indicate that given sufficient time, E6AP binding
to E6 will occur. Though I did not have the opportunity to properly replicate this experiment,
and so cannot be sure that this is not due to some artifact or fluke of induction, it seems unlikely
that the two E6AP samples would have the same fluke, while the others do not.
Given that binding is good, but not great (2.3 ± μM as measured by SPR in [190]), and the ac-
cepted measurements use relatively high concentrations, it is possible that our more complicated


















Figure A.9: E6 Binding by Displayed E6AP, 20 hr. Incubation After 20 hours of incubation with sfGFP
or sfGFP-E6 there was a clear positive population. A The difficulty was that this population was off the
scale, so I re-adjusted the voltage (thereby making the instrument less sensitive) so that all events were on
scale, and B ran the samples again. Both histograms also contain one Sac7d-E6AP sample incubated with
30 μM Though quantitating this improvement is difficult due to the continuing presence of a “shouler”
from the negative samples, but ~30% of E6AP/Sac7d-E6AP samples are positive compared to the ~10% of
the comparable Aga2 control.
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hindered, and uses more structured peptides (thus, possibly structured in a sub-optimal config-
uration), it is possible that the interaction takes longer to occur, but is still robust. I also suspect
that there is some issue with the folding of the sfGFP-E6 fusion when it is not bound to E6AP,
meaning that our effective reagent concentration is lower than expected.
In any case, though not conclusive, these data demonstrate the high likelihood that yeast
display is a good platform on which to simulate peptides based on E6AP (both separately and as
a Sac7d fusion), and it may be possible to use this platform to select for variants with improved
binding.
A.6 sfGFP-E6/E6AP Binding via ITC
A.6.1 Protocol
In addition to yeast display, I also attempted to measure the E6/E6AP interaction by ITC. I
opted to use the same sfGFP-E6 fusion protein as my E6 source, and purified Sac7d-E6AP (Se-
quence: C.5.6). Experimental conditions are given in the appropriate figures, but ITC experi-
ments were performed on an ITC200, with 10× concentration/2× molar quantity in the syringe.
Total cell volume was 350 μL, and total syringe volume 40 μL. Experiments were performed at
25 °C with a stirring speed of 750 RPM. Reference power was 3 μcal/second. The first injection of
0.4 μL occurred after 60 seconds, followed by 15 injections of 2.49 μL at 180 second intervals.
I opted to put the Sac7d-E6AP in the syringe, since it seems to be more stable, and is certainly
easier to purify at high concentrations. The data shown in Figure A.11 indicate that it may be
better to reverse this, however.
A.6.2 Results
Like the yeast display data, the ITC data indicates that Sac7d-E6AP binds to E6 (in the form




KD = 4.8 ± 2.3 μM
N defined as 0.5
ΔH = 1.0 ± 0.1 kcal/mol
S = 27.7 cal/mol/deg
KD = 10.8 ± 1.5 μM
N defined as 0.1
ΔH = 5.4 ± 0.5 kcal/mol
S = 41.1 cal/mol/deg
Experimental Parameters
193 μM Sac7d-E6AP in syringe




KD = 25.8 ± 8.3 μM
N = 0.949 ± 0.05
ΔH = 0.118 ± 0.01 kcal/mol
S = 21.4 cal/mol/deg
Experimental Parameters
1.95 mM Sac7d-E6AP in syringe
1.95 μM sfGFP-E6 in Cell
25 °C
Figure A.10: ITC Titrations of Sac7d-E6AP into sfGFP-E6 In A an ITC titration and line of best fit is
shown for a 193 μM Sac7d-E6AP into 19.3 μM sfGFP-E6, along with the thermodynamic results of two
seperate fit equations. Drastic spikes can be seen in the raw ITC heat. I assume they correlate to aggre-
gation events, and those data have been discarded. B shows the results of a similar titration with ~10x
concentration in both cell and syringe.
I used Origin 7.0 to analyze the data shown in Figure A.10, and the fitting algorithm contin-
ually drove the N-value toward zero as best-fit iterations were performed. In order to get con-
vergence I instructed the program to hold this value constant. This is obviously not ideal, and
indicates some discrepancy in concentration measurement (either due to the protein measure-
ment being flawed, or some protein being inactive), as well as a sub-optimal c-value. The latter,
especially, is not surprising, given that (assuming the thermodynamic values are accurate) my
c-value for this titration is fairly low (~2–5). The fact that varying the N-value has minimal effect
on the KD indicates that these KD values are reasonable, if not precisely trustworthy.
This becomes an even more reasonable assumption given that the titration shown in Fig-
ure A.10, which is done at a more reasonable c-value of ~10, has a similar KD . Therefore, I believe
it is accurate to conclude that there is a binding interaction between Sac7d-E6AP and sfGFP-E6.
Also worth noting is that this binding interaction seems to be entropically driven, and at high
concentrations even endothermic.
The most obvious caveat to this is shown in Figure A.11, which puts side by-side the titration
from Figure A.10B and a titration of 1.44 mM Sac7d into buffer. In this case, the Sac7d into buffer
generates ~4 times more heat than Sac7d-E6AP into sfGFP-E6. My own supposition is that this is
215
due to some kind of non-covalent oligomerization in the extra-concentrated Sac7d. The fact that
the heats are so drastically different between the two samples, as well as the fact that this is not
an effect I have seen every time I’ve titrated Sac7d into buffer, suggest that whatever is occurring
in Figure A.10B is distinct from the dilution-driven heats in Figure A.11B.
Sac7d-E6AP into sfGFP-E6 Sac7d into buffer
A B
Figure A.11: ITC of Sac7d into Buffer Compared to Sac7d-E6AP into sfGFP-E6 A shows the same data
seen in Figure A.10B (1.93 mM Sac7d-E6AP into 193 μM sfGFP-E6) side-by-side with B 1.44 mM Sac7d into
buffer, with molar heats calculated as if it were being titrated into 193 μM sfGFP-E6, as a means of nor-
malization.
Again, the corpus of data suggest that Sac7d-E6AP binds to sfGFP-E6, and that this binding
is measurable by ITC. That said, a technique more suited to μM KD values, such as fluorescence
polarization, might be a better choice.
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A.7 “Helical Grafting of E6AP” Conclusions
In conclusion, I appear to have succeeded at my goal of creating a stable platform for expres-
sion and study of the E6AP peptide. I hope that, if this project is advanced in the future, this
platform will be used to generate better binders to E6. As it is, there is interesting functional
possibility in simply replacing binding between E6 and the full E6AP protein (which is, after all,
a ubiquitin ligase) with a binding interaction between E6 and the harmless E6AP peptide.
A.8 Future Directions
A.8.1 Replication
The first and most obvious future direction of this project is replication. The data in this
chapter are suggestive, but not beyond reproach. The key to this, is, I believe, making sure that
all materials are as fresh as possible. This is challenging, because the E6 especially is prone to
degradation and aggregation, and does not purify efficiently. Related to this replication would
be the determination of a KD curve via yeast display (as in Section 2.8.3, which should confirm
past ITC experiments, and guide future possibilities.
A.8.2 Yeast Display
The next step for the yeast display/flow cytometry route is an incubation time series. It has
been established that ~1 hour is too short a time for a full incubation, but ~1 day is probably
too long, and is likely introducing artifacts. I predict that 4–6 hours of incubation will result in
differentiation between samples without the massive “off-scale” signal of the ~1 day incubation.
A competition assay utilizing multiple concentrations of non-fluorescent E6 fusion protein
would help rule out the possibility of artifacts. E.g. a population of yeast displaying E6AP should
have lower fluorescent signals when incubated with 5 μM sfGFP-E6 and 45 μM MBP-E6 (for in-
stance) than they would if they were incubated with only the 5 μM sfGFP-E6. If this is not the
case, it could be an indication that the yeast are somehow taking up the protein, rather than
merely binding it on the surface.
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A.8.3 ITC
The next step for ITC is to either do a more extended titration utilizing multiple refills of the
syringe, or to use more concentrated materials. I believe that more concentration of materials
will involve co-dialysis of the proteins together at high concentration. A dialysis at such high
concentration will result material loss. Of course, such a dialysis would need to be done in se-
ries and/or at hight volume to prevent the contamination of the buffer at large with significant
amounts of protein.
Alternate E6 Forms
Since purification of sufficient quantities of the sfGFP-E6 has proven to be a bottleneck, it
may be worthwhile to try out other stabilizing domains (such as MBP) for ITC assays.
A.8.4 Other Assays
As a general statement, more types of assays means more confirmation, and any positive re-
sult is more believable if it is corroborated in multiple systems. I think the best choices of alter-
native assays for this system would be:
• Fluorescence Polarization: because it seems to work well in the μM range of this interac-
tion, and because it can be done with constructs on hand.
• SPR: because it has already been used extensively for the E6/E6AP system [190], and be-
cause SPR will allow a kinetic comparison between free and stabilized peptide that should
illuminate the other assays (especially incubation time of the yeast display assay)
• ELISA: because it is sensitive, robust and well-suited to binary “yes/no” determinations of
binding. An anti-GFP antibody would work
A.8.5 Introducing p53 to E6/E6AP Interaction
The next experimental step (as opposed to technical step) would be to probe the system in
the presence of p53. The assays would be similar to those already performed, but with co- and
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pre-incubation of p53. Since flow cytometry seems to be the most promising avenue at the mo-
ment, obtaining the p53 with an orthogonal fluorophore, and/or using Förster resonance energy
t (FRET) pairs would enable determination of correlation between E6 and p53 binding events.
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Appendix B
Other Experiments of Possible Interest
Very few theses are exhaustive lists of a graduate student’s time, the main body of this one
probably doesn’t even manage a simple majority of my time and energy. As such, I wish to devote
a few pages to some of the side projects related to the work in Chapters 1-5 (Sections B.1-B.3), as
well as a few independent projects .
B.1 Binding of TBP 6.7 to ΔC25 TAR RNA
B.1.1 Introduction
The affinity of TBP 6.7 for a canonical TAR sequence (with a trinucleotide bulge) has been
well-established (Chapter 3). But the HIV-1 TAR Element does have some variation in the wild
[39], and the canonical TAR element in HIV-2 is a dinucleotide bulge [191].
As part of a grant application, I tested the affinity of TBP 6.7 for a variant of TAR with a di-
nucleotide bulge, designated as TAR ΔC25. There was never a good publication in which to in-
clude it. It was temporally separate from the data in Figure 3.9, and has additional concentra-
tions, that I decided to not simply blend the data.
B.1.2 Methods
The methods used are essentially identical to those used to gather the data in Figure 3.9, and
are described in detail in Section 3.3.1.
The TBP 6.7 sequence can be found in Section C.2.3. I once again used the C-terminal His6
and FLAG Tag variant.
The TAR ΔC25 (5′-biotin-GCAGAUCGAGCCUGGGAGCUCUCUGC-3′ also lacks the ex-
tensive G·C clamp at the 5′/3′ extremes, but is otherwise identical to the canonical TAR used





Figure B.1: Dinucleotide Bulge TAR The sequence and putative secondary structure A of the ΔC25 TAR
analyzed here as well as the sequence of TAR used extensively in Chapters 2-5. Shown in B is a crystal
structure of TAR with the trinucleotide bulge outlined in red, demonstrating its significance to the overall
structure.
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In the experimental design TAR was used as a positive control, and a bulgeless variant (hp1
from Figure 3.9) was used as a negative control.
B.1.3 Results
TBP 6.7 binds ΔC25 TAR nearly as well as it binds the canonical TAR used throughout this
thesis. At a protein concentration of 2 nM, the ELISA signal for ΔC25 TAR was somewhat less
than half of the signal for TAR (which is still quite high). At 20 nM, the signal was ~75%, and at
100 nM was essentially identical. Based on these data, I would estimate a KD of around 10 nM,
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Figure B.2: Binding of TBP 6.7 to ΔC25 TAR TBP 6.7 binds ΔC25 TAR nearly as well as it binds the TAR
sequence used throughout this thesis.
B.1.4 Conclusions
This outcome was unexpected when considering the crude mutation data shown Figure 3.9
because TBP 6.7 binding is so sensitive to the presence of the trinucleotide bulge. However, it
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is less surprising in the face of the crystallography data, which indicate that TBP 6.7 does not
engage much with the bulge directly, but rather that the bulge helps form the major groove that
TBP 6.7 binds in a double-stranded mode (Chapter 4). A dinucleotide bulge has a similar effect
in this sense as a trinucleotide bulge does, and therefore similar affinities.
What is most promising is that TBP 6.7 engages with TAR under approximately the same
conditions as Tat itself does. That is to say that mutations which would result in abolishment
of TBP 6.7 binding would also likely result in a lack of Tat/TAR-dependent transcription activity.
For instance, the Tat peptide from HIV-1 (which recognizes a trinucleotide bulge-containing TAR
element) is able to transactivate the dinucleotide bulge (similar to ΔC25 TAR) from HIV-2
B.2 Alternate β2β3 Loop Display Strategies
B.2.1 Introduction
The data presented in Section 5.8.1 was only a part of an ambitious program to display vari-
ants of the TBP 6.7 β2β3 peptide on bacteria. I attempted to create a cysteine-flanked version, and
synthesized a molecule—6,6′-sulfonylbis(1,2,3,4,5-pentafluorobenzene)—which had been used
to create similar cyclic libraries on bacteriophage [192].
However, such a library would only be useful if it could be shown that the conjugation had
worked robustly, which would be best demonstrated by the presence of free thiol groups prior
to the conjugation, and the absence of same following conjugation.
Two basic methods were attempted to determine the viability of this plan: a mass spectrome-
try probe based on TEV cleavage (Figure B.3A), and a flow cytometry based probe based on FITC
conjugation (Figure B.3B). To enable these tests, I constructed a version of the TBP 6.7 β2β3 loop
(loop only, analogous to peptide 1s from Chapter 5) flanked by cysteines and TEV cleavage sites,
fused with eCPX for display on E. coli.
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Figure B.3: Schemes for Detection of Cyclization of Displayed β2β3 Loop Peptide The proposed
schemes for confirmation that the β2β3 loop library had indeed been cyclized via A TEV cleavage with
differentiation between cyclized and uncyclized via mass spectroscopy, and B fluorophore conjugation
detected via flow cytometry.
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B.2.2 TEV-cleavage displayed β2β3 loop peptides
I tested the feasibility of using TEV cleavage to determine whether cyclization had occured.
An additional benefit of this assay is that it could potentially be used in a pulldown assay, or
manipulated for use in assays using cleavage-dependent logic.
Methods and Results
TEV protease was purified per standard purification protocols.
Bacteria displaying either TEV-Cys-β2β3-Cys-TEV or Z-peptide (used as a negative control,
sequence from [193]) as eCPX fusions were inoculated and induced according to the protocol
in Section 5.8.1. After a 1 hour incubation with FITC-conjugated anti-myc antibody, they were
measured via flow cytometry and found to be displaying at high levels (Figure B.4)A. ~109 cells
were then incubated with ~1 μM TEV protease in 1 mL of PBS for ~16 hours, and once again tested
for display by use of FITC-conjugated anti-myc antibody.
Subsuquently, a similar experiment was performed with 10× the number of cells in 10× the
volume. After the initial centrifugation, the supernatant (which should contain β2β3 peptide
for the TEV-Cys-β2β3-Cys-TEV sample) was saved, lyophilized to reduce volume ~10-fold, and
analyzed for presence of peptide via mass spectrometry.
This incubation with protease had little effect on the autofluorescence of the cells (Fig-
ure B.4B), nor the display of Z-peptide (Figure B.4C), but reduced display of TEV-Cys-β2β3-Cys-
TEV by ~⅔ (Figure B.4D).
However, it was not possible to detect the cleaved β2β3 in the supernatant via mass spec-
trometry (Figure B.5) even with a 10-fold increase in bacteria (for a total of 8.8 × 109 cells in a 1
mL reaction. This is perhaps not surprising, since assuming 105 displayed proteins on each cell,
there would only be a small amount of peptide present, even at 100% cleavage—about 15 μMafter
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Figure B.4: Display of β2β3 Peptide Variants Before and After TEV Cleavage A shows the levels of dis-
play prior to TEV cleavage. Following ~16 hours of incubation with ~1 μM TEV proteaseBThe uninduced
cells and C the cells displaying Z-peptide were largely unaffeced, while D a great deal (~⅔) of the TEV-
Cys-β2β3-Cys-TEV had apparently been cleaved away.
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Expected Mass of β2β3 loop peptide = 2410 Da
Figure B.5: Mass Spectrum of Supernatant Following TEV Cleavage There is no obvious peak for the
β2β3 peptide in this spectrum, with only the peaks at ~800 Da and ~1257 Da possibly corresponding to
some version of a Z=2 and Z=3 β2β3 peptide post-cleavage.
B.2.3 Maleimide FITC Conjugation of TEV-Cys-β2β3-Cys-TEV
Methods and Results
I inoculated and induced bacterial cells displaying either a Z-peptide eCPX fusion (as a neg-
ative control), or Cys-β2β3-Cys. Display was confirmed via incubation with FITC conjugated
anti-myc antibody.
I then tested the using the number of free thiols by incubating (for 1 hr. with 500 μM
maleimide-FITC in PBS) the Z-peptide cells, Cys-β2β3-Cys cells that had been incubated for 30
min. with 2 mM of the reducing agent tris(2-carboxyethyl)phosphine (TCEP), and Cys-β2β3-Cys
cells that had not been treated with TCEP. Results are shown in Figure B.6.
Given that the the most positive sample was that displaying Z-peptide, which does not have
any cysteines (Figure B.6A), this does not appear to be a promising method for identifying the
presence of free thiols on a displayed protein. I suspect this is due to the fact that the bacterial
surface itself has numerous membrane proteins containing accessible cysteines. This assertion is
supported by the fact that the “negative” population of the cells treated with TCEP (Figure B.6B)
is clearly shifted to the right compared to the cells that were not treated with reducing agent
(Figure B.6C), which would occur if the membrane proteins of cells not actively displaying eCPX
fusion were being reduced. It is also likely that the porin-like eCPX protein facilitates diffusion
of the relatively small maleimide-FITC into the cell interior.
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Figure B.6: Results of Incubating Cys-β2β3-Cys with Maleimide-FITC A negative control, consisting
of bacteria displaying Z-Peptide, but not incubated with maleimide-FITC is shown against the results of
incubating maleimide-FITC with A bacteria displaying Z-peptide (91.6% positive) B Bacteria displaying
Cys-β2β3-Cys after pre-treatment with TCEP (81.6% positive) and C Bacteria displaying Cys-β2β3-Cys, but
not treated with TCEP (76.6% positive)
B.2.4 Conclusions and Future Directions
Conclusions
Though we chose not to pursue these avenues further, there are some promising results here.
Most notable is that both TEV-Cys-β2β3-Cys-TEV and Cys-β2β3-Cys do, in fact, display on bac-
teria, even with their cysteines.
The results of the assays themselves, though not ideal, are also not abject failures. Especially
interesting is the apparently straightforward use of TEV protease to cleave surface-displayed
proteins. To my knowledge, the first such use of TEV protease in a bacterial display system.
Future Directions
I believe that the TEV-cleavage based detection of the cyclization of TEV-Cys-β2β3-Cys-TEV
shows promise. Though it did not generate enough signal here, some of the peaks in the spec-
trum (Figure B.4) could well be our peptide of interest. It is possible that at higher concentration,
and with more specialized instrumentation, the cyclized and non-cyclized peptides would be vis-
ible and distinct.
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Further, one can imagine interesting assays in which a binding event obscures the TEV site.
With such a system, the target of binding would not need to be fluorescently labelled. Instead, a
pre-incubated sample could be subjected to TEV cleavage (where TEV cleavage would remove
the myc tag used to measure display) and washed. Following this wash, an incubation with FITC
conjugated anti-myc antibody would highlight only those cells which had been binding the tar-
get. A flow chart is shown in Figure B.7
The maleimide-FITC conjugations represent a different sort of challenge, since the non-
specific binding/uptake seem inherent. My best proposal for moving this project avenue forward
is to titrate the maleimide FITC, rather than adding it all at once, but I have no real hope that
that would actually solve the non-specificity problem. It is possible that some specific kind of
reaction conditions could provide the necessary selectivity, but I have no particular suggestions
about what those could be.
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FigureB.7: ProposeduseofTEVCleavageonaBacterial Surface toDetectBindingEventsThe protocol
proposed here could allow flow cytometry screening without the necessity for the “bait” protein to have a
fluorophore attached. Additionally, it could allow some level of kinetic control and detection—intuitively,
a fast on/fast off interaction will have more TEV cleavage activity than a slow on/slow off interaction.
230
B.3 TBP 6.7 Expresses in Mammalian Cells
B.3.1 Introduction
While my in vitro work with TBP 6.7 and TAR was enlightening, any real pharmaceutical
conclusions can only be drawn from data gathered from in cellulo settings. Though I was not
responsible for the full experimental work, and it has yet to be published, I did prepare the con-
structs to be used and do some basic due diligence to make sure they expressed.
B.3.2 Materials Preparation
Cloning
TBP 6.7 sequence was codon-optimized for expression in mammalian cells, and the sequence
ordered as a gBlock from IDT. This sequence was PCR amplified to add three different termi-
nal possiblities, a C-terminal FLAG Tag, a C-terminal Nuclear Localization Site (NLS) (specif-
ically the NLS from residues 155–170 of nucleoplasmin [194]), or simply a stop codon following
the TBP 6.7 sequence. Primers were designed to give each PCR amplicon the appropriate end-
ing sequence: a stop codon alone (TBP 6.7-*), a FLAG tag (TBP 6.7-FLAG), or the selected NLS
(TBP 6.7-NLS). A pcDNA3.0 vector was prepared by digesting with BamHI and XbaI followed
by CIP treatment. Amplicons were digested with BsaI, which had been designed to contain the
appropriate overhangs to ligate with the cut pcDNA3.0 vector.
Primer and gBlock, as well as DNA and protein sequences can be found in Sections C.6.5-
C.6.9.
Cell Culture
HEK 293T cells were prepared according to standard mammalian cell culture protocol in
Dulbecco’s Modified Eagle Medium (DMEM) with 10% Fetal Bovine Serum in 75 cm2 Corning
flasks. HEK cells were transfected with 3 μg of the TBP 6.7-FLAG construct, using a Lipofec-
tamine 2000 kit (Thermo), with a separate untransfected culture kept as a control.
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Western Blot
HEK 293T cells were resuspended in 1 mL and lysed. 2 or 10 μL of lysate was analyzed via
Western Blot with an anti-FLAG primary antibody, and a fluorescently labelled secondary an-
tibody. Blots were imaged with a Typhoon imager. The 10 μL samples were too concentrated,
and did not run properly via PAGE, but the 2 μL samples ran cleanly. Though there was the non-
specific signal associated with use of a FLAG tag in mammalian cells, there was a clear band at
the proper molecular weight for TBP 6.7 (~15 kDa) in the transfected cells, but not in the untrans-
















































Figure B.8: Western Blot Demonstrating TBP 6.7 Expression in HEK 293T Cells This Western Blot
shows that TBP 6.7 expresses cleanly in HEK 293T cells, without apparent toxicity, but only in cells trans-
fected with the appropriate plasmid.
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B.3.3 Conclusions
Though this section doesn’t represent any data regarding the properties of TBP 6.7 binding
to TAR, or preventing HIV infection, it does demonstrate that TBP 6.7 expresses, folds, and is
apparently non-toxic in the context of a mammalian cell.
B.4 Sac7d Based Binders of CUG10RNA
My initial exposure to Sac7d-based yeast display and libraries was in the context of finding
potential α-helical binders to CUG10 RNA. This project was primarily the purview of my lab-
mate Rachel Tennyson, with the assistance of our labmate Patrick Beardslee, but as I was deeply
involved in both experimental design and assay performance, especially of the yeast display por-
tion of the project, I would like to include a short summary here.
B.4.1 Introduction
CUG repeat RNA is a tempting target, since mis-spliced CUG-repeat RNA is largely responsi-
ble for certain forms of muscular dystrophy [29]. As a proxy for expanded CUG repeats, we used
CUG10 RNA (5′-CCG CUG CUG CUG CUG CUG CUG CUG CUG CUG CUG CGG-3′), with a 5′
cyanine-5 fluorescent dye to measure binding.
We designed our library to be used with yeast display. The primary difference between this
yeast display system and the other systems discussed in this thesis (i.e. Sections 2.4 and A.5) is
that the myc tag was located on the N-terminal of the displayed protein. This is due to the fact
that we did not want interference between the myc tag and the possible helical binding of CUG10
RNA.
B.4.2 Library Creation and Screening
The library was created by randomizing 5 positions on the Sac7d helix (theoretical library
size of 3.2 × 106 protein sequences). Library screening was performed in a similar fashion to that
described in Section 2.6, with Cyanine-5 labelled CUG10 as the target and E. coli tRNAs as the off-
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target competitor. Though there was no diversification step, the general idea was the same, with
each round decreasing CUG10 RNA concentration and/or increasing E. coli tRNA concentration.
The Sac7d based library was screened against other RNAs as well, but the CUG10 RNA library
had the most promise, and was therefore analyzed most extensively.
B.4.3 Yeast Display Methods
Generally speaking, yeast display for these experiments was conducted in a similar fashion
to the many other yeast display experiments throughout this thesis (notably Section 2.4.2).
Briefly, samples which involved FITC-conjugated anti-myc antibody were incubated with
1:1000 antibody. All yeast display samples also contained a 1:2000 dilution of rRNasin (Promega).
All RNA underwent a standard melt and refold (Section 2.4.2) prior to use in yeast display. Incu-
bations were 45 minutes to 1 hour, in 200–1000 μL sample volumes with PBS-BSA as the buffer.
B.4.4 Analysis of the Best Binder: CUG10 Binding Protein 5.21
Antibody vs. CUG10 RNA Binding
The apparent best binder of RNA was CUG10 Binding Protein 5.21 (CBP 5.21). There were
some issues characterizing this protein. One prominent concern is the fact that both antibody
and CUG10 RNA binding seemed to occur reasonable robustly separately, but not concurrently.
Graphically, what this looks like is robust positive signals for both the FITC channel (represent-
ing binding to FITC conjugated anti-myc antibody, generally the X-axis) or the Cy-5 channel (rep-
resenting CUG10 RNA binding, generally the Y-axis), but with minimal signal in the “double pos-
itive” quadrant (data shown in Figure B.9).
CBP 5.21 Binding to CUG10 RNA
Ultimately, comparing the apparent ability to bind CUG10 RNA of CBP 5.21 and the original
Sac7d upon which the library was based makes CBP 5.21 seem like a promising lead, shown by the
concentration series in Figure B.10. In this experiment, yeast displaying either Sac7d or CBP 5.21
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Figure B.9: CBP 5.21 Binding to Cy-5 Labelled CUG10 RNA or FITC conjugated anti-myc Antibody
CBP 5.21 binds to antibody or CUG10 RNA, but does not display the expected behavior of binding anti-
body and CUG10 RNA.
ing is that these concentrations are quite high, and simple non-specific binding increased the
fluorescence of the negative population appreciably. Gating was adjusted throughout the exper-
iment in order to exclude this negative population.
B.4.5 Conclusions
Though we never were able to fully demonstrate CUG10 binding via an in vitro method (such
as ITC or ELISA), the yeast display data is fairly promising. The Sac7d-displaying yeast always
exhibit a similar level of non-specific binding no matter the concentration, while the CBP 5.21-
displaying yeast bind more RNA in absolute terms (both percent positive and with higher signal),
and exhibit concentration dependence.
There are, of course, concerns. The most notable issue is the difficulty in correlating display
and binding. One possible explanation is that the displayed protein is not being displayed at all,
and is simply being cleaved off at the myc tag. If this is the case, our FITC-conjugated anti-myc































































































































































Figure B.10: Concentration Series of DisplayedCBP 5.21 Incubatedwith 1–10 μMCy5-CUG10RNA]This
concentration series indicates that our CBP 5.21 protein binds CUG10RNA in the context of yeast display.
The percent of the population in each quadrant is indicated on the respective graph.
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only way around this is to add the display tag to the C-terminal, which could interfere with the
essential helical nature of this region.
Another possibility is that there is a steric problem with antibody binding between the N-
terminal of the Sac7d protein and the Aga2/yeast surface. In this case, antibody-binding would
favor (and possibly force) odd conformations and folding patterns which may create a contradic-
tion between the Sac7d variant’s ability to bind antibody and RNA. In this case, a possible way
forward is to use a smaller tag/detector combo, for instance a BC2 tag and BC2 nanobody pair,
with a fluorescent tag on the BC2 nanobody [195, 196].
Ultimately, though it would be desirable to have more clarity, the data in Figure B.10 demon-
strates a clear concentration-dependent increase in CUG10 10 RNA binding which is dependent
upon the presence of the Sac7d variant CBP 5.21, which can only be seen as a promising sign.
B.5 Others
Finally, I’d like to give brief mention of a few additional projects
B.5.1 Enzymatic Creation of Inorganic Nanoparticles
My first publication was not, in fact, in the McNaughton Lab, but came from work done dur-
ing my initial six-week rotation in the lab of Prof. Chris Ackerson [197]. There was a developing
project relating to the ability of Pseudomonasmoraviensis stanleyae to high levels of selenite, possi-
bly reducing the selenite—SeO3)-2—into insoluble, neutral selenium (Se). It was suggested that
the enzyme responsible was glutathione reductase, and I discovered that it was possible to use
commercially available glutathione reductase to perform the transformation. I also hit upon the
idea of monitoring the reaction via NADPH, which absorbs at 340 nM (spectra shown in Fig-
ure B.11).
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Figure B.11: NADPH-basedMonitoring of Enzymatic Selenite ReductionMy first experimental success
in graduate school was in determining a protocol for measuring the rate (and therefore allowing condition
optimization) of glutathione reductase based reduction of selenite to neutral selenium.
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B.5.2 Alternate Library SelectionMethod
I probably spent as much time working on an original idea of mine involving a proposed
general method to evaluate and screen a library based on selection rather than flow cytometry
based screening as I did on everything described in Chapters 2-5. Publication forthcoming.
B.5.3 Small Molecule Induced Dimerization
I also worked closely with graduate student colleague Patrick Beardslee and undergraduate
researcher Zachary Fleishhacker on a project involving the well-known FRB–FKBP–rapamycin
interaction [198]. FRB and FKBP are proteins which only interact when small molecule ra-
pamycin is present. We worked to build a bacterial-display platform to study this interaction,
but had no success. Between the work in this section and the prior section, I would guess that
my experience with bacterial display is even more extensive than the significant yeast display
work described throughout this thesis.
B.5.4 Library Screening for Other RNAs
I worked closely with graduate student colleague Angeline Ta, and post-doc Gayani Perera
to retreat the steps in Chapter 2 to find binders for the VP30 RNA, and miR-21. Though we built




Protein and DNA Sequences
C.1 Sequences from Chapter 2, “Affinity Maturation of U1A
E19S for TAR RNA Binding”
C.1.1 Selected Primers from Chapter 2
Fwd U1A NheI
5′-ATA TAG CTA GCA TGG CCC AGG TGC AGC-3′
Rev U1A BamHI
5′-CGG GAT CCT GCG GCC GCA ACC-3′
Fwd BsaI Out
5′-CAA GGA GGT GTC GAG C GCC ACC AAC-3′
Rev BsaI Out
5′-CTC GAC ACC TCC TTG AAG ATG ACA AAA GCT TGG CC-3′
FWDU1A BsaI
5′-ATA TAG CTA GCA GCT AGC TAG CTA GAT GGT CTC AGG GGC CAA GCT TTT GTC
ATC TTC AAG GAG GTT TCG-3′
Rev b2- b3 lib
5′-TAT AT GGT CTC GCC CCT MNN MNN MNN MNN CCG MNN TAC CAG GAT ATC CAG
GAT CTG GCC-3′
HR FP
5′-CTC TGG TGG AGG GCG TAG CGG AGG CGG AGG GTC GGC TAG C-3′
240
HRRP
5′-CGA GCT ATT ACA AGT CCT CTT CAG AAA TCA GCT TTT GTT CGG ATC C-3′
Fwd c-helix receiving
5′-CGC GTC CTA ACC ACA CTA TTT ATA TGA GAC CAC TCT AGA GGT TCC CCG GTT
GC-3′
Rev c-helix receiving
5′-GGC CGC AAC CGG GGA ACC TCT AGA GTG GTC TCA TAT AAA TAG TGT GGT TAG
GA-3′)
Rev c-helix lib
5′-TAT ATG GTC TCT TGG CMN NGA TMN NMN NGT CGG TGC GCG CAT ACT GGA TAC
G-3′
Fwd b1a1
5′-ATA TAG GTC TCT TAT ATC NNK NNK CTC AAT NNK AAG ATC AAG AAG GAT GAG
CTC AAA AAG-3′
C.1.2 wtU1A in pCTcon2
Protein Sequence
DNA Sequence
The text in bold corresponds to the NheI and BamHI cut sites. The DNA sequence of all
pCTcon2 fusion proteins listed for the remainder of this thesis will be shown beginning at the














C.1.3 U1A E19S in pCTcon2
Protein Sequence












C.1.4 1st Gen Library Receiving Plasmid/BsaI U1A
















C.1.6 2nd Gen Library Receiving Plasmid




C.1.7 2nd Gen Library Amplicon











C.2 Sequences fromChapter 3, “Characterization ofTARBind-
ing Proteins”
C.2.1 Selected Primers from Chapter 3
U1A NcoI FP
5′-ATA TAC CAT GGC CCA GGT GCA GC-3′
U1A His FLAG PacI RP
5′-GTT AAT TAA CTA TTA CTT GTC GTC ATC GTC TTT GTA GTC GTG ATG ATG GTG ATG
ATG TGC GGC CGC AAC C-3′
U1A His PacI RP






C.2.2 Generic TAR Binding Protein with C-terminal His6 and FLAG Tags
Protein Sequence
Variable positions in β2β3 loop or C-helix designated with [#], where # is the position number.





ORF denoted by “||”.
β2β3 loop variable bases denoted by X, C-helix variable bases with Y.










Protein Sequence of TBP 6.7 with C-term His6 and FLAG Tags





DNA Sequence of TBP 6.7 with C-terminal His6 and FLAG Tags









Protein Sequence of TBP 6.7 with C-terminal His6 Tag





Protein Sequence of TBP 6.6 with C-terminal His6 and FLAG Tags




DNA Sequence of TBP 6.6 with C-terminal His6 and FLAG Tags










Protein Sequence of TBP 6.6 with C-terminal His6 Tag






The TAR RNA used in the ITC assay shown in Figure 3.15 did not have a biotin modification.
5′-biotin GGC AGA UCU GAG CCU GGG AGC UCU CUG CC-3′
U1hpII
5′-biotin AGC UUA UCC AUU GCA CUC CGG AUG AGC-3′
C.2.6 Tat Sequences
Tat peptide (Used in ITC)
N-RKKRRQRRRPPQGSQTHQVSLSKQPTSQPRGDPTGPKE-C
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Tat Protein from Prospec (Used in Transcription Assay)
ProSpec Recombinant HIV-1 TAT Clade-B (Cat. No. HIV-129)
N-MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGlSYGRKKRRQRRRPP
QGSQTHQVSLSKQPTSQSRGDPTGPKE-C
C.2.7 PLAI-BS Transcript Sequence
















C.3 Sequences from Chapter 4, “Crystallization of TBP 6.7 and
TAR”
C.3.1 TBP 6.7 Variants
Full-Length TBP 6.7







TBP 6.7 for Crystallography
TEV cleavage site indicated by \\. Protein was only used in crystallography following removal of














F75 and R88 in bold
N-MAVPETRPNHTIYINNLNSKIKKDELKKSLYAIFSQFGQILDILVPRQRTPRGQAFVIFKEV
SSATNALRSMQGFPFYDKPMRIQYAKTDKRIPAKMKAHHHHHHDYKDDDDK-C
C.4 Sequences fromChapter 5, “PeptideDerivatives ofTBP6.7”
C.4.1 TBP 6.7 Used in ITC Assays
TEV cleavage position indicated by //. Protein was only used in crystallography following re-















































C.4.4 TBP 6.7 β2β3 Loop for Yeast Display
DNA Sequence




The AS and GS sequences at the beginning and end of the sequence correspond to the NheI and
BamHI cloning sites.
N-ASLDILVPRQRTPRGQAFVIFGS-C
C.4.5 TBP 6.7 β2β3 Loop–eCPX for Bacterial Display
DNA Sequence























C.5 Sequences from Appendix A, “Helical Grafting of E6AP”

















Division between Sac7d R60 and E6AP E372 marked with //
N-ASSVKVKFLLNGEEKEVDTSKIRDVSRQGKNVKFTYNDNGKYGAGNVDEKDAPKELLD
MLAR//ELTKQELLGEER-C
































sfGFP residue Ser2 in bold, E6 residue Phe2 also in bold. The end of sfGFP and the beginning




































sfGFP residue Ser2 in bold, E6 residue Phe2 also in bold. The end of sfGFP and the beginning




















C.5.7 Sac7d-E6AP for Expression
DNA Sequence








































NdeI and XhoI cloning sites in bold, the beginning of the in-frame TEV-Cys-β2β3-Cys-TEV se-





The G and A flanking this sequence are part of the NdeI and XhoI sites respectively.
TEV cleavage sites in italics









The G and A flanking this sequence are part of the NdeI and XhoI sites respectively.









The G and the A flanking this sequence are part of the NdeI and XhoI sites respectively.
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Z-peptide sequence bolded N-GALKKELQANKKELAQLKWELQALKKELAQA-C
C.6.5 Gblock sequence from Section B.3, “TBP 6.7 Expresses inMammalian
Cells”









C.6.6 Primers from Section B.3, “TBP 6.7 Expresses in Mammalian Cells”
TBP 6.7 gBlock FP
5′-TATAGGTCTCTGATCATGGCACAGGTCCAACTGC-3′
TBP 6.7 * RP
5′-tataGGTCTCACTAGTCAGGCAGCGGCGACTGG-3′
TBP 6.7 FLAG RP
5′-AGGTCTCACTAGTCACTTATCGTCGTCATCCTTGTAATCGGCAGCGGCGACTGG-3′
























































NheI, BamHI, and XhoI cloning sites bolded.
N-terminal myc tag italicized.







Canonical Sac7d Val2 bolded.
Randomized positions given by “X.”
N-VKVKFLLNGEEKEVDTSKIRDVSRQGKNVKFTYNDNGKYGAGNVDEKDAPKELLXMLX
XAEXXKKLN-C
C.6.11 Sac7d with N-terminalmyc
DNA sequence
NheI, BamHI, and XhoI cloning sites bolded.













NheI, BamHI, and XhoI cloning sites bolded.
N-terminal myc tag italicized.







Canonical Sac7d Val2 at start of sequence and all results of library screening (positions 56, 59, 60,
63, and 64) bolded.
N-VKVKFLLNGEEKEVDTSKIRDVSRQGKNVKFTYNDNGKYGAGNVDEKDAPKELLSML
RTAETFKKLN-C
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